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A. INTRODUCTION 
A.1  Chronic Granulomatous Disease 
A.1.1  Clinical manifestations 
In 1954, Janeway and colleagues first reported five cases of children suffering from 
recurrent severe infections and hypergammaglobulinemia (Janeway et al., 1954). Later 
on,  more  cases  of  children  with  the  same  symptomatology  were  described.  These 
patients additionally showed granulomatous lesions and infiltration of visceral organs 
(Landing and Shirkey, 1957; Bridges et al., 1959). 
The disease was first named “fatal granulomatous disease” of childhood, since it was 
considered as a syndrome whose sufferers invariably died in the first decade of life. In 
1966  it  was  shown  that the disease is related to a failure in phagocytic function of 
granulocytes (Holmes et al., 1966). 
It is currently accepted that the failure of phagocytes to generate reactive oxygen species 
(ROS),  which  are  important  for  the  microbicidal  activity,  is  responsible  for  the 
development of the disease. As a consequence of this defect, patients are unable to ward 
off infections caused by catalase-positive bacteria and fungi (Winkelstein et al., 2000). 
Nowadays, infections of the soft tissues and upper and lower respiratory tracts, lung 
abscesses,  bronchitis,  liver  abscesses,  gastroenteritis  and  development  of  sterile 
granulomas in hollow organs without clinical evidence of infection are, inter alia, the 
most common clinical manifestations described as symptoms of this disease which is 
now termed “Chronic Granulomatous Disease” (CGD) (Rosh et al., 1995; Barese and 
Goebel, 2006). 
A.1.2  The NADPH oxidase enzyme complex 
Phagocytosis  of  invading  pathogens  is  normally  accompanied  by  an  increase  of  O2 
consumption of the cell (up to 100-fold), known as respiratory burst (Light et al., 1981). 
The O2 accepts electrons from the reduced nicotinamide adenine dinucleotide phosphate 
generating  superoxide  anion.  The  superoxide  anion  is  the  precursor  of  a  number  of 
reactive  oxygen  species  (ROS)  that  plays  an  essential  role  in  killing  many  types  of 
microorganisms.  This  conversion  is  catalyzed  by  the  NADPH  oxidase,  which  is  a 
phagocytic, multi-protein enzyme complex present in the plasma and specific granule 
membranes  of  phagocytes.  It  is  comprised  of  gp91
phox  and  p22
phox,  which  form  a 
membrane-bound heterodimer referred to as flavocytochrome b558, and several cytosolic 
components (p47
phox, p67
phox, p40
phox, the small G-protein Rac2 and MRP8/MRP14). A. INTRODUCTION  2 
A.1.2.1  The flavocytochrome b558 complex of NADPH oxidase 
Flavocytochrome b558 is a stable membrane-associated heterodimeric complex, which 
comprises not only the gp91
phox and p22
phox subunits (Parkos et al., 1987), but also a 
flavin adenine dinucleotide (FAD) and two heme prosthetic groups (Fig. 1). 
Fig. 1: Model of flavocytochrome b558. Both gp91
phox and p22
phox are shown, with the aligned hemes 
(solid and hatched diamonds) and the sites for FAD and NADPH binding on gp91
phox indicated (Quinn 
and Gauss, 2004). 
 
Gp91
phox (β-subunit) is a post-translationally glycosylated protein essential for oxidase 
function.  This  subunit  is  synthesized  as  a  glycosylated  65-kDa  precursor  in  the 
endoplasmatic  reticulum microsomes and contains high mannose-type carbohydrates. 
Mature  gp91
phox  has  N-linked  complex  carbohydrate  chains  which  are  acquired  for 
further  processing  in  the  Golgi  complex  and  are  resistant  to  digestion  with 
endonuclease H (Porter et al., 1994). The cytosolic N-terminal and C-terminal domains 
of gp91
phox are linked through six transmembrane α-helices with conserved histidine 
residues that coordinate two heme prosthetic groups (Cross et al., 1995; Yu et al., 1998; 
Biberstine-Kinkade et al., 2001; Biberstine-Kinkade et al., 2002). FAD and NADPH 
cofactors bind to the C-terminal domain, which serves as a redox center and may also be 
involved  in  the  recruitment  of  the  cytosolic  factors  required  for  activation  and 
functionality of the oxidase (Rotrosen et al., 1990; Rotrosen et al., 1992; Sumimoto et 
al., 1992; Doussiere et al., 1993). The presence of all redox components in gp91
phox 
supports  the  theory  that  this  subunit  mediates  the  sequential  electron  transfer  from 
cytosolic NADPH via FAD to molecular oxygen to form superoxide anion. 
Compared to gp91
phox, the topology of p22
phox (α-subunit) is less well characterized. 
However,  antibody  and  proteolysis  experiments  in  combination  with  computational 
predictions suggest that, in addition to two membrane-spanning domanins, a large part 
of the N-terminal region of p22
phox is intracytoplasmic. The carboxy terminus of p22
phox 
is hydrophilic and contains a prolin-rich sequence providing a high affinity binding site 
for p47
phox, which is essential for recruitment of cytosolic components. The N-terminus A. INTRODUCTION  3 
plays  an  important  role  in  gp91
phox-p22
phox  heterodimer  assembly  as  inferred  from 
deletion mutagenesis analysis of this region (Taylor et al., 2004; Zhu et al., 2006). 
P22
phox  forms  a  mutually  stabilizing  complex  with  gp91
phox  in  a  stoichiometric 
1:1 noncovalent association. The heterodimerization process of gp91
phox and p22
phox is 
coupled to the maturation of gp91
phox and to the transport of the heterodimer into the 
membrane.  Full  maturation  of  gp91
phox  includes  the  sequential  incorporation  of  two 
heme prosthetic groups into the 65-kDa precursor, the heterodimerization with p22
phox 
in  the  endoplasmatic  reticulum  and the addition of N-linked oligosaccharides in the 
golgi  complex.  All  these  events  are  required  for  the  following  transport  of  the 
heterodimer to the plasma membrane (Yu et al., 1997; Yu et al., 1998). Therefore, a 
defect in one of the two subunits completely prevents insertion of the heterodimer into 
the plasma and specific granule membranes of phagocytes (Parkos et al., 1989). 
A.1.2.2  The cytosolic components of NADPH oxidase 
The  flavocytochrome  b558  complex  recruits  two  essential  cytoplasmatic  subunits 
(p47
phox and p67
phox) and several cofactors (Rac2, p40
phox, MRP8/MRP14, etc.). 
The  p47
phox  subunit  contains  four  domains:  i)  an  N-terminal  phox  homology  (PX) 
domain, which has a membrane-targeting role via its specific phosphoinositide-binding 
module (Kanai et al., 2001), ii) two tandemly organized Src homolgoy (SH3) domains 
(Leto  et  al.,  1994),  iii)  an  auto-inhibitory  domain  and  iv)  a  C-terminal  proline-rich 
(PRR) domain with six potential serine phosphorylation sites (Fig. 2a). 
In resting phagocytes, p47
phox can be found as a monomer as well as in a multimeric 
complex  (1:1:1)  with  p67
phox  and  p40
phox.  P47
phox  remains  in  an  auto-inhibitory 
conformation  by  an  intermolecular  interaction  of  the  SH3  domains  with  the 
auto-inhibitory region. Phosphorylation of serines at the C-terminus induces unfolding 
of p47
phox which is a prerequisite for its translocation to the plasma membrane and for 
direct binding to p22
phox (Fontayne et al., 2002). P47
phox seems to act as an adaptor 
protein  by  generating the optimal sterical conformation enabeling p67
phox to bind to 
gp91
phox. 
The p67
phox is known as activator of the NADPH oxidase and is able to bind to NADPH 
and gp91
phox. Therefore it is likely that p67
phox is directly involved in electron transfer. 
However, translocation to the plasma membrane and cytochrome association of p67
phox 
is  dependent  on  co-translocation  of  p47
phox  and  its  prior  interaction  with  the 
flavocytochrome b558 (Fig. 2b). 
The  central  middle  part  of  p67
phox  possesses  a  PRR  domain  followed  by  two  SH3 
domains that mediate interaction with p47
phox. There is also a protein-binding module, 
PB1, which is located between two SH3 domains.The PB1 domain interacts with the PC 
motif  of  p40
phox  (Nakamura  et  al.,  1998;  Ito  et  al.,  2001)  in  the  cytosol  of  resting A. INTRODUCTION  4 
polymorphonuclear  cells.  The  N-terminus  of  p67
phox  contains  the  gp91
phox 
binding-domain or activation domain enrolled in oxidase activation. A tetratrico-peptide 
repeat  (TPR)  motif,  which  is  the  last  motif  at  the  N-terminus  end,  is  the  NADPH 
binding site of the protein (Dang et al., 2000) and includes a unique type of binding 
domain for monomeric GTPases like Rac2 (Fig. 2b). 
PX SH3 SH3 NH2 COOH
a)   p47phox PRR
Domain
Autoinhibitory
Domain
TPR SH3 SH3 NH2 COOH
b)   p67phox PRR
Domain
Activation
Domain
PB1
 
Fig. 2: Structure and major functional domains of p47
phox and p67
phox. (a) Functionally important 
domains  of  the  p47
phox  protein  include  the  amino  terminus  PX  domain,  tandem  SH3  domains,  the 
autoinhibitory domain and the proline-rich (PRR) domain. (b) The N-terminal domain of p67
phox contains 
a  tetratrico-peptide  repeat  (TPR)  motif  and  an  activation  domain  that  is  essential  for  activity  of  the 
assembled oxidase. Additionally, p67
phox contains a PRR motif followed by tandem SH3 domains with an 
intervening PB1 motif. (Quinn and Gauss, 2004). 
 
It  has  been  demonstrated  that  p67
phox  clearly  undergoes  phosphorylation  at  some 
residues  situated  at  both  C-  and  N-terminal  ends  (Dang  et  al.,  2003),  although  the 
physiological role of this event is still unclear. 
The small G-protein Rac2 (21 kDa) is a member of the Ras superfamily and is required 
to  activate  the  NADPH  oxidase.  Rac2  is  the  predominant  Rac  isoform  in  human 
neutrophils.  It  plays  essential  and  unique  roles  in  neutrophils  including  rolling  via 
L-selectin, cytoskeletal reorganization by the induction of F-actin assembly, chemotaxis 
in  response  to  several  chemoattractants,  and  superoxide  generation  in  response  to 
several agonists (e.g. phorbol 12-myristate 13-acetate (PMA) or formyl-Met-Leu-Phe 
(fMLP)) (Roberts et al., 1999; Martyn et al., 2005). 
Upon  cell  stimulation,  Rac2  is  released  from  its  cytosolic  binding  protein  Rho 
guanine-nucleoside  dissociation  inhibitor  (GDI),  translocates  to  the  membrane  and 
alternates from an inactive GDP-bound form to an active GTP-bound state. Thus, Rac2 
acquires a conformation able to interact with the TPR motif of p67
phox by its effector 
domain  (also  called  Switch  I  domain).  It  also  to  binds  directly  to  the 
flavocytochrome b558 by its insert domain in a GTP-dependent manner (Diebold and 
Bokoch, 2001). This last binding event, however, is still uncertain and an alternative 
model has been proposed where the Switch I domain of Rac2 plays a dual role in the 
GTP-dependent assembly of the oxidase. This model proposes that the N-terminal half A. INTRODUCTION  5 
of  the  Switch  I  domain  binds  to  p67
phox,  while  the  C-terminus  mediates  binding  to 
flavocytochrome b558 (Hoffman and Cerione, 2001). 
Some  other  roles  of  Rac2  in  NADPH  oxidase  assembly  and  activation  have  been 
proposed.  It  has  been  postulated  that  Rac2  acts  as  activator  of  signaling  pathways 
leading to p47
phox/p67
phox translocation in a Rac-GTP/p67
phox interaction-independent 
manner (Price et al., 2002). Additionally, other studies showed PAKs as target of Rac2 
proteins,  which  may  phosphorylate  p47
phox,  therefore  inducing  translocation  to  the 
membrane (Knaus et al., 1995). 
The particular contribution of the p40
phox cytosolic subunit of the NADPH oxidase to 
the  assembling  process  and  to  the  underlying  electron-transfer  mechanism  is  still 
unclear. P40
phox contains a single SH3 domain, an N-terminal PX domain, as found in 
p47
phox,  and  a  C-terminal  PC  motif  which  binds  to  the  PB1  domain  in  p67
phox  (as 
mentioned  above).  So  far,  it  has  been  found  in  the  cytosol  of  fractionated,  resting 
neutrophils and it has been shown not to be required for superoxide formation (Someya 
et  al.,  1993).  A  widely  accepted  theory  implies  that  p40
phox  might  play  a  role  in 
stabilizing  the  assembly  of  multimeric  complexes  of  p67
phox  and  p47
phox.  However, 
some additional roles have been postulated for p40
phox such as enhancing translocation 
to the plasma membrane by its interaction with PI-3 phosphates via the PX motif (Kanai 
et  al.,  2001),  and/or  regulating  activation  responses  dependent  on  specific  stimulus 
(Malech and Hickstein, 2007). 
S100A8 (calgranulin A) and S100A9 (calgranulin B), also designated as MRP8 and 
MRP14,  respectively,  belong  to  the  S100  multigenic  family  of  calcium-modulated 
proteins of the EF-hand type, which exhibit functions during various cellular processes 
such as cell cycle progression and modulation of cytoskeletal-membrane interactions. 
MRP8  and  MRP14  are  highly  expressed  in  neutrophils  and  macrophages  and  are 
involved in inflammation and myeloid cell maturation. Additionally, these proteins form 
MRP8/MRP14 heterocomplexes which have been shown to be secreted by activated 
monocytes. MRP8/MRP14 complexes are involved in several functions. They directly 
interact with tubulin to induce polymerization of microtubules (Vogl et al., 2004) and 
act as transport proteins carring arachidonic acid in its secreted form thereby modulating 
inflammatory processes (Kerkhoff et al., 1999). 
It is generally thought that neutrophil activation is also dependent on increase in the 
cytoplasmatic  free  calcium  concentration.  This  augment  induces  MRP  proteins 
translocation from the cytosol to the cytoskeleton and to the plasma membrane (Pozzan 
et al., 1983; Roth et al., 1993). 
More recently, a direct role for the two calcium-binding proteins in oxidase activation 
has been demonstrated in a heparin-bound purified cytochrome b558 complex. Even in 
absence of all cytosolic factors and stimulating agonists, the MRP8/MRP14 heterodimer A. INTRODUCTION  6 
is able to partially activate the oxidase. However, addition of p67
phox to the same system 
has shown to be required to obtain a fully active oxidase, suggesting a cumulative effect 
of both proteins (Paclet et al., 2007). 
A.1.3  Regulation of the oxidase assembly 
To  prevent  damage  to  surrounding  healthy  tissue  by  an  excessive  or  inappropriate 
superoxide release, the assembly of the NADPH oxidase complex must be under tight 
control. This is achieved by partitioning components of the system in different cellular 
compartments. 
In resting phagocytes only 15% of the flavocytochrome b558 is located in the plasma 
membrane  whereas  the  remaining  85%  is  stored  within  the  membrane  of  specific 
granules  and  secretory  vesicles  (Borregaard  et  al.,  1983;  Ginsel  et  al.,  1990).  The 
activating and assembling components are present in the cytosol either alone, like Rac2, 
or in complexes linked via reciprocal SH3-domain interactions, like p67
phox, p47
phox and 
p40
phox. 
NADPH oxidase assembly is triggered upon cell activation by binding of opsonized 
bacteria  or  inflammatory  mediators  to  cell  surface  receptors.  Activation  of  the  cells 
initiates several molecular events that result in membrane translocation of the cytosolic 
components and their assembly with the flavocytochrome b558 (Fig. 3). 
Briefly, the stimulated receptors initiate signaling pathways leading to the activation of 
several  protein  kinases.  These  kinases,  including  protein  kinase  C  (PKC)  mediate 
phosphorylation  of  p47
phox.  Unfolding  of  the  intramolecular,  autoinhibitory 
conformation of p47
phox is most likely the initial step in oxidase activation. The exposed 
SH3 domains are then able to mediate an interaction with p22
phox, which creates an 
optimal conformational context for p67
phox to bind to gp91
phox through its N-terminus. In 
Rac2 GDP is exchanged for GTP, then Rac2 translocates to the membrane and binds to 
p67
phox  to  complete  the  assembly.  The  role  of  p40
phox  in  this  process  is  still  under 
debate. A well accepted theory suggests that p40
phox is an inhibitory element of the 
oxidase,  which  only  functions  as  a  membrane  recruitment  mediator  in  resting  cells 
(Kuribayashi et al., 2002). Upon activation Rac2 might replace p40
phox (Rinckel et al., 
1999) and thereby release the enzymatic complex from its major inhibitor (Vergnaud et 
al., 2000). 
Each step in the assembly process seems to induce several conformational modifications 
in the different subunits in order to mediate more intimate interactions and to obtain a 
properly assembled and fully active structure (Nauseef, 2004; Sheppard et al., 2005). 
There  are  some  other  events  related  to  NADPH  oxidase  activation  including  the 
generation of arachidonic acid by phospholipase A2 and binding of the NADPH to the 
assembled complex to finally initiate electron transfer. A. INTRODUCTION  7 
 
Fig. 3: Model for the activation and assembly of the NADPH oxidase. Changes in the phosphorylation 
state of p47
phox induce unfolding from an autoinhibitory conformation. This leads to activation and to 
unmask essential binding domains. The exposure of PX domains of p47
phox facilitates translocation to the 
cell  membrane.  Final  interaction  of  the  p67
phox  and  Rac2  with  flavocytochrome  b558  induces 
conformational change, resulting in electron flow (Quinn and Gauss, 2004). 
 
Thus,  the  oxidase  becomes  activated  in  the  phagosomal  membrane  of  neutrophils 
producing  high  concentrations  of  superoxide  into  this  compartment  with  subsequent 
generation  of  additional  ROS.  Superoxide  anion  radical  (O2
-)  can  react  to  generate 
hydrogen superoxide (H2O2) in a reaction known as dismutation. In the presence of iron, 
superoxide  and  H2O2  react  to  generate  hydroxyl  radicals.  In  inflamed  areas  the 
phagocyte  enzyme  myeloperoxidase  (MPO)  form  hypochlorous  acid  from  H2O2  and 
chloride; as well as singlet oxygen, by catalyzing the oxidation of halide ions. Recently, 
it has been shown that also ozone can be generated by exposure of singlet oxygen to 
antibodies normally bound to microorganisms (Cross and Segal, 2004). 
Although the high production of ROS is generally assumed to be the anti-microbial 
mechanism  of  polymorphonuclear  (PMN)  cells,  some  other  theories  have  been 
described. It is possible that the depolarizing effect of ROS in the plasma membrane and 
its  further  compensating  flux  of  H
+  and  K
+  into  the  phagosome  mediates  killing of 
microorganisms through ionic activation of proteases (Reeves et al., 2002). 
Ultimately, the inactivation of the oxidase is the result of a shift in the balance between 
the activating and deactivating signals. The phosphorylation and hyperphosphorylation A. INTRODUCTION  8 
of p47
phox, an increase in the rate of GTP hydrolysis on Rac2 and the disassembly of the 
complex  are  the  major  factors  contributing  to  the  termination  of  NAPDH  oxidase 
activity (Decoursey and Ligeti, 2005). 
A.1.4  Molecular defects 
Mutations in one of the four genes coding for the essential subunits of the NADPH 
oxidase (gp91
phox, p47
phox, p67
phox and p22
phox) lead to CGD (1:200.000 births). 
Approximately 75% of the 410 known defects are due to mutations in the gp91
phox gene 
(CYBB, GenBank accession number X04011). This gene maps to the X chromosome 
(Xp21.1 locus) resulting in an X-linked mode of inheritance. Therefore, males bearing a 
gp91
phox  mutation  will  be  affected  and  females  who  inherited  the  mutation  will  be 
carriers. The carrier state for a gp91
phox defect is also detrimental, depending on the 
percentage  of  normal  neutrophils.  During  embryogenesis  one  of  the  two 
X chromosomes  present  in  female  cells  undergoes  lyonization,  a  random  process  of 
inactivation by packaging of one of the X chromosomes in repressive heterochromatin. 
This is required for the so-called dosage compensation, so that the female does not have 
double the amount of X chromosome gene products as compared to male individuals 
(Mills et al., 1980). There appears to be no selective advantage for functional cells over 
non functional cells. Some female carriers presenting 5-10% functional cells are healthy 
whereas others have experienced symptomatology resembling CGD (Johnston et al., 
1985; Woodman et al., 1995). These observations suggest that not only the presence of 
healthy cells is important, but also the levels of superoxide production within individual 
cells. 
The  remaining  cases  (about  25%)  of  CGD  are  autosomal  recessively  (AR-CGD) 
inherited and therefore equally distributed between males and females. About 25% of all 
AR-CGD  cases  are  caused  by  mutations  in  the  NCF1  gene  (7q1.23  locus)  which 
encodes the p47
phox protein. Deficiencies in the NCF2 gene (1q25 locus) which encodes 
p67
phox represent only about 5% of cases, and aberrant p22
phox encoded by the CYBA 
gene (16q24 locus), are even less common. 
Rac2 deficiency causes severe neutrophil dysfunction, actin dysfunction, predisposition 
to  bacterial  infections  similar  to  CGD,  and  leukocyte  adhesion  deficiency  type  1 
(LAD-1), as observed in an infant with dominant-negative mutation in Rac2. Although 
Rac2  is  not  essential  for  superoxide  formation,  clearly  there  is  an  agonist-specific 
deficiency in oxidase function (Williams et al., 2000). Moreover, genetic defects neither 
in p40
phox nor in MRP8/14 have been reported for CGD so far. 
About 95% of all mutations identified in these genes result in a complete absence or 
greatly reduced level of the corresponding protein. The mutations include partially or 
completely deleted genes, aberrant protein expression or mutations that affect mRNA A. INTRODUCTION  9 
stability (Kaneda et al., 1999). In the remaining 5% of cases the presence of a normal 
oxidase does not imply the absence of phenotype (Barese and Goebel, 2006). In these 
cases  immunological  crossreaction  against  the  oxidase  also  leads  to  the  absence  of 
superoxide  production.  Alternatively,  loss-of-function  mutations  possibly  result  in 
normal  protein  levels  but  they  are  inactive  or  only  weakly  active  (Heyworth  et  al., 
2003).  Therefore,  a  classification  of  several  phenotypic  subtypes  depending  on  the 
expression level of the oxidase, assessed by immunoblot analysis, was established. The 
subtypes  are  referred  to  as  X91,  A47,  A67,  and  A22,  with  superscripts 
0, 
-,  or 
+ 
indicating absent, low or normal protein levels, respectively (Heyworth et al., 2003). 
A.1.5  Current therapy for CGD 
The survival of CGD patients has vastly improved due to early diagnosis of the disease, 
advancements  in  identification  of  acute  infections  and  their  prompt  and  aggressive 
treatment with intravenous broad-spectrum antibiotics or antifungal drugs (for example, 
Amphotericin  B  and/or  Intraconazol).  Although  lifelong  prophylactic  antibacterial 
handling has also been crucial for the observed reduction in the incidence of infections; 
the overall mortality is still about 5% per year for X-CGD patients and 2% per year for 
patients with AR-CGD (Assari, 2006; Barese and Goebel, 2006). 
Recombinant human interferon gamma (IFN-γ) is used to treat CGD patients because it 
partially  corrects the CGD phenotype in selected patients with low gp91
phox activity 
(Ezekowitz et al., 1988). Normally, IFN-γ is secreted from CD4
+ Th1 cells, CD8
+ cells, 
γ/δ T cells and activated NK cells. It plays a role in activating lymphocytes to enhance 
anti-microbial  and  anti-tumor  effects.  In  addition  it  regulates  the  proliferation, 
differentiation, and the response of lymphocyte subsets. A follow up study of 76 patients 
demonstrated that the prolonged use of recombinant IFN- γ in CGD patients is safe and 
its  administration  correlates  with  a  persistent  reduction  in  the  frequency  of  serious 
infection  and  mortality  (Weening  et  al.,  1995).  However,  the  mechanism  by  which 
IFN-γ may enhance oxidase activity is not well understood (Ahlin et al., 1999; Ishibashi 
et al., 2001). 
As a disease that affects the myeloid cell compartment of the hematopoietic system, 
CGD has been cured by matched sibling or unrelated allogeneic bone marrow (BM) 
transplantation several times (Hobbs et al., 1992; Ho et al., 1996). In a retrospective 
study  with  27  patients  underwent  human  leukocyte  antigen  (HLA)-identical 
hematopoietic stem cell (HSC) transplantation after myeloablative conditioning. About 
80% of the cases (22 of 27) reached a cure of the disease, even if pre-existing infections 
resistant  to  conventional  therapies,  inflammation  or  inflammatory  sequelae  were 
present. The overall survival rate was 89%; the 4 patients that died after transplantation 
belonged to a group of patients with one or more contra-indications. In one case the 
reinfused  HSC  cells  did  not  engraft  after  immunosuppressive  conditioning  and  had A. INTRODUCTION  10 
autologous  reconstitution.  This  implies  that  transplantation  of  unmodified  HSC  in 
combination with myeloablative regimen is a valid therapeutic option for CGD patients 
having an HLA-identical donor (Seger et al., 2002). 
If there is a lack of a suitable donor for the patients, allogeneic BM transplantation is not 
commonly recommended to treat CGD for several reasons. First, the limited availability 
of  highly  compatible  donors.  Second,  the  risk  of  infections  during  myeloablative 
conditioning  and  post-transplant  immunosuppression.  Third,  the  occurrence  of 
graft-versus-host disease (GVHD). Therefore, the genetic modification of autologous 
hematopoietic stem cells represents a real alternative. Moreover, even correction of a 
minority  of  leukocytes  could  likely  lead  to  a  clinical  improvement,  since  partial 
chimerism in X-CGD females carriers has been observed (Mills et al., 1980; Johnston et 
al., 1985) and after allogeneic bone marrow transplantation often lead to reduced or 
absent symptomatology (Kamani et al., 1988; Hobbs et al., 1992). 
A.2  Gene therapy 
Gene therapy is a promising biomedical technology that uses nucleic acid transfer, either 
RNA or DNA, to treat or prevent a disease (Mulligan, 1993). Gene therapy attempts to 
reach a direct, long-term curative effect by restoring the gene defect rather than to treat 
the symptomatology as almost all conventional therapies do. Although it was considered 
as  a  curative  therapy  per  se,  it  may  also  be  regarded  as  a  complementing  or  an 
improving strategy for conventional therapies (Robbins and Ghivizzani, 1998). 
Several  diseases  are  proposed  as  good  candidates  for  gene  therapy.  Cancer  diseases 
represent almost 70% of all gene therapy trials up to date and the remaining 30% is 
shared between cardiovascular and neurological diseases, monogenic hereditary diseases 
and infectious diseases (preferentially HIV/AIDS) (Chuah, 2005). 
There  are  many  requirements  for  a  successful  gene  therapy,  including  a  clear 
understanding  of  the  pathogenesis  of  the  disease  with  extensive  knowledge  of  the 
molecular defect(s), the availability of an effective therapeutic gene(s), an appropriate 
target tissue or cell for gene delivery, and an animal model that closely simulates the 
disease for preclinical studies (Robbins and Ghivizzani, 1998). 
A  gene  therapy  vector  is  a  vehicle  that  delivers  the  therapeutic  sequence  into  the 
patient’s target cells. There are several vectors available and the choice of the most 
appropriate one for each particular disease is crucial for the outcome of the therapy. 
Many factors must be taken into consideration. One important factor determining the 
choice of vector type is the delivery method; e.g. if the gene transfer has to be done in 
the body of the patient by injection, inhalation or cutaneous application (in vivo) or if 
into subrrogate viable cells that have been temporarily removed from the patient and are 
subsequently  transferred  back  into  the  target  tissue  (ex  vivo)  (Wood  and  Fry,  1999; A. INTRODUCTION  11 
Selkirk, 2004). The ex vivo delivery is clearly more time consuming, expensive, and 
cumbersome, but permits selection of the genetically altered cells before re-implantation 
(Evans et al., 1998). Other factors that play a role in the selection of the best gene 
transfer system are i) the timing of expression needed (length or special time points), ii) 
the  type  and  dividing  state  of  the  target  cell,  iii)  the  size  of  the  transgene,  iv)  the 
efficient and easy production of the vector, v) the risk of an immune response against 
proteins encoded by the vector, vi) the requirement to administer the vector more than 
once and vii) the safety and regulatory issues (Wood and Fry, 1999; Pfeifer and Verma, 
2001). 
A.2.1  Gene transfer vector systems and their application 
Several systems have been or are being developed ranging from non-viral vectors to 
viral-based vectors. Unfortunately, there is no such thing as a ‘perfect universal vector’; 
the  vectors  that  are  currently  available  all  have  both  advantages  and  disadvantages. 
Some of the actual vectors and their characteristics are represented in Table 1. 
Table 1: Classification and characteristics of gene transfer vectors  
Vector classification  Advantages  Disadvantages 
Gammaretroviruses 
(ssRNA) 
•  Permanent integration 
•  Well characterized 
•  No immune response against vector 
•  Long term expression 
•  About 8 kb packaging capacity 
•  Ease of production 
•  Infects only dividing cells 
•  Insertional mutagenesis 
•  Low titers 
Lentiviruses (dsRNA) 
•  Permanent integration 
•  Infects non-dividing cells 
•  High titers 
•  About 8 kb packaging capacity 
•  Stable expression 
•  Insertional mutagenesis 
Adenoviruses (dsDNA) 
•  High titers 
•  Infects non-dividing cells 
•  Up to 36 kb packaging capacity 
•  Broad infectivity 
•  Life threatening immunogenicity 
•  Short term expression 
•  Does not integrate 
Adeno-associated 
viruses (ssDNA) 
•  Broad infectivity 
•  Infects non-dividing cells 
•  Non-cytophatic 
•  Stable expression 
•  Low immunogenicity 
•  <5 kb packaging capacity 
•  Limited integration (10% 
integrated and 90% episomal) 
•  Lower transduction efficiency 
than adenovirus 
Liposomes  •  Avoids use of cytopathic virus 
•  Cell-specific targeting 
•  Low efficiency of transfection 
Ballistic delivery  •  Simple method 
•  Requires “exposed” tissues or 
cells 
•  Transient expression 
Direct DNA injection  •  Simple method  •  Short-term expression 
(Wood and Fry, 1999; Selkirk, 2004; O'Connor and Crystal, 2006) 
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The major advantages of non-viral vectors lie in the large size capacity for therapeutic 
DNA and in the fact that they are generally safer as they don’t elicit major immune 
responses.  Thus,  at  least  theoretically,  they  represent  the  best  choice.  However,  the 
drawbacks are three fold. These systems are far less efficient in nucleic acid transfer to 
the nucleus in comparison to viral vectors, the expression of transgene is transient and 
DNA vectors are rapidly inactivated in the presence of serum (Lechardeur and Lukacs, 
2002; Witlox et al., 2007). 
Up to date about 70% of the gene therapy trials have used viral vectors derived from 
naturally infecting viruses. The adenovirus-based vectors are the most commonly used 
vectors  (25%  of  all  the  gene  therapy  trials).  They  are  efficient  vehicles  with  high 
transduction  efficiency  and  high  level  of  gene  expression.  However,  their  genetic 
material  does  not  integrate  into  cell  genome  and  is  not  replicated  at  cell  division. 
Therefore,  usage  of  these  viruses  is  not  appropriate  for  therapies  which  require 
transmission  of  the  transgene  also  into  the  derivative  cells  (Evans  et  al.,  2001). 
Additionally, the adenoviral vectors are known to elicit strong immunogenic reactions, 
an undesired side effect which has promoted further improvement of the system. The 
most common strategy is based on deletion of all coding non-essential viral regions 
apart from the packaging signal and the inverted terminal repeats which are needed for 
genome  packaging  and  replication.  To  generate  viral  particles  of  these  so-called 
helper-dependent or gutless adenoviruses, all viral genes and the proteins needed for its 
genome  replication,  packaging  and  capside  formation  are  supplied  in  trans  by 
coinfecting  the  virus  producing  cells  with  helper  virus.  Although  this  system  has 
reduced  the  immunogenicity  and  toxicity  of  these  vectors  and  has  increased  the 
packaging  capacity  of  transgenic  DNA  up  to  36  kb,  technical  limitations  make
  it 
extremely difficult to obtain vector stocks devoid of replication-competent
 particles. The 
replication-competent particles account for 0.1–1% of all of the viral
 particles present. 
This drawback may hinder their general use in clinical applications especially when high 
doses need to be administrated. These stocks may therefore be strongly immunogenic 
(Dai et al., 1995; Schiedner et al., 1998; Raper et al., 2003). Nowadays, new systems 
are  being  developed  to  reduce  or  even  avoid  the  packaging  of the helper vector by 
flanking the packaging region of the helper virus with loxP sites or attP/attB sites, which 
are then induced to recombine in coinfected recombinase-expressing cells. Thus, the 
packaging region of the helper virus is eliminated avoiding packaging of the helper 
adenovirus (Ng et al., 1999; Alba et al., 2007). 
In those cases where a steady protein expression in the target cell and its progeny is 
required only retroviral and adeno-associated viral (AAV) vectors are able to promote 
stable  integration  into the genome and therefore remain life-long within the cellular 
genome. It was previously observed that in the absence of a helper virus, wild-type 
AAV  integrates  by  site-specific  recombination  into  chromosome  19  of  the  host  cell 
genome. Therefore AAV vectors were believed to mediate stable protein expression in A. INTRODUCTION  13 
the target cell and its progeny by a site-specific integrative gene transfer mechanism 
(Coffin,  1992).  However;  recent  data  suggest  that  although  AAV  vectors  drive 
long-term expression of the transgenes, they integrate randomly into the host genome at 
sites of dsDNA breaks in a very inefficient manner (Miller et al., 2004). The majority of 
AAV vectors seems to persist in tissues as tandemly organized episomes formed by 
head-to-tail recombination (McCarty et al., 2004) which are the responsibles for the 
long-term expression found in preclinical and clinical trials (Schnepp et al., 2005; Choi 
et al., 2006). Furthermore, AAV vectors display two more disadvantages limiting their 
possibility  of  application.  Their  restricted  packaging  capacity  is  less  than  5  kb,  and 
large-scale production of the virus is very inefficient (Seth, 2005). 
In contrast to AAV, the proviral DNA of retroviruses efficiently integrates in the target 
cell  genome,  which  is  an  essential  step  in  their  replication  cycle.  In  this  way, 
retrovirus-based  vectors  ensure  chromosomal  integration  and  life-long  persistence of 
viral genomes into the infected cell and their daughters. However, it has been shown 
that  retroviral  vectors  may  also  bring  about  untoward  side  effects  related  to  their 
inherently mutagenic capacity after genome integration. This phenomenon is also known 
as  insertional  mutagenesis  (for  more  details  see  A.2.2.3  Self-inactivating  retroviral 
vectors and A.2.3 Success and risks of gene therapy). 
Nevertheless, 23% of all gene therapy trials have used retrovirus-based vectors while 
AAV were used in only 3.7% of studies. These numbers underline the usefulness and 
success  of  the  retroviral  vectors  in  preclinical  studies  which  is  mainly  due  to  the 
achieved therapeutic effect and its observed biological safety (Fig. 4). 
Fig. 4: Vectors used in Gene Therapy Clinical Trials. 
http://www.wiley.co.uk/genetherapy/ 
 
A.2.2  Retroviral vectors 
Retroviruses are RNA viruses belonging to the viral family of Retroviridiae. Some of 
them are pathogenic in humans leading to diseases such as immunodeficiencies and 
neurological disorders or malignancies. Retroviruses are classified into three genera: the 
gammaretroviruses including the Murine Leukemia Virus (MLV), the lentiviruses to A. INTRODUCTION  14 
which classifies the Human Immunodeficiency Virus 1 (HIV), and the spumaviruses 
with the Human Foamy Virus (HFV) as prototype of the genus (Coffin et al., 1997; 
Heneine et al., 1998). 
A.2.2.1  Retroviruses and their replication 
Retroviruses are enveloped viruses that carry a 7–12 kb RNA genome which is linear, 
single-stranded, nonsegmented, and of positive polarity. Through the attachment of their 
surface glycoproteins (SU) to specific plasma membrane receptors, retroviruses enter 
the host cell. The association between SU and the receptor is a highly specific event, and 
is required to trigger a conformational change of the viral transmembrane (TM) protein 
(Fig. 5b). 
 
Fig. 5: The retroviral life cycle (Goff, 2007). See text for detailed information. 
 
The fusion of the lipid bilayers of the cell with the viral membrane is initiated by this 
interaction (Coffin et al., 1997), either directly at the cell surface or after internalization 
by an endocytic route (Mothes et al., 2000; Katen et al., 2001). This allows delivery of 
the virion core (RNA) into the cytoplasm. Reverse transcription of the viral RNA into 
double-stranded  linear  DNA  is  initiated  in  the  cytoplasm  in  the  context  of  a  large 
complex;  the  reverse  transcription  complex  (RTC).  Viral  DNA  synthesis  may  be 
completed before (e.g. MLV) or after delivery into the nucleus (Fig. 5a). Delivery is 
supported  by  the  formation  of  preintegration  complexes  (PIC)  containing  a  double 
stranded DNA copy of the viral genome together with a number of viral and cellular 
proteins required for subsequent incorporation of viral DNA into the host’s genome 
(Fassati and Goff, 2001). Upon integration, the provirus achieves the status of a cellular 
gene and can be transcribed by the cellular RNA polymerase II (Fig. 5b). The viral DNA 
is transcribed and the viral RNAs are processed and exported out of the nucleous into 
the  cytoplasm  by  a  highly,  redundant,  regulated  mechanism.  Three  viral  structural A. INTRODUCTION  15 
protein  precursors  are  translated  in  the  cytoplasm  and  transported  to  the  plasma 
membrane. Nascent virions are assembled from these proteins on host membranes, and 
immature particles are released from the cells. Finally maturation of the virions, results 
in a reorganization of the core and the acquisition of virus infectivity (Goff, 2007). 
Retrovirus genomes commonly contain three essential genes, among other accessory 
genes. They encode three proteins with multiple functions in the mature virus.The gag 
protein directs the synthesis of internal virion proteins that form the matrix, the capsid, 
and  the  nucleoprotein  structures.  The  pol  protein  codes  for  a  reverse  transcriptase, 
integrase and protease.The env protein is initially synthesized as a larger poly-protein 
from  which  the  envelope  proteins  SU  and  TM  are  derived  after  translation.  An 
additional, smaller, coding domain, pro, which encodes the virion protease is commonly 
found between gag and pol genes. Gag, pro and pol genes are transcribed in a single 
unique  transcript,  which  undergoes  posttranscriptional  processing  to  generate  the 
required proteins. The messenger RNA (mRNA) of env is a subgenomic RNA, created 
by alternative splicing of the polycistronic gag-, pro- and pol-coding mRNA (Fig. 6 and 
Fig. 7). 
Two identical repeats, the long terminal repeats (LTR), are placed at both ends of the 
integrated  proviral  DNA.  These  noncoding  sequences  contain  the  major  regulatory 
elements for viral gene expression (promoter, enhancer and polyadenylation signals) and 
can  be  divided  into  three  elements:  U3,  R  and  U5.  The  promoter  region,  with  the 
regulatory sequences such as the TATA box and the transcription start site are situated 
at the 5’LTR, and the polyadenylation signal is found at the boundary between R and U5 
of the 3’LTR (Fig. 7). 
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Fig. 6: Schematic representation of a retroviral particle. Two copies of the single stranded genomic 
RNA  are  packaged  in  a  viral  particle.  The  capsid  contains  the  viral  RNA  in  interaction  with  the 
nucleoproteins. Three enzymatic proteins (reverse transcriptase, protease and integrase) are also packaged 
into the capsid. The matrix interconnects the capsid with the outer envelope that is formed by a lipid 
bilayer of cellular origin in which complexes of viral proteins (SU and TM) are inserted. 
 
The origin of the LTR duplications lies in the process of reverse transcription, where the 
enzyme jumps from one end of the template to the other. The new viral genomic RNA, A. INTRODUCTION  16 
transcribed  from the integrated DNA, spans the entire coding region and contains a 
sequence  named  psi  (Ψ)  which  is  important  in  the  viral  replication  process.  The  Ψ 
sequence is located at the 5’ untranslated region (5’ UTR), or leader, and represents a 
packaging signal. Thus all Ψ-containing RNA molecules, and no other, are efficiently 
packaged into the new emerging virions (Coffin et al., 1997). Furthermore, the leader 
region contains the primer binding site (PBS) and the splice donor site (SD) required as 
regulatory sequences for the splicing event that drives translation of the env gene. The 
PBS  is  the binding site for a transfer RNA that functions as the primer for reverse 
transcriptase which initiates synthesis of the minus (-) strand complementary to the viral 
RNA. 
Gammaretroviruses depend on an actively dividing host cell for replication (Miller et 
al., 1990). Viral entry and DNA synthesis can be completed at normal rate in all stages 
of  the  cell  cycle.  However,  complete  DNA  integration  is  dependent  on  nuclear 
membrane disassemble during mitosis (Roe et al., 1993). Besides gammaretroviruses, 
lentiviral PICs are able to penetrate the nucleus and mediate integration, also in non-
dividing cells (von Schwedler et al., 1994). Although nuclear localization signals and 
removal of capsid protein from the PICs have been proposed as mediators of this event, 
this process is still unclear (Dismuke and Aiken, 2006; Fassati, 2006; Hearps and Jans, 
2006). 
   
Fig. 7: Schematic representation of the generalized retrovirus genome. The proviral DNA integrated 
into the genomic DNA of the host cell is shown at the top. The genomic transcript is shown on the second 
line and the spliced messenger RNA for the Env protein is shown on the third line. 
 
A.2.2.2  Gene therapy vectors derived from retroviruses 
The  extensive  investigations  and  the  obtained  deep  knowledge  of  the  retroviral 
replication system have been crucial for the development of retroviral-based vectors. 
Safety issues and enhanced properties for both the transgene expression as well as the 
increase  in  titer  of  viral  particles  were  achieved.  The  establishment  of  a 
three-component system, the pseudotyping of viral particles (transductional targeting), A. INTRODUCTION  17 
the  use  of  cis-actin  modules  for  improvement  of  virus  production  and  transgene 
expression  and  the  transcriptional  targeting  of  transgenes  all  contributed  to  the 
development of safe and efficient retroviral gene therapy vectors. 
The three-component system was introduced as a result of the need for larger transfere 
inserts  and  safety  reasons.  This  system  consists  in  a  three  vector  packaging  design 
(Markowitz et al., 1988). The vector construct carrying the transgene contains merely 
the LTR sequences needed for integration of the virus into the target cell and the Ψ 
signal for packaging the genomic viral RNA into the viral capsid. The gag, pol, and env 
genes,  which  are  essential  for  the  normal  replication  cycle,  are  separated  onto  two 
different  plasmids  (helper  plasmids)  in  which  the  Ψ  signal  and  LTRs  are  removed 
(Fig. 8). 
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Fig. 8: Representation of gammaretroviral particle production and transduction of a target cell. See 
text for detailed information. 
 
In the case of lentiviral vectors, viral accesory sequences are commonly included in the 
transfer and helper plasmid such as the Rev Response Element (RRE) and the rev gene 
sequence since they have shown to be involved in the cytoplasmatic accumulation of 
viral  RNA  (Coffin  et  al.,  1997).  These  three  plasmids  are  then  co-transfected  into 
producer  cells.  The  helper  plasmids  give  rise  to  all  the  components  required  for 
formation of the new viruses. The retroviral vector is transcribed and encapsidated in the 
emerging virions. These new virions are able to infect cells and promote integration of 
the transgenes into the cellular genome, but no viral particles can be further generated 
(Fig.  8).  This  system  not  only  offers  more  space  for  transgene  sequences  into  the 
transfer vector, but also avoids the possibility of homologous recombination between 
the three plasmids which could give rise to replication-competent retroviruses (Miller 
and Buttimore, 1986; Miller et al., 1986b). Nowadays, there are some packaging cell A. INTRODUCTION  18 
lines available which are stably transfected with the gag, pol and env genes. None of 
them contains the Ψ sequence avoiding the formation of replication competent particles 
after transient transfection of the transfer vector. 
The  host  range  of retroviral vectors is defined by the specificity of the SU/receptor 
interaction  and  can  be  expanded  or  altered  by  a  process  known  as  pseudotyping. 
Pseudotyped  vectors  consist  of  vector  particles  bearing  glycoproteins  (GPs)  derived 
from  other  enveloped  viruses.  Such  particles  possess  the  tropism  of  the  virus  from 
which  the  GP  was  derived.  However,  not  every  combination  of  envelope  GP  and 
retroviral core give rise to highly infectious pseudotyped particles. The viral assembly 
and  budding  seems  to  be  governed  by  the  intracellular  trafficking  and  the  direct  or 
indirect interaction between these two elements (GP and core) (Sandrin and Cosset, 
2006; Bouard et al., 2007). 
Murine  leukemia  virus  (MLV)  core  particles  are  efficiently  pseudotyped  with  many 
surface  proteins  from  most  heterologous  retroviruses  and  from  many  families  of 
enveloped  viruses  (Kolokoltsov  et  al.,  2005).  Among  others,  two  envelopes  are 
extensively used for pre-clinical and clinical studies due to their attractive cell tropism, 
the envelopes of Gibbon-ape Leukemia Virus (GaLV) and Feline Endogenous Virus 
(RD114). GaLV pseudotyped gammaretroviral vectors have shown great viral particle 
stability and excellent gene transfer efficiencies for primary T lymphocytes and human 
hematopoietic  cell  (CD34
+)  (Bauer  et  al.,  1995; Bunnell et al., 1995; Uckert et al., 
2000).  RD114  pseudotyping  has  shown  to  promote  efficient,  single  exposure 
transduction  of  human  repopulating  cells  capable  of  establishing  multilineage 
hematopoiesis in immunodeficient mice (Kelly et al., 2001). 
Vesicular  stomatitis  virus  glycoprotein  (VSV-G)  is  one  of  the  most  efficiently  used 
envelopes for lentiviral vectors derived from Human immunodeficiency virus (HIV) and 
Simian  Immunodeficiency  Virus  (SIV)  (Sandrin  et  al.,  2004).  VSV-G  pseudotyping 
implies not only an efficient assembly and budding of viral particles but also expands 
the host range of cell and tissue types, and allows efficient concentration of virions to 
produce  high-titer  vector  stocks  (Akkina  et  al.,  1996).  However,  it  has  two  main 
drawbacks;  the  cellular  toxicity  if  expressed  continouslly  at  high  levels  and  its 
inactivation in the presence of human serum (Cronin et al., 2005). 
The  tropism  of  the  RD114  and  GaLV  viruses  is  of  great  interest  also  for  lentiviral 
vectors;  however,  these  combinations  of  GP  and  transfer  vector  showed  reduced 
infectivity.  Therefore,  an  alternative  to  VSV-G  pseudotyping  was  developed  by 
replacing the cytoplasmatic tail of the RD114 and GaLV envelope with that of MLV GP 
or by replacing the env cleavage site sequence with a HIV protease site. Both strategies 
have been tested resulting in increased titers and preserving the host range of the former A. INTRODUCTION  19 
GPs (Christodoulopoulos and Cannon, 2001; Sandrin et al., 2002; Di Nunzio et al., 
2007). 
Moreover,  engineered  peptide  ligands  are  currently  being  developed  for  cell  surface 
receptors  into  retroviral  recombinant  Env  glycoproteins  currently.  This  enhances  the 
efficient targeting of specific cell types. However, these attempts are still hampered by 
low  transduction  efficiencies  and  further  investigations  are  required  (Maurice  et  al., 
2002; Verhoeyen et al., 2005). 
Known sequences that improve post-transcriptional processing and RNA transport from 
the  nucleus  into  the  cytoplasm  are  splice  sites  (SS),  post-transcriptional  regulatory 
elements (PRE) and the retroviral constitutive RNA transport elements (CTE). 
Cellular  pre-mRNAs  that  retain  functional  splice  sites,  are  actively  retained  in  the 
nucleus by splicing commitment factors (Chang and Sharp, 1989; Legrain and Rosbash, 
1989). Efficient splicing may promote mRNA export and translation. Thus, introduction 
of SS creating artificial introns may increase the transgene expression level when placed 
in the 5’ untranslated region (UTR) of the transgene (Huang and Carmichael, 1996; Luo 
and Reed, 1999). 
On  the  other  hand,  unspliced-RNA  is  required  to  complete  retroviral  replication. 
Therefore many retroviruses have evolved several systems to evade the requirement for 
splicing in nuclear export of RNA. Complex retroviruses (including lentiviruses) use 
virally encoded proteins (e.g. the Rev protein of lentiviruses) to couple the export of 
intron-containing viral RNAs to the Crm1 pathway of the host cell. In contrast, simple 
retroviruses such as the gammaretroviruses act through cis-acting RNA export elements 
termed constitutive transport elements (CTE) which bind to the cellular tip-associated 
protein (TAP) (Bray et al., 1994; Gruter et al., 1998). 
Besides the above mentioned systems, the PRE of woodchuck hepatitis virus (WPRE) 
has shown to act independently of transcription and splicing. With this element, the 
nuclear export of the viral RNA is directly coupled to the Crm1 pathway (Popa et al., 
2002).  If  the  WPRE  sequence  is  introduced  into  the  3’  untranslated  region  of  both 
gammaretroviral  and  lentiviral  vectors  it  is  possible  to  enhance  both  virus  titer  and 
transgene expression by 2-10 fold in many cell types (Ailles and Naldini, 2002; Kraunus 
et al., 2004). The ability of the WPRE to act directly and independent of the presence or 
absence of the Rev system when positioned in the 3’ UTR, indicates additional effects 
on the termination and/or polyadenylation process (Popa et al., 2002). However; the use 
of the WPRE sequence also containing fragments of the promoter and protein coding 
sequences  of  the  WHV  X  protein  raised  concerns  about  the  safety  in  clinical 
applications (Kingsman et al., 2005). Several studies have shown that expression of the 
X-gene  is  linked  to  liver  oncogenesis  under  some  circumstances  (Terradillos  et  al., 
1997; Kim et al., 1998). Therefore, a modified version devoid of promoter and residual A. INTRODUCTION  20 
open  reading  frames  (ORFs)  was  developed  thereby  reducing  the  potential  harmful 
effects, but retaining the beneficial effects on titer and transgene expression (Schambach 
et al., 2006a). 
Cell- or tissue-specific transgene expression, also known as transcriptional targeting, 
may  be  achieved  by  utilization  of  tissue-specific  regulatory  sequences  to induce the 
expression  of  the  therapeutic  genes  only  in  a  determined  cell  type.  Conventional 
transcription from retroviral vectors is dependent on promoter and enhancer elements 
located in the U3 region of the LTR, which impel in almost all the cases, a constitutive 
expression. Although an independently controlled transcriptional unit can be introduced 
in the backbone, the expression obtained is usually influenced by the activity of the 
LTR. Some strategies have been proposed to solve this problem. One approach is the 
replacement  of  the  constitutive  transcriptional  control  elements  (promoter  and 
enhancers)  within  the  U3  region  of  the  retroviral  LTR  with  cell-specific  promoter 
sequences (Moore et al., 1991; Ferrari et al., 1995; Diaz et al., 1998; Jager et al., 1999). 
Another alternative is the use of a self-inactivating vector configuration (see below). In 
this  case  an  internal  promoter  is  required  to  drive  transgene  expression  since 
SIN-vectors  originate  integrated  proviruses  lacking  the  LTR  promoter/enhancer 
sequences (Yu et al., 1986; Dai et al., 2004; Almarza et al., 2007). 
A.2.2.3  Self-inactivating retroviral vectors 
As already mentioned, the integration of retroviral vectors in the host genome could lead 
to the transactivation of hit genes due to the presence of enhancer/promoter elements in 
the LTRs. If the retroviral insertion occurs near to, or into proto-oncogenes this might 
lead  to  clonal  dominance  or  even  malignant  transformation.  Recent  preclinical  and 
clinical studies have demonstrated that the potential of the insertional mutagenesis event 
to generate clonal imbalance or leukemic outgrowth is even higher than predicted (Otsu 
et al., 2000; Soudais et al., 2000). This difference is due to the semi-random integration 
pattern  of  the  used  vectors.  MLV  derived  vectors  strongly  tend  to  integrate  in 
transcriptional  units  preferentially  near  transcriptional  start  sites  and  CpG  islands 
whereas  HIV-1  and  related  lentiviral  vectors  favor  insertions  within  the  transcribed 
regions (Laufs et al., 2003). Recently these differences have been mainly attributed to 
the  integrase  gene  and  associated  cellular  factors  (Lewinski  et  al.,  2006).  Both 
insertional strategies may be deleterious and most likely deregulate expression of the 
affected gene or disrupt active transcription units in the case of lentiviral vectors. 
To  prevent  undesired  transcriptional  effects  on  the  internal  transgene  and  hit  genes 
caused  by  the  enhancer  and  promoter  in  the  LTRs,  self-inactivating  vectors  were 
constructed by deleting the transcriptional enhancers and promoter in the U3 region of 
the 3’ LTR. After one round of vector replication, these changes are also copied into 
both the 5’ LTR producing an inactive provirus. The transcription of the therapeutic A. INTRODUCTION  21 
gene should then be driven by an internal promoter placed downstream of the RNA 
packaging  signal  and  immediately  upstream  of  the  transgene  (Yu  et  al.,  1986; 
Dougherty and Temin, 1987; Hawley et al., 1987). 
The first drawback of this strategy is the suboptimal RNA processing that leads to a 
lower virus titer obtained with the self-inactivating vectors in comparison with their 
LTR-driven  counterparts  (at  least  ten-fold  lower).  Lower  titers  implies  higher 
manipulation of target cells which could lead to a decrease in the repopulation capacity 
(Guenechea et al., 2000; Puig et al., 2002). Moreover, the concentration of infectious 
virions  was  found  to  be  critical  since  higher  virus  titers  promote  more  efficient 
transduction than promoted by a longer exposure to a large volume of virus suspension 
with a low titer (Miller et al., 1986a; Hogge and Humphries, 1987). This problem was 
solved by the incorporation of cis-acting modules to enhance both RNA processing in 
packaging cells and transgene expression (see above). With this strategy new vectors 
were  designed  with  an  increased  safety  and  enhanced  viral  particle  production 
(Schambach  et  al.,  2000;  Schambach  et  al.,  2006c).  In  vitro  studies  with  primary 
hematopoietic cells infected with SIN viral vectors containing a strong internal promoter 
still  have  transforming  abilities  caused by insertional mutagenesis, but this occurred 
with significantly lower frequency than their LTR-driven counterparts (Modlich et al., 
2006). Additionally, recent studies have shown that the characteristics of the internal 
promoter  used  are  also  an  important  issue.  For  example,  the  incorporation  of  more 
physiological promoter sequences (such as the human elongation factor 1α promoter 
(Schambach et al., 2006b)) or promoters which are less dependent on enhancer elements 
may further decrease the potential of insertional activation (Baum et al., 2004). 
The onset and harmfulness of clonal imbalances, both non-malignant and malignant, 
might  be  associated  with  the  up-regulation  of  a  cellular  proto-oncogene  near  the 
integration site as well as due to several characteristics of the virus used. They include 
vector dose (copy number f the vector in the cellular genome), the effects caused by the 
expression of the transgene (Li et al., 2002) and/or other elements within the vector 
backbone, which are likely to be context dependent (Baum et al., 2004). Moreover, it is 
clear that not only the vector sequence and the insertion site prompt a clonal imbalance, 
but that other factors, such as genetic and epigenetic lesions, pre-existing self-renewal 
potential,  age  of  the  treated  patients,  etc.,  may  also  play  and  important  role.  The 
conjunction of all these factors ultimately influence the fate of the gene-corrected cell 
clones  in  vivo,  whereby  those  cells  with  a  selective  advantage  are  clearly  favoured 
(Baum, 2007b). 
A.2.3  Success and risks of gene therapy 
In  1989  Rosenberg  and  colleagues  launched  the  first  well-documented  gene  therapy 
study  with  melanoma  patients  treated  with  retrovirally  transduced  tumor-infiltrating A. INTRODUCTION  22 
lymphocytes encoding the antibiotic resistant gene neomycin (Rosenberg et al., 1990). 
One  year  later,  in  1990,  the  first  therapeutic  human  gene  trial  was  approved.  Two 
children  suffering  from  a  severe  combined  immunodeficiency  (SCID)  caused  by  a 
genetic  defect  in  the  purine  catabolic  enzyme  adenosine  desaminase  (ADA)  were 
enrolled  in  the  study.  In  the  patients,  large  amounts  of  deoxyadenosine,  an  ADA 
substrate, accumulate intra- and extra-cellularly. In T-cells, this product is preferentially 
converted into the toxic compound deoxyadenosine triphosphate in T-cells, leading to 
defective  T-  and  B-cell  functions.  Unfortunately,  gene  therapy  failed  in  these  two 
patients. They received polyethylene glycol-ADA (PEG-ADA) as enzymatic substitution 
as  well  as  infusion  of  autologous,  genetically  modified  T-cells  transduced  with  a 
retroviral  vector  encoding  ADA,  a  setting likely to abrogate the selective advantage 
conferred to the transduced cells (Blaese et al., 1995). 
These first clinical gene therapy trials served as a proof of principle for the safety and 
feasibility of gamma-retroviral gene transfer in peripheral blood leucocytes (PBLs) or 
hematopoietic stem cells (HSCs). Since then, over 1200 trials have been completed, are 
ongoing or have been approved world wide (Edelstein et al., 2004). 
The first successful clinical trial has been performed in patients with X-linked severe 
combined immunodeficiency (X-SCID) by the groups of Drs. M. Cavazzana-Calvo and 
A. Fisher in Paris in 1999 (Cavazzana-Calvo et al., 2000). X-SCID patients generally 
present an early block in T and natural killer (NK) lymphocyte differentiation associated 
with mutations of the gene encoding the gamma chain (γc) cytokine receptor subunit. γc 
is  an  essential  part  of  the  interleukin-2,  -4,  -7,  -9,  -15  and  -21  receptors,  which 
participate  in  the  delivery  of  growth,  survival,  and  differentiation  signals  to  early 
lymphoid progenitors. Although, patients with X-linked SCID generally have normal 
B-cells  numbers  they  function  poorly,  because  of  the  lack  of  T-cell.  X-SCID  is 
invariably  fatal  if  therapeutic  bone  marrow  transplantation  is  not  performed.  Ten 
X-SCID children, who met the eligibility criteria, where chosen for the clinical trial. 
Autologous  CD34
+  cells  were  transduced  ex  vivo  with  a  Moloney  MLV 
(Mo-MLV)-based vector carrying the γc chain gene. The cells were then transplanted 
into the patients by infusion. 9 out of 10 patients, who received more than 1x10
6 gene 
corrected cells/kg, developed a functional adaptive immune system. The strong selective 
advantage observed for the transduced lymphocyte precursors was the crucial factor for 
the positive outcome of the therapy (Cavazzana-Calvo et al., 2000; Fischer et al., 2000). 
However, between 2002 and 2005 three of the 9 successfully treated children developed 
a clinical disease related to the uncontrolled proliferation of mature or immature T cells 
with leukemia-like characteristics. One of the patients did not respond to the treatment 
and died from a relapse of this complication. Subsequent studies revealed, in two of the 
three cases, malignant T-cell leukemia clones carrying proviral integrations within or 
near  to  the  LMO2  oncogene  (Hacein-Bey-Abina  et  al.,  2003b).  LMO2  encodes  a 
cysteine-rich  protein  with  two  LIM-domains  that  has  a  central  and  crucial  role  in A. INTRODUCTION  23 
hematopoietic development and is highly conserved. There is a tissue-specific negative 
regulator in the promoter region (Hammond et al., 2005) and its specific role in T-cell 
tumorigenesis  results  from  a  reprogramming  of  gene  expression  after  enforced 
expression in T-cell precursors (McCormack et al., 2003). 
The  strong  enhancer  activity  of  the  LTR  leading  to  ectopic  expression  of  the 
endogenous  hit  genes,  but  not  the  conjunction  with  the  effect  of  the  therapeutic 
transgene,  was  responsible  for  the  development  of  the  leukemia-like 
lymphoproliferative  disease  (Thrasher  et  al.,  2006;  Pike-Overzet  et  al.,  2007). 
Nevertheless,  the  overall  success  rate  of  the  gene  therapy  and  the  frequency  of 
accompanying  side  effects  should  be  considered  in  relation  to  the  mortality  rate  of 
X-SCID patients who undergo unrelated allogeneic transplantation, which is about one 
third of the treated patients (Haddad et al., 1998). 
Several clinical trials were later performed evaluating the efficacy and feasibility of the 
gene  therapy  (Aiuti  et  al.,  2002).  The  adverse  events  have  led  to  a  more  accurate 
analysis of the risks raised by these vectors (genotoxicity) and to the development of 
chromosomally integrating vectors with reduced risks of oncogenesis (SIN vectors). 
A.3  Gene therapy for CGD 
As mentioned in the begining CGD is a primary immunodeficiency disease resulting 
from  a  monogenetic  defect  of  the  hematopoietic  system.  Although  significant 
improvement in the life expectancy of patients occurred with the use of antimycotics, 
broad-range antibiotics and/or recombinant IFN-γ in combination with a early diagnosis 
of  the  disease  (Cale  et  al.,  2000),  CGD  is  still  associated  with  high  morbidity  and 
mortality (Winkelstein et al., 2000). 
HSC  transplantation  is  a  highly  recommended  treatment  in  those  cases  where  a 
HLA-identical  donor  exists  even  with  active  infections  that  are  refractory  to 
conventional therapy. However, the availability of such a suitable donor is limited and 
the  HSC  transplantation  with  a  non-matched  donor  is  inadvisable  due  to  the  high 
mortality rates. Therefore, the genetic modification of autologous HSC by gene therapy, 
is proposed as a curative and reasonable alternative treatment of the disease in patients 
lacking a compatible donor (Barese et al., 2004). 
The firsts gene therapy trials for CGD were initiated in 1995 based on the observation 
that reconstitution of NADPH oxidase activity can be achieved in vitro and in vivo by 
means  of  transduction  with  retroviral  vectors  carrying  the  defective  gene  of  the 
enzymatic complex (Pollock et al., 1995; Mardiney et al., 1997). Preclinical in vitro 
experiments  have  shown  the  restoration  of  oxidase  activity  in  Epstein-Barr  virus 
(EBV)-transformed B cell lines obtained from the 4 subgroups of CGD patients as well 
as in human myeloid leukemia X-CGD cell line generated by gene knock out of gp91
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in PLB-985 cells (Zhen et al., 1993; Chanock et al., 1996). CGD human bone marrow 
progenitor  (CD34
+)  cells  have  also  been  used  to  assess  the  restoration  of  NADPH 
oxidase activity with retroviral vectors. These cells were first transduced with vectors 
carrying  the  corresponding  therapeutic  gene  and  then  in  vitro  differentiated  to 
granulocyte-like cells. These experiments showed that high and stable reconstitution of 
the respiratory burst in vitro can be obtained in gene corrected X-CGD CD34
+ patient 
derived  cells  (Becker  et  al.,  1998;  Ott  et  al.,  2002).  Moreover,  transplantation  of 
transduced  X-CGD  CD34
+  peripheral  blood  stem  cells  (PBSC)  into  non-obese 
diabetic/severe  combined  immunodeficient  mice  (NOD/SCID)  achieved  up  to  22% 
corrected human neutrophils in vivo (Brenner et al., 2003). Knockout mouse models 
have also served to ensure the ability of the gene corrected cells to ward off occurring 
infections by challenging experiments. The mice were also used to define the required 
percentage  of  corrected  neutrophils  to  achieved  clear  protection  against  frequently 
infecting agents (Mardiney et al., 1997; Dinauer et al., 2001). 
Dr. H. L. Malech and colleagues conducted the first two human clinical gene therapy 
trials for CGD. The first trial included 5 adult patients suffering from p47
phox deficiency 
and 5 X-CGD patients were treated in the second study. In these trials no conditioning 
was used prior to reinfusion of the gene modified, mobilized autologous CD34
+ HSCs 
(Malech et al., 1997; Malech, 2000). Although gene transfer efficiencies were estimated 
to be high in vitro, the percentage of corrected granulocytes in vivo did not reach 1% and 
rapid decrease over time was observed. Various modifications were introduced in the 
second trial. The use of flt-3 ligand and GM-CSF for the mobilization procedure instead 
of G-CSF, the use of RetroNectin to co-localize target cells and virions (Hanenberg et 
al.,  1996;  Moritz  et  al.,  1996)  and  to  avoid  the  negative  effect  of  supernatant 
components (Kuhlcke et al., 2002). Transduction was performed for 4 days instead of 3 
and  the  multiple  cycles  of  mobilization-infusion.  Although  all  these  modifications 
slightly  increased  the gene transfer efficiency, it was not possible to reach effective 
levels in vivo (Malech et al., 2004). 
These  results  emphasized  the  need  for  improved  transduction  efficiencies  by 
optimization  of  the  cytokines  that  need  to  be  used,  improving  RetroNectin-based 
transduction, optimization of pseudotyping and by the use of “activated” cells (Kiem et 
al.,  1998;  Uchida  et  al.,  1998).  Moreover,  in  contrast  to  the  SCID  diseases,  the 
functional  NADPH  oxidase  does  not  confer  any  survival  or  proliferative  advantage. 
Therefore a bone marrow conditioning of the recipient prior to reinfusion might help 
increasing  the  engraftment  capacity  of  the  modified  repopulating  cells  (Malech  and 
Hickstein, 2007). 
In 2004 the groups of Dr. M. Grez and Prof. R. A. Seger conducted a successful clinical 
CGD  gene  therapy  trial.  Long-term  high-level  oxidase  activity  was  restored  in  two 
X-linked CGD patients by ex vivo retroviral-mediated gene transfer (Ott et al., 2006). A A. INTRODUCTION  25 
major  difference  between  this  study  and  former  studies  was  the  myelosuppressive 
conditioning regime using busulfan applied to the patients prior to reinfusion of the gene 
corrected cells. Transduction efficiency, measured as gp91
phox expressing CD34
+ cells, 
achieved 45.2% and 39.5% respectively. Thereafter, 15% gene corrected granulocytes 
were detected at day +65 and +84, respectively. These levels of gene marked cells where 
sufficient  to  eradicate  previous  existent  bacterial  and  fungal  infections,  which  were 
refractory to conventional therapy in both patients. Furthermore, between the 2nd and 
8th month after gene therapy, corrected granulocytes expanded to over 55% and 48% 
respectively and stabilized at that level for more than a year. Analysis of the clonality of 
the  marked  cells  at  this  plateau  phase  by  linear-amplification  mediated  PCR 
(LAM-PCR) (Schmidt et al., 2002) revealed that only a minority of clones contributed 
to hematopoiesis. This clonal dominance is not likely due to the transgene and neither to 
the busulfan conditioning because in former clinical trials, nor gp91
phox as transgene 
alone  and  neither  busulfan  conditioning  treatment  alone  conferred  any  selective 
advantage to gene marked clones (Aiuti et al., 2002; Barese et al., 2004). Indeed, the 
most predominant clones were associated with and appeared to be activated by vector 
insertion in one of three genes, MDS1-Evi1, PRDM16 or SETBP12. These genes are 
involved  in  myeloid  cell  growth  and  differentiation,  and  their  activation  by  vector 
integration  provided  them  a  selective  advantage  (Ott  et  al.,  2006).  MDS/Evi1  has 
previously  been  related  to  severe  clonal imbalance and even malignant processes in 
murine models due to retroviral insertion (Kustikova et al., 2005; Modlich et al., 2005). 
In contrast, rhesus macaques engrafted with retroviral vector transduced CD34
+ cells 
showed  14  MDS/Evi1  insertions  in  9  different  animals,  without  evidence  of  clonal 
expansion of these MDS/Evi1 hit population. 
The high frequency of integrations in a particular locus, regardless of the dysregulation 
of the expression, suggests that there might be a cluster of retroviral insertion which 
cannot be due to chance (Calmels et al., 2005). It indicates that the retroviral insertion 
alters the self-renewal or hematopoietic fitness potential of HSCs following integration 
(Stein  et  al.,  2006).  Nevertheless  the  expansion  of  gene  marked  cells  provided  a 
substantial  therapeutic  benefit  since  this  phenomenon  strengthened  the  immune 
response against new bacterial and fugal infecting pathogens of both patients. 
However, despite of the positive results one of the patients died almost two years after 
transplantation due to a colon perforation which led to a severe bacterial sepsis. The 
cause of death is still under investigation but the observation that the percentage of 
expressing  cells  decreased  over  the  time  although  maintaining  constant  numbers  of 
proviral integrations points out the silencing of the transgene as responsible mechanisms 
for a loss in oxidase function (Dr. M. Grez, pers. commun.). 
In 2005 Prof. R. A. Seger and colleagues treated a 5 year old boy using again the same 
protocol  (conditioning,  dose  and  gene  transfer  vector).  Although  the  levels  of A. INTRODUCTION  26 
superoxide producing cells did not reach 6% after transplantation and decreased until 
almost  undetectable  levels,  the  therapeutic  benefit  was  even  clearer.  The  treatment 
helped to cure a cord compression due to a fungal infection leading to an excellent 
improvement in the clinical situation of the patient. 
These data indicated that gene therapy can be considered as a curative therapy per se 
with great therapeutic potential and also as a temporary treatment until a subsequent 
BMT is feasible in late stage disease patients. However, there is still the requirement for 
new safer gene transfer vector with improved performance for later clinical applications. 
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A.4  Aims of the present study 
Insertion  of  self-inactivating  retroviral  vectors  in  the  host  genome  offers  a  major 
advantage for gene therapy due to their estimated reduced genotoxicity. Therefore, the 
aim  of  the  present  study  was  the  generation  of  gp91
phox  driving,  self-inactivating 
retroviral  vector  for  the  efficient  transduction  and  functional  reconstitution  of  the 
NADPH oxidase activity in X-CGD cell lines and in an X-CGD mouse model. The 
following objectives were tackled: 
o  Increase  the  biological  safety  of  gene  transfer  as  a  therapy  for  CGD  by 
constructing a self-inactivating retroviral vector encoding the gp91
phox gene. 
o  Efficient transduction of X-CGD PLB-985 human derived cells which can be 
used as a model to study gene therapy of CGD using the retroviral vector. 
o  Analysis of the NADPH oxidase activity in the transduced X-CGD PLB-985 
cells. 
o  Assess the tissue specificity of myeloid-specific promoters in the context of 
SIN vectors both in vitro and in vivo using the X-CGD cell line and mouse 
model. 
o  Evaluate  the  ex  vivo  and  in  vivo  reconstitution  of the oxidase activity after 
transduction of primary murine X-CGD Sca-1
+ and Lin
Neg cells. 
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B. MATERIALS AND METHODS 
B.1  Equipment and Necessary Materials 
Ajustable Pippetors - Pipetman  Gilson, BadCamber, Germany 
Autoclave  Integra Biosciences, Baar, Switzerland 
HyperfilmTM MP  Amersham Pharmacia, Little Chalfont, UK  Autoradiography-film  
Kodak BioMac MS  Sigma-Aldrich, Steinheim, Germany 
Balance – EMB600-2  Kern and Sohn GmbH, Germany 
Biodyne B positively-charged nylon 6.6  Pall Corporation, Darmastadt, Germany 
Blooting Paper  Carl Roth GmbH and Co., Karlsruhe, Germany 
Bright Star-Plus® Membrane #AM10104  Ambion Inc., Cambridgeshire, UK 
Electrophoresis Combs  Bio-Rad Laboratories Inc, Munich, Germany 
Electrophoresis Trays  Bio-Rad Laboratories Inc, Munich, Germany 
Hypercassette
TM  Amersham Pharmacia, Little Chalfont, UK 
Horizontal gel electrophoresis chamber 
– DNA SubCell
TM 
Bio-Rad Laboratories Inc, Munich, Germany 
Electrophoresis chamber for SDS-PAGE 
- Mini Protean 3 
Bio-Rad Laboratories Inc, Munich, Germany 
Intensifying screens  Amersham Pharmacia, Little Chalfont, UK 
Hybridization tubes  Appligene Oncor, Illkirch, France 
Hyb-oven  Gesellschaft für Labortechnik GmbH, Burgwedel, Germany 
Thermomixer comfort  Eppendorf GmbH, Wesseling-Berzdorf, Germany 
Immobilon-FL PVDF #FL00010  Milipore, Billerica, MA 
Liquid scintillator analyzer #TRI-CARB® 1500  Packard, Frankfurt am Main, Germany 
1.5 and 2 ml Microcentrifuge tubes  Eppendorf, Hamburg; Sarstedt, Nümbrecht, Germany 
Microspin S-300HR Columns #27-5130-01  Amersham Biosciences, Freiburg, Germany 
NucAway
TM spin Columns #AM10070   Ambion Inc., Cambridgeshire, UK 
PCR-block  (GeneAmp 2400) Perkin-Elmer, Weiterstadt, Germany 
Ph-meter  Knick, Berlin, Germany 
Pipete helper – Pipetus®-akku  Hirschmann Laborgeräte, Eberstadt, Germany 
Power Source – Power Pac300  Bio-Rad Laboratories Inc, Munich, Germany 
Spectra MAX 340 reader  Molecular Devices 
Stratalinker
TM 1800  Stratagene Company, Zuidoost, Netherlands 
Thermomixer comfort  Eppendorf GmbH, Wesseling-Berzdorf, Germany 
Vortexer  Janke and Kunkel, Staufen, Germany 
Water bath  Gesellschaft für Labortechnik, Burgwedel, Germany 
B.2  Materials for Molecular Biological Experiments 
B.2.1  Chemicals, Enzymes and Reagents for Molecular Biological Experiments 
Acetic acid  Carl Roth GmbH and Co., Karlsruhe, Germany 
AEBSF #A8456  Sigma Aldrich, Taufkirchen, Germany 
Agarose Electrophoresis Grade #15510.027  Invitrogen Corporation, Scotland, UK 
Ammonium acetate – NH4OAc  Carl Roth GmbH and Co., Karlsruhe, Germany 
Ampicillin  Roche, Mannheim, Germany 
Ampli-Taq-DNA-polymerase  Biosystems, Weiterstadt, Germany 
Antarctic Phosphatase #M0289L  New England Biolabs, Inc., Inc. GmbH, Frankfurt a B. MATERIALS AND METHODS  29 
APS (ammonium peroxydisulfate)  Merck, Darmstadt, Germany 
Boric acid – H3BO3  Carl Roth GmbH & Co., Karlsruhe, Germany 
Bromphenolblue #B8026  Sigma Aldrich, Taufkirchen, Germany 
Bradford-reagent  Bio-Rad Laboratories, Inc., CA, USA 
Β-mercaptoethanol #M3148  Sigma Aldrich, Taufkirchen, Germany 
Chloridric acid - HCl #4625.1  Carl Roth GmbH & Co., Karlsruhe, Germany 
Chloroform  Carl Roth GmbH & Co., Karlsruhe, Germany 
Chymostatin #C-726878  Sigma Aldrich, Taufkirchen, Germany 
DEPC (Diethyl Pyrocarbonate) #D5758  Sigma Aldrich, Taufkirchen, Germany 
DNA Polymerase I, Large (Klenow)  New Engl& Biolabs, Inc., Frankfurt a M 
Fragment #M0210S  , Germany 
DNeasy
TM Tissue Kit  Carl Roth GmbH & Co., Karlsruhe, Germany 
Dried milk powder  Carl Roth GmbH & Co., Karlsruhe, Germany 
EDTA #4706.1000  AppliChem, Darmstadt, Germany 
Ethanol, 100% #T1713  Carl Roth GmbH & Co., Karlsruhe, Germany 
Ethidium Bromide #2218.2  Carl Roth GmbH & Co., Karlsruhe, Germany 
Formaldehyde loading dye #8552  Ambion Inc., Cambridgeshire, UK 
Glycerine #3783.1  Carl Roth GmbH & Co., Karlsruhe, Germany 
Glycine   Carl Roth GmbH & Co., Karlsruhe, Germany 
Glycogen #901393  Roche, Mannheim, Germany 
Hyb Hybridization Buffer  Ambion Inc., Cambridgeshire, UK 
IPTG (Isopropyl-β-D-1-thiogalactopyranoside)  Sigma Aldrich, Taufkirchen Germany, 
Isopropanol  Carl Roth GmbH & Co., Karlsruhe, Germany 
JumpStart
TM REDTaq® ReadyMIX
TM PCR   Sigma Aldrich, Taufkirchen,  
Reaction Mix #P0982  Germany 
Leupeptin #1017101  Roche Diagnostics, Indianapolis, USA 
LB Agar #22700-025  Life Technologies, Karlsruhe, Germany 
LB Broth Base #12780-029  Life Technologies, Karlsruhe 
Magnesium chloride  Perkin Elmer, Weiterstadt, Germany 
MAXIscript® Kit #AM1316  Ambion Inc., Cambridgeshire, UK 
Methanol  Carl Roth GmbH & Co., Karlsruhe, Germany 
MicroSpin S-300 HR Columns   Amersham Biosciences, Freiburg, Germany 
NEBlot® Kit #N1500S  New England Biolabs, Inc., Frankfurt a M, Germany 
NorthernMax® Kit #AM1940  Ambion Inc., Cambridgeshire, UK 
NucAway
TM columns  Ambion Inc., Cambridgeshire, UK 
NucleoSpin®RNA II Kit #740955.50  Macherey-Nagel Inc., Düren, Germany 
Carl Roth GmbH & Co., Karlsruhe,  Phenol/Chloroform/Isoamylalcohol (25:24:1) 
Germany 
Pfu Turbo DNA-polymerase  Stratagene Company, Amsterdam, The Netherlands 
PMSF (phenylmethylsulfonyl fluoride) #P7626  Sigma Aldrich, Taufkirchen, Germany 
Potassium acetate – KAc  Sigma Aldrich, Taufkirchen, Germany 
Potassium chloride – KCl  Carl Roth GmbH & Co., Karlsruhe, Germany 
Potassium phosphate – KH2PO4  Carl Roth GmbH & Co., Karlsruhe, Germany 
pTRI RNA 18S #AM7339  Ambion Inc., Cambridgeshire, UK 
QIAquick- gel extraktion kits  Qiagen GmbH, Hilden, Germany 
QuikChange®Site-Directed Mutagenesis Kit #200519  Strategene, La Jolla, 
Restriction endonucleases  New England Biolabs, Inc., Frankfurt, Germany 
RNase A  Sigma Aldrich, Taufkirchen, Germany 
RNA secure
TM reagent  Ambion Inc., Cambridgeshire, UK B. MATERIALS AND METHODS  30 
RotiLoad loading buffer  Carl Roth GmbH & Co., Karlsruhe, Germany 
Rotiphorese® Gel 30  Carl Roth GmbH & Co., Karlsruhe, Germany 
Roti®szint ecoplus #0016.2  Carl Roth GmbH & Co., Karlsruhe, Germany 
BenchMarkTM Prestained Protein Ladder 
Invitrogen Corporation, Karlsruhe, Germany  Protein 
Bio-Rad Laboratories, Inc., CA, USA 
Smart Ladder; Eurogentec, Seraing, Belgium  DNA 
2-Log Ladder, NEB Inc., Frankfurt a.M., Germany 
Size Marker 
RNA #15623-200  Invitrogen Corporation, Karlsruhe, Germany 
Sodium chloride – NaCl #9265.2  Carl Roth GmbH & Co., Karlsruhe, Germany 
Sodium hydroxide – NaOH #6771.1  Carl Roth GmbH & Co., Karlsruhe, Germany 
Sodium phosphate – Na2HPO4  Carl Roth GmbH & Co., Karlsruhe, Germany 
SuperScript
TMReverse transcriptase  Invitrogen Corporation, Scotland, UK 
SuperSignal ® West Pico Chemiluminescent Substrate #34080  Pierce, Rockford, USA 
Carl Roth GmbH & Co., Karlsruhe,  TEMED (N,N,N',N'-Tetramethylethylendiamin) 
Germany 
Tris #AE15.2  Carl Roth GmbH & Co., Karlsruhe, Germany 
Tris HCl  Carl Roth GmbH & Co., Karlsruhe, Germany 
Triton X-100  Sigma, Taufkirchen, Germany 
T4 DNA-ligase  New England Biolabs, Inc., Frankfurt, Germany 
10x SDS #24730.020  Gibco, Scotland, UK 
10x SSC #15557.044  Invitrogen Corporation, Scotland, UK 
10x TBE #15581.026  Invitrogen Corporation, Scotland, UK 
 
B.2.2  Antibodies (Ab) for Molecular Biological Methods (Western Blot) 
Actin (I-19): sc-1616  Santa Cruz Technologies 
MoAb48 (Verhoeven et al., 1989)  Kindly provided by Dick Roos 
IRDye 800 Conjugated Goat (polyclonal) Anti-Rabbit IgG  LI-COR Bioscience GmbH 
# 926-32211  Bad Homburg, Germany 
IRDye 680 Conjugated Goat (polyclonal) Anti-Rabbit IgG  LI-COR Bioscience GmbH 
# 926-32220  Bad Homburg, Germany 
 
B.2.3  Oligonucleotides 
B.2.3.1  Primer for PCR 
Gp91
phox wild-type cDNA (human) 
5'-Primer (gp-for-01)  TTGTACGTGGGCAGACCGCAGAGA 
3'-Primer (gp-rev-02)  CCAAAGGGCCCATCAACCGCTATC 
β-actin cDNA 
5'-Primer (ACT5’)  ATGATATCGCCGCGCTCGTCGTC 
3'-Primer (ACT3’)  TTCTCGCGGTTGGCCTTGGGGTTCAG 
Synthetic gp91
phox cDNA (human) 
5’-Primer (gp91S-2for)  AAAGAGTGCCCCATCCCCCAGTTC 
3’-Primer (gp91S-2rev)  CGCCCACGATTCTGATGT 
GAPDH 
5’-Primer (GAPDH/5)  ACCACAGTCCATGCCATCAC 
3’-Primer (GAPDH/3)  TCCACCACCCTGTTGCTGTA B. MATERIALS AND METHODS  31 
B.2.3.2  Oligonucleotides for Cloning 
Gp91
phox wild-type cDNA – Modified primers to mutate the cryptic splice acceptor 
5'-Primer (BM-P9)  GCTGTCCTTCCTCCGGGGTTCCAGTGCG 
3'-Primer (BM-P10)  CGCACTGGAACCCCGGAGGAAGGACAGC 
Leader 11 – Modified primers to introduce a NotI cleavage site at the 3’ end 
P1 – standard primer also used for sequencing  GGAGGTTCCACCGAGATTTGG 
BM-P7 – modified primer  GCAGCTAGCTGCGGCCGCTATTTTC
MRP8 intron – Modified primers to introduce a NdeI cleavage site at both ends of the first 
5’-Primer (BM-P1)  GCATATGGATCCTTGGGGAGGGTCAGGGAAGTG 
3’-Primer (BM-P2)  GCATATGGATCCCCAGGGCAGTACGCAGAGGA 
c-fes promoter – Modified primers to introduce a 5’NotI and a 3’SalI sites 
5’-Primer (NotI TOPO fes 7)  GAATGCGGCCGCGAATTCCGTG 
3’-Primer (SalI TOPO fes7)  AGTGTGCTGGAAGTCGACCTTCGG 
c-fes promoter and gp91
phox - Modified primers to introduce a 5’HindIII and a 3’NdeI sites 
5’-Primer (cfes for HindIII)  AAGCTTCGAATTCCGTGAGGTG 
3’-Primer (gp91rev NdeI)  CATATGGTTAGAAGTTTTCCTTGTTG 
EFs promoter - Modified primers to introduce a 5’NotI and a 3’SalI sites 
5’-Primer (EF1 for)  CCGGTACCGAGCGGCCGCTTCGTGAGGC 
3’-Primer (EF1 rev)  GGTGTGTGCCGTCAGCTGACACAAGACC 
SP146 promoter – Modified primers to introduce a 5’NotI and a 3’SalI sites 
5’-Primer (Li NotI for)  AAGCGGCCGCCGGTACCGAGCTCTTAC 
3’-Primer (Li SalI rev)  GGATCCGTCGACAACCGGTACTGGG 
B.2.3.3  Oligonucleotides for Sequencing 
BM-P7  GCAGCTAGCTGCGGCCGCTATTTTCAG 
BM-P8  GTGAATTCGATATCGCTAGCGG 
BM-P11  CCATTCCTACCCTGCTGCC 
BM-P12  CCCACTCCCATGCCCTCTCCAC 
fes 4 for  GGCGGCCGCTCGAATTCCG 
gp91S-1for  CGTGTGCCGGAACCTGCTGTC 
gp91S-1rev  CGCTGTAGGGGTCGCTGTTGTTCA 
gp91S-2for  AAAGAGTGCCCCATCCCCCAGTTC 
gp91S-2rev  CGCCCACGATTCTGATGT 
gp91S-3for  AAGTACTGCAACAACGCCACCAAC 
gp91S-3rev  GGTGCTGGCTGGCGATGGTCTTA 
gp91S-4for  GCAGAGCATCAGCAACAGCGAGAG 
gp91S-4rev  CCCCGCAGGAAGGACAGCAGGTT 
Int-prom-for  TCCCGCCCCCGTCTGAAT 
MHforLEAD  GCCCCCGTCTGAATTTTTGCTTTCGG 
M13for  ACGACGTTGTAAAACGACGGCCAG 
M13rev  TTCACACAGGAAACAGCTATGACC 
MRP8ex1for1  CCTGCATGTCTCTTGTCAGCTGTC 
MRP8for1  GGAGGAATGTTCTCACTGAGTGC 
MRP8int1for  CCGTGTGTGTGCACATGT 
MRP82rev  AGGAAAGCTTGGCCAGCTGC 
P1  GGAGGTTCCACCGAGATTTGG 
P5  GAACGTCTTCCTCTTTGTCTGG 
P6  GGCATGGATGATTGCACTTCACTC B. MATERIALS AND METHODS  32 
P9  CCGCATCGTTGGGGACTGGACAG 
P10  CTACTTCTACTGGCTGTGCCGGG 
P11  GCAAGTCAACACCCTAATACCAG 
P11N1  TCTGGCCCTCGGGGAGTGCATTTC 
P12  CCCCCTGCTTAAAAATGGAC 
P16  CCGCGAGTGCACACGCTGGGCC 
R8  GAGCATTTGGCAGCACAACCCAC 
R11  CCGCTATCTTAGGTAGTTTCCACG 
R13  CTGTTATATTATGCACAGCC 
R15  GAAAGGTGAGATTCCTGTCCAG 
R16  GCCAGTGCCAGTGCTGACCCAAG 
R20  CCTCAGGTCGGGCCACAAAAACG 
R21  GAAACGACCGCTGGCCAGCTTAC 
RSVfor1  TCTGACATGGATTGGACGAAC 
RSVfor2  TTATTAGGAAGGCAACAGAC 
WPREdown  ACGAGTCGGATCTCCCTTTGGGC 
WPRE1for  CCCAAGCTTCAATCAACCTCTGGATTAC 
WPRE M661 for1  AATCCTGGTTGCTGTCTCTTTTAG 
WPRErev2  TACCAGTCAATCTTTCAC 
B.2.4  Bacterial E.Coli strains 
One Shot
® (TOP 10F’)  Invitrogen Corporation, Karlsruhe, Germany 
Genotype: F [lacI
q Tn10 (tet
R)] mcrA  (mrr-hsdRMS-mcrBC) Ф80lacZ M15  lacX74  
recA1 deoR araD139  (ara-leu)7697 galU galK galK rpsL (str
R) endA1 nupG 
MAX Efficiency
® Stbl2
TM #10268  Invitrogen Corporation, Karlsruhe, Germany 
Genotype: F
- mcrA  (mcrBC-hsdRMS-mrr) recA1 endA1 lon gyrA96 thi supE44 relA1 λ
-  
 (lac-proAB) 
DH5α  Stratagene Company, Zuidoost, Netherlands 
Genotype. F ¢80dlacZ M15  (lacZYA-argF) U169 deoR recA1 endA1 hsdR17(rk- , mk+) 
PhoA supE44 λ- thi-1 gyrA96 relA1 
XL1-Blue Supercompetent cells #200236  Stratagene Company, Zuidoost, Netherlands 
Genotype: supE44 hsdR17 recA1 endA1 gyrA96 thi relA1 lac¯ F'  
[proAB
+lacIq lacZ  M15 Tn10 (tet
R)] 
 
B.3  Molecular biological methods 
B.3.1  Phenol/Chloroform/Isoamyl alcohol extraction of nucleic acids 
To  remove  undesired  protein  contaminants  from  nucleic  acids  an  equal  volume  of 
Tris-buffered phenol/chloroform/isoamyl alcohol at a ratio of 25:24:1 (v/v/v) was added 
to the sample in a microcentrifuge tube and the mixture was vortexed for 30-60 sec. The 
two phases were separated by centrifugation at 13.000 rpm for 10 min. The aqueous 
nucleic acid-containing phase, which is normally the upper phase except for the case of 
high concentration of salt-containing sample, was transferred to a fresh reaction tube 
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B.3.2  Ethanol (or 2-propanol) precipitation of nucleic acids 
In order to recover nucleic acids from solution, the salt concentration was brought to 
200 mM with 3 M NaOAc (pH 4.8-5.0) and 2.5 volumes of -20ºC ethanol or 1 volume 
2-propanol were added. After 30 min to overnight incubation at -20ºC or 15 min at 
-80ºC (only ethanol precipitation), the precipitate was centrifuged at 13.000 rpm for 
20 min.  The  pellet  was washed with 70% ethanol, centrifuged for another 3 min to 
remove the salt and air dried. DNA was re-suspended in dH2O. 
B.3.3  Determination of nucleic acid concentration 
The concentration of nucleic acid was determined by measuring their optical density 
(OD) at 260 and 280 nm. An OD260=1 is equivalent to 50 µg/ml double stranded DNA 
or 40 µg/ml RNA. The OD280 is used as an indication of the purity of the nucleic acid; 
for pure nucleic acid it should be 1.8 for DNA and 2 for RNA. 
B.3.4  Restriction endonuclease digestion of DNA 
Usually 3-5 units of restriction enzyme (New England Biolabs, Inc. GmbH, Frankfurt 
am  Main,  or  Fermentas  GmbH,  St.Leon-Rot)  were  used  for  each  µg  DNA.  For 
analytical digestions 0.5 µg DNA was cleaved in 1x endonuclease buffer for 1 hour at 
37ºC (unless otherwise recommended by the supplier) and analyzed in a 0.5-1% agarose 
electrophoresis gel. For preparative digestions, with further processing such as cloning, 
southern blot, etc., DNA was digested at a concentration of 1 µg/10 µl in recommended 
buffer. This reaction was carried out for 4 hours to overnight at adequate temperature. 
The quality of the digestion was controlled by gel electrophoresis. 
B.3.5  Removal of 5’ phosphate groups of DNA (Antarctic Phosphatase) 
Since phosphatase-treated fragments lack the 5’ phosphoryl termini required by ligases, 
they can not self-ligate. This property can be used to decrease the vector background in 
cloning strategies. Typically, 10 U of enzyme were added either to the digestion mixture 
or  to  the  eluted  fragment  and  incubated  under  recommended  conditions  for  1  hour. 
Thereafter the reaction was heated at 65ºC to inactivate the enzyme prior to subsequent 
cloning steps. 
B.3.6  Blunting ends reaction (DNA Polymerase I, Large (Klenow) Fragment) 
This  methodology  is  usually  applied  to  fill-in  5’  overhangs  and/or  to  remove 
3’ overhangs to form blunt ends. DNA polymerase I, Large (Klenow) Fragment is a 
proteolytic  product  of  E.Coli  DNA  Polymerase  I  which  retains  polymerization  and 
3’→5’ exonuclease activity, but has lost the 5’→3’ exonuclease activity. It is useful for 
cloning strategies that require a blunt end fragments for ligation.  Usually, 10 U of 
enzyme were added to the digestion mixture or to the eluted fragment in combination B. MATERIALS AND METHODS  34 
with 33µl dNTPs. This new mixture was incubated 30 min at 25ºC and heat inactivated 
by heating for 20 min at 75ºC. 
B.3.7  Size separation of nucleic acids by agarose gel electrophoresis  
The required amount of agarose was dissolved in 100 ml electrophoresis buffer TBE 
(90 mM  Tris-base,  90  mM  H3BO3,  2.5  mM  EDTA,  pH  8.3)  (Miura  et  al.,  1999). 
Ethidium  Bromide  was  added  at  a  concentration  of  0.3  µg/µl.  The  molten  gel  was 
poured into a horizontal chamber. Combs with the appropriate number and size of the 
teeth were used to make the loading slots. Once the gel was set, electrophoresis buffer 
was  added  and  samples  were  loaded  onto  the  gel  in  6x  loading  buffer  (0.25% 
Bromophenol blue, 0.25% Xylencyanol and 30% Glycerin in water). The gel was run at 
35-45  mA  (50-100  V)  at  RT  for  the  required  time.  DNA  was  finally  visualized  by 
transillumination with 302 nm UV radiation. 
B.3.8  Isolation/ purification of DNA fragments from agarose gels 
To  isolate  an  appropriate  DNA  fragment  from  an  agarose  gel,  Gel  Extraction  Kit 
(Qiagen GmbH) was used as recommended by the manufacturer. Briefly, the DNA band 
of choice was cut out from the gel under long wave UV light with the aid of a scalpel. 
The gel piece was melted at 50ºC in the high-salt supplied buffer. 1 volume of Ethanol 
was added prior to bind the DNA to a silica membrane. After washing away the agarose 
and unbound impurities, the DNA was eluted in TE buffer (10 mM Tris·HCl, 1 mM 
EDTA, pH 8.0). 
B.3.9  DNA fragment ligation 
This  method  was  used  to  combine  two  DNA  fragments  which  were  obtained  by 
endonuclease restriction of plasmid DNA, size separation by agarose gel electrophoresis 
and finally purification of the fragments from agarose gel.  
50-100 ng vector DNA were incubated with a 1:1 up to a 3:1 molar ratio of insert DNA 
in a total volume of 15 µl with 4 U of T4 DNA ligase (New England Biolabs, Inc.) and 
incubated for 6 hours to overnight at 16ºC. As a control sample a reaction which only 
contains vector DNA was set up and processed as the experimental samples. 
B.3.10  Topo cloning kit 
For some cloning steps, an intermediate PCR (see. Polymerase chain reaction) process 
was used to introduce specific cleavage sites for further endonuclease restriction and 
ligation  with  the  required  vector.  In  these  cases,  the  digestion  of  the  obtained  PCR 
products  is  often  ineffective  leading  no  ligation  products.  Therefore,  by  means  of a 
topoisomerase, these fragments were first ligated to a plasmid, the pCR
®2.1-TOPO
® 
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polymerase which has an error rate lower than Taq polymerase, 10 min incubation with 
1 U of Taq polymerase was required to hang TAs at the ends of the fragments. These 
TA ends were needed to efficient ligate the PCR- fragments to the Topo vector by the 
topoisomerase.  The  TA-containing  PCR  product  was  incubated  with  the 
pCR
®2.1-TOPO
® vector for 5 min at RT. The recombinant plasmid, which harbors the 
required fragment with the new cleavage sites, was finally amplified by transformation 
into E. Coli bacteria (see. Chemical transformation of E. Coli). 
B.3.11  Chemical transformation of E.Coli 
This technique is used both for propagation of different plasmids and for screening of 
ligation reactions as follows. A DNA sample (typically 0.01-1 µg) in 0.5-2  l volume 
was added to ice thawed CaCl2-competent E. Coli (50  l). After mixing by pipetting up 
and down, the mixture was incubated on ice for 30 minutes. Cells were heat-shocked in 
a water 42° C bath for generally 30 seconds, then immediately cooled on ice for 2 min. 
The transformed E. Coli cells were finally mixed with 250  l SOC medium (supplied 
from Invitrogen Corporation), incubated for 1 hour at 37ºC in the shaker, plated onto 
LB-agar plates supplemented with ampicillin (100 µg/ml) and grown overnight at 37ºC. 
The  antibiotic  resistance  is  used  for  subsequent  selective  outgrowth  of  bacteria 
containing plasmid which encodes for the antibiotic resistance gene β-lactamase. 
B.3.12  Plasmid DNA preparation 
Small scale method 
This method is suitable for preparation of small amounts of DNA (5-10 µg). Briefly, a 
2 ml overnight culture of E. Coli harboring an appropriate plasmid or a ligation product 
was transferred to a microcentrifuge tube and centrifuged at 13.000 rpm for 5 min. The 
bacterial pellet was re-suspended in 300  l buffer 1 (10 mM HCl, 10 mM EDTA, pH 8) 
containing 100 mg/ml RNAase. After incubation for 5 minutes at RT, the cells were 
lysed  by  addition  of  300  µl  buffer  2 (200 mM NaOH; 1% [w/v] SDS) and several 
inversions of the suspension. Thereafter 300  l buffer 3 (3 M KAc, pH 4.8) were added 
in order to neutralize the lysis. The samples were then incubated for 5 minutes on ice 
and further centrifuged at 13.000 rpm for 15 min at 4°C. The supernatant containing the 
low molecular plasmid DNA was transferred into a new Eppendorf tube and precipitated 
by addition of two volumes of ethanol. After centrifugation at 13.000 rpm for 20 min at 
4°C, the obtained plasmid DNA pellets were washed two times with 70% ethanol and 
air dried at RT. At last the DNA was re-suspended in 30 µl dH2O.  
Large scale method 
To  prepare  a  high  amount  of  plasmid  DNA  for  further  cell  culture  applications, 
NucleoBond®PC 500 EF (Macherey-Nagel) was used essentially as recommended by 
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plasmid was centrifuged at 4.000 rpm for 20 min at 4ºC. The bacterial cell pellet was 
prepared  for  plasmid  purification  by  lysis  procedure  employing  an  alkaline/SDS 
solution. KAc was then added to the lysate, which causes the formation of a precipitate 
containing chromosomal DNA and other cellular compounds and which neutralizes the 
lysate. Plasmid DNA, which remains in solution was bound to the anion-exchange resin 
and eluted after washing of the column. The eluted DNA was finally precipitated with 
one volume of 2-isopropanol and centrifugation at 4.000 rpm for 30 min at 4ºC. 
B.3.13  Nucleic Acid isolation from cultured cells 
Total DNA isolation from cultured cells 
DNeasy Blood & Tissue Kit was used for rapid purification of total DNA from fresh or 
frozen  animal  cultured  cells  as  recommended  by  the  manufacturer  (Qiagen  GmbH). 
Briefly, up to 5x10
6 cells were centrifuged 5 min at 1.200 rpm and re-suspended in 
phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4*7H20, 
1.4 mM KH2PO4). Samples were lysed using proteinase K and guanidine hydrochloride 
buffer.  This  chaotropic  salt  removes  water from hydrated molecules in solution and 
thereby  provides  also  the  optimal  DNA-binding  conditions  for  the  silica-based 
membrane. After binding to the membrane and wash away the contaminants, the DNA 
was eluted in elution buffer (10 mM Tris·Cl, 0.5 mM EDTA, pH 9.0). 
Total RNA isolation from cultured cells 
Total RNA was purified using a Nucleospin® RNA II kit (Macherey Nagel) according 
to the instructions of the manufacturer. Briefly, up to 5x10
6 cells were centrifuged 5 min 
at 1.200 rpm and re-suspended in a solution containing large amounts of chaotropic salts 
and β-mercaptoethanol which immediately lysate cells, inactivated RNases and creates 
appropriate binding conditions for the silica membrane. The sample was homogenized 
by passing through a 0.9 mm syringe needle and loaded to the column. After desalting 
the membrane, digestion of the DNA and wash away the contaminants, the total RNA 
was  eluted  in  DEPC  water.  Integrity  of  prepared  RNA  was  assessed  by  denaturing 
agarose gel electrophoresis. As the RNA is degraded, the 28S and 18S rRNA bands 
become less distinct, the intensity of the ribosomal bands relative to the background 
staining in the lane is reduced, and there is a significant shift in their apparent size as 
compared to the size standards. 
B.3.14  Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) is a method for oligonucleotide primer directed 
enzymatic  amplification  of  a  specific  DNA  sequence  of  interest.  A  prerequisite  for 
amplifying a sequence using PCR is to know, unique sequences flanking the segment of 
DNA to be amplified so that specific oligonucleotides can be obtained. Generally the 
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from Thermus aquaticus (Taq DNA polymerase) and using an automated thermal cycler 
(Perkin-Elmer/Cetus)  to  put  the  reaction  through  25  or  more  cycles  of  denaturing, 
annealing of primers, and polymerization. After amplification by PCR, the products are 
separated by polyacrylamide gel electrophoresis and are directly visualized after staining 
with Ethidium Bromide. 
This method was used routinely to quantify the mean copy number of proviral integrants 
in the transduced populations. A multiplex semi-quantitative system was standardized 
using a sample with known copy number. In this case the sample and the PCR program 
was set up as follows: 
1 x Semi-quantitative PCR-Mix:  Semi-quantitative PCR-Program: 
12.5 µl JumpStart
TM REDTaq® 
ReadyMIX
TM 
1 µl gp91
phox Primer for (10 µM) 
1 µl gp91
phox Primer rev (10 µM) 
1 µl GAPDH Primer for 
1 µl GAPDH Primer rev 
8.5 µl Template (25, 50 and 100 ng) 
1. 95°C ￿ 5 min 
2. 95°C ￿ 30 sec 
3. 59°C ￿ 30 sec 
4. 72°C ￿ 35 sec 
5. 72°C ￿ 7 min 
6. 4°C ￿ ∞ 
 
25 x Steps 2 – 4 
 
In the case of X-CGD PLB-985 cells, a stock of 10 µM GAPDH primers was used, and 
a 1.5 µM stock was used for the primary mouse cells. The different loaded genomic 
DNA quantities were used to verify the efficiency of the primers. Following the PCR 
cycling the samples were loaded and run onto a 1% agarose gel containing Ethidium 
Bromide, and visualized under UV light. The intensity of bands was quantified with the 
Quantity One software (Bio-Rad Laboratories Inc). 
Furthermore, this method was also used to amplify fragment from genomic DNA or 
plasmid DNA for further cloning steps. Usually modified primer sequences were used in 
order to introduce specific cleavage sites for future designed cloning strategies. In that 
case,  the  PCR  was  preformed  with  PfuI  turbo polymerase which has an exonuclase 
5’ → 3’ and proof reading activity to avoid possible mistakes during the amplification 
process. For a high fidelity synthesis maximal allowable template DNA quantities in 
conjunction with limiting number of PCR cycles were performed. 
B.3.15  Reverse transcription polymerase chain reaction (RT-PCR) 
This technique is used to amplify DNA fragments from a cDNA template that has been 
obtained from RNA. For this purpose the SUPERSCRIPT
TMII reverse transcriptase Kit 
was used following manufacturer instructions (Invitrogen Corporation). Briefly, total 
RNA  from  transfected  cells  was  mixed  with  dNTPs,  random  primers  and B. MATERIALS AND METHODS  38 
SUPERSCRIPT
TMII reverse transcriptase. After heat the mixture to 65ºC for 5 min and 
quick  chill  it  on  ice,  enzyme  buffer,  DTT  and  RNase  OUT were also added to the 
microcentrifuge tube. The mixture was incubated 2 min at 25ºC prior to addition of 
200 U of Reverse Transcriptase. An incubation step for 50 min at 42ºC was performed 
to let the transcriptase work. And finally, after heat inactivation of the polymerase for 
15 min  at  70ºC  the  DNA  was  ready  to  be  amplified  by  the  DNA  polymerase  as 
commented above. 
B.3.16  Site-Directed Mutagenesis 
In  vitro  site-directed  mutagenesis,  also  known  as  site-specific  mutagenesis  or 
oligonucleotide-directed  mutagenesis  is  a  molecular  biology  technique  in  which  a 
mutation is created at a defined site in a DNA molecule, usually a circular molecule 
known as a plasmid. In general, site-directed mutagenesis requires that the wild-type 
gene sequence be known. 
The  QuickChange®  Site  Directed  Mutagenesis  Kit  (Stratagene  Company)  was  used 
following the instructions of the manufacturer. The primer reaction was prepared by 
mixing  25ng  of  template  dsDNA  with  125ng  of  each  primer  containing  the  desired 
mutation, dNTPs, 1x reaction buffer and 2.5 U of PfuI Turbo DNA polymerase. The 
reaction was set in a PCR-cycler with the following parameters: 
Segment  Cycles  Temperature  Time 
1  1  95ºC  30 sec 
95ºC  30 sec 
55ºC  1 min  2  12 
68ºC  1 min / kb of plasmid 
 
After temperature cycling, the reaction was placed on ice for 2 min to cool the reaction, 
and  then  10  U  of  DpnI  restriction  enzyme  were  added  to  the  mixture  to  digest  the 
methylated,  nonmutated,  parental  dsDNA.  The  digestion  was  incubated  at  37ºC  for 
1 hour prior to chemically transformation into XL1-Blue supercompetent cells. 
In the present study this technique was applied to mutate one cryptic splice acceptor site, 
however maintaining the same codified aminoacid (Fig. 17). 
B.3.17  Preparation of high specific activity DNA probe 
Radiolabeling  of  a  specific  DNA  probe  was  performed  with  the  NEBlot®  Kit  as 
indicated by the provider (New England Biolabs, Inc.). Summarizing, in an RNase-free 
tube, 25 ng of template DNA was dissolved in nuclease free H2O. After denaturing by 
boiling in a water-bath for 5 min the tube was placed in ice for 5 min. Thereafter the 
DNA was mixed with the following reagents in the order listed: i) 5 µl 10x Labeling 
buffer, ii) 2 µl of dATP, 2 µl of dTTP and 2 µl dGTP, iii) 5 µl α
32P dCTP and iv) 1 µl 
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Purification from unincorporated nucleotides was performed by gel filtration on spin-
column  (MicroSpin  S-300  HR  Columns,  GE  Healthcare)  following  manufacturer 
instructions. Briefly, the resin in the column was re-suspended by vortexing and the cap 
was loosened one-fourth turn and the bottom closure was snap off. After placing the 
column in microcentrifuge tube for support a centrifugation step at 3000 rpm for 1 min 
was preformed. Then the column was placed new microcentrifuge tube, and the sample 
was applied to the top-center of the resin being careful not to disturb the bed. After a 
new centrifugation set at 3000 rpm for 3 min the purified sample was collected in the 
bottom of the support tube. To determine the radioactive nucleotide incorporation 2 µl 
of the purified sample were mixed with 1 ml of Roti®szint Ecoplus and analyzed in a 
Liquid scintillation analyzer. 
B.3.18  Southern Blot 
A  Southern  blot  is  a  method  routinely  used  in  molecular  biology  to  check  for  the 
presence of a DNA sequence in a DNA sample. Southern blot combines agarose gel 
electrophoresis for size separation of DNA with methods to transfer the size-separated 
DNA to a filter membrane for probe hybridization. 
A 0.7% TBE agarose gel was prepared as previously described. The gel was poured to 
about 0.6 cm in thickness and allowed to solidify at RT. Restriction digested DNA (up 
to  15  µg)  was  mixed  with  the  appropriated  volume  of  6x  loading  buffer  (0.25% 
Bromophenol  blue,  0.25%  Xylencyanol  and  30%  Glycerin  in  water)  and  loaded  the 
wells of the gel. The gel was run at ~ 5 V/cm (distance measured between the electrodes 
of  the  electrophoresis  chamber)  until  the  bromophenol  blue  dye  front  had  migrated 
almost to the bottom of the gel. A picture of the gel was taken under UV light exposure 
with a transparent ruler placed alongside the gel so that the distance that any band of 
DNA had migrated could be read directly from the photographic range. 
A  partial  depurination  of  DNA  was  performed  by  soaking  the  gel  in  1/50  HCl  for 
10 min at RT with constant gentle agitation. Then the gel was rinsed with dH2O and 
denatured  in  1.5  M  NaCl;  0.4  M  NaOH  for  at  least  30  min.  In  the  meanwhile  the 
preparations for the downward transfer was done: i) the unused gel above the wells was 
removed using a scalpel, ii) the membrane (Biodyne B positively-charged nylon 6.6, Pall 
Corporation, Darmastadt, Germany) was cut slightly larger than the gel, iii) 6 filter paper 
sheets were cut to the same size than the membrane, iv) enough paper towels were cut to 
the same size than the membrane and v) a filter paper bridge large enough to cover the 
area of the gel and reach across into the transfer buffer (1.5 M NaCl; 0.4 M NaOH) 
reservoirs was cut. 
Thereafter the downward transfer was assembled as follow depicted: B. MATERIALS AND METHODS  40 
 
Adapted from www.piercenet.com 
The  transfer  was  let  for  3  -  4  hours,  thereafter  was  disassembled  and  verified  by 
examining the gel under UV light. The position of the bands of size marker was marked 
and  then  the  lane  was  cut  to  avoid  crosslink  with  the  probe.  The  membrane  was 
neutralized by incubation in 0.5 M Tris pH 7.5, 1 M NaCl for at least 30 min before 
incubation with 8-12 ml ULTRAhyb hybridization buffer (Ambion Inc.) for 1 hour to 
O/N at 65ºC. The PRE fragment, present in all retroviral vectors, was used as a probe 
for  hybridization.  The  volume  of  radiolabeled  specific  probe,  prepared  as  above 
described, needed for a final concentration of ~10
6 cpm/ml of hybridization solution was 
denatured by 5 min incubation in boiling water and immediately added direct to the 
ULTRAhyb  hybridization  buffer  (Ambion  Inc.)  used  to  prehybridize  the  blot.  The 
hybridization  was  preformed  at  65ºC  and  O/N  incubation. Membranes were washed 
with  2x  SSC  0.5%  SDS  and  0.1x  SSC  0.1%  SDS  at  42°C  until  elimination  of  the 
background  radioactivity.  The  membrane  is  then  sealed  and  exposed  to  X-ray  film 
(Kodak BioMax MS Film) for at least 16 hours at -80°C with intensifying screens. 
B.3.19  Northern Blot  
Analysis  of  3  to  7.5  µg  total  RNA  by  Northern  Blot  was  accomplished  using  the 
NorthernMax® Kit according to the instructions of the manufacturer (Ambion Inc.). The 
samples were mixed with loading buffer in a proportion of 1:2 and Ethidium Bromide 
was  added  to  a  final  concentration  of  10  µg/ml.  After  denaturation  of  RNA  by 
incubation  15  min  at  65ºC  the  samples  were  loaded  into  a  MOPS  formaldehyde 
denaturing gel. The gel was run at ~ 5 V/cm until the bromophenol blue dye front had 
migrated almost to the bottom of the gel. Examination of the gel by exposure to UV 
light, was preformed to asses the integrity of the RNA. A downward transfer from gel to 
a positively charged nylon membrane was set up and let it proceed for approximately 
3 hours  with  the  provided  transfer  buffer.  After  transfer  the  RNA  was  immediately 
crosslinked  to  the  membrane  by  ultraviolet  light  exposure.  Prehybridization  and 
hybridization were performed with 8-12 ml of supplied hybridization buffer at 42ºC for B. MATERIALS AND METHODS  41 
1 hour and overnight respectively in a hybridization tube. The PRE fragment, present in 
all retroviral vectors, was used as a probe for hybridization. The volume of radiolabeled 
specific  probe,  prepared  as  described  above,  needed  for  a  final  concentration  of 
~10
6 cpm/ml of hybridization solution was denatured by 5 min incubation in boiling 
water and immediately added directly to the hybridization buffer used to prehybridize 
the blot. The hybridization was preformed at 65ºC and O/N incubation. Membranes 
were washed, sealed and exposed to X-ray film (Kodak BioMax MS Film) for 4 hours at 
-80ºC. In order to assess the loaded quantity of RNA, 
32P-αCTP 18S rRNA probe was 
prepared by in vitro transcription with the MAXIscript® kit (Ambion Inc.) following 
manufacturer recommendations. Summarizing, the pTRI-18S plasmid (Ambion Inc.), 
T3 polymerase and the rest of the components needed for the transcription reaction were 
mixed and incubated at 37ºC for 1 hour. Turbo DNA was then added to the mixture to 
remove the template DNA, and finally the reaction was purified from free nucleotides 
by  gel  filtration  using  Ambion’s  NucAway
TM  spin  columns.  The  membrane  was 
incubated for 1 hour with new ULTRAhyb hybridization buffer (Ambion Inc) (without 
stripping step) and then hybridized with the loading control probe overnight at 68ºC. 
After extensive washing of the membrane, it was again sealed and exposed to X-ray film 
(Kodak BioMax MS Film) for about 4 hours at -80ºC. 
B.3.20 Western Blot 
Western blotting is based on the one-dimensional gel electrophoresis of proteins and can 
provide information about the molecular size of a certain protein. The whole procedure 
of  western  blotting  comprises  gel  electrophoresis,  transfer  of  the  proteins  to  a 
polyvinylidene difluoride (PVDF) membrane, incubation of the membrane with specific 
antibodies and the detection of specific signals. 
B.3.20.1  Preparation of protein from cultured cells 
Cultured selected cell lines were harvested by ultracentrifugation at 500 x g for 5 min at 
4ºC and washed once with cold-phosphate-buffered saline. The cells were re-suspended 
to  a  concentration  of  5x10
7  cells/ml  in  fresh  prepared  immunoprecipitation  buffer 
(20 mM  Tris·HCl,  pH  8.0,  150  mM  NaCl,  1  mM  EDTA  and  1%  Triton  X-100) 
containing protease inhibitors (20 µg/ml chymostatin, 2 mM PMSF, 10 µM leupeptin 
and 1 mM AEBSF). After incubation on ice for 30 min with occasionally vortex, the 
mixture  was  centrifuged  at  14.000  rpm  for  2  min  at  4ºC.  The  supernatant  was 
transferred  to  a  new  microcentrifuge  tube  and  freezed  at  -80ºC  until  required.  To 
measure protein concentration, 1 µl sample or protein standard was mixed with 250 µl 
of Bradford Reagent in a 96 well plate. The mixture was incubated for 5 min at RT and 
the absorbance was measured at 595 nm wave length on a plate reader (SoftMaxpro). 
The obtained values were then compared with the linear regression obtained from the 
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B.3.20.2  SDS polyacrylamide gel electrophoresis 
30 µg of cell extracts were separated by SDS-PAGE. To this end a 5% polyacrylamide 
stacking gel and a 10% resolving gel were prepared in between the Spacer and Short 
glass plates. After complete polymerization, the gel was placed into the electrophoresis 
tank and mounted with running buffer (25 mM Tris-Base; 192 mM Glycine; 0.1% [w/v] 
SDS; pH 8.3). The protein samples were mixed with an equal volume 4x sample buffer 
(350 mM Tris pH 6.8; 30% Glycerin; 10% SDS; 9.3% DTT; 0.01% Bromphenolblue), 
and then loaded onto the lanes. Gels were run about 30 min at 80 V throughout the 
stacking gel and further 3-4 hours at 120 V. 
B.3.20.3  Immuno-blot / Western Blot 
After separation by SDS-PAGE, proteins were blotted via electrophoresis onto a PVDF 
membrane using a semi-dry technique (Towbin et al., 1979). The membrane was cut to 
gel size, soaked in methanol and placed on top of 3 filter papers which where placed on 
a fiber pad. Both the filter papers and the fiber pad were pre-soaked in blotting buffer 
(2.01 mM Tris-Base; 15 mM Glycin; 20 [v/v] Methanol) and placed on the anode. The 
SDS-PAGE gel was removed from the glass plates and placed on top of the membrane. 
Another 3 sheets of filter paper and one fiber pad pre-soaked with blotting buffer were 
placed on top of the gel and followed by the cathode. Protein transfer was conducted for 
2 hours at 120 V. 
B.3.20.4  Immunostaining of blotted proteins 
Blotted membranes were blocked at RT for 45 min with 3% non-fat dried milk in PBST 
(0.1% Tween20 PBS) with moderate shaking. Blots were then incubated with 5 ml of 
moAb48 primary Ab 1:400 diluted in 3% non-fat dried milk in PBST for O/N at 4°C 
with shaking. The next day an incubation of 1 hour at RT was performed. Blots were 
then washed three times in PBST for 10 min. Incubate with IRDye 680 Conjugated Goat 
(polyclonal) Anti-Rabbit IgG Ab 1:10.000 diluted in 3% non-fat dried milk in PBST for 
45 min at room temperature. At last the blots were washed again three times for 10 min 
with PBST and one last time with PBS. Then the blots were scanned with the Odyssey 
Scanner.  To  control  for  equal  protein  loading,  the  blots  were  incubated  with  Actin 
(I-19)-R SC-1616-R rabbit polyclonal IgG 1:500 diluted in 3% non-fat dried milk in 
PBST for 2.5 hours, then wash 3 times in PBST for 10 min each wash. An incubation of 
30 min  with  IRDye800  secondary  Ab  1:10.000  diluted  in  3%  non-fat  dried  milk  in 
PBST was performed and followed by 3 washed for 10 min with PBST and one last 
time with PBS. Finally the blots were scanned with the Odyssey Scanner. B. MATERIALS AND METHODS  43 
B.4  Specific equipment for cell culture 
Greiner, Frickenhausen, Germany  Cell culture dishes 
Becton Dickinson, Heidelberg, Germany 
Greiner, Frickenhausen, Germany  Cell culture flasks  
Becton Dickinson, Heidelberg, Germany 
Cell scraper  Corning, Wiesbaden, Germany 
Cell strainer (100  m, 40  m)  Becton Dickinson, Heidelberg, Germany 
Cryocontainer  Nalgene, Rochester, NY, USA 
Cryotube  Nalgene, Rochester, NY, USA 
FACS-scan  Becton Dickinson, Heidelberg, Germany 
FACS-calibur  Becton Dickinson, Heidelberg, Germany 
14ml Polypropylene Round-Bottom Tube #35.2059  Becton Dickinson, NJ, USA 
Incubator  Heraeus, Hanau, Germany 
KOVA Glasstic® Slide  Hycor #87144, Kassel, Germany 
Light microscope  Zeiss, Göttingen; Leica, Wetzlar, Germany 
Microcentrifuge  Eppendorf, Hamburg, Germany 
MiniMACS
TM separator #130-042-102  Miltenyi Biotec, Bergisch Gladbach, Germany 
MS Columns #130-041-301  Miltenyi Biotec, Bergisch Gladbach, Germany 
Non-Tissue Culture Treated Plate, 24Well  Becton Dickinson, NJ, USA 
Stericup-filter  Millipore, Eschborn, Germany 
Sterilbank  Heraeus, Hanau, Germany 
Sterilfilter (0,22  m; 0,45  m)  Millipore, Eschborn, Germany 
Tissue culture flask  Greiner, Frickenhausen, Germany 
 
B.5  Materials for cell culture 
B.5.1  Chemicals and Reagents for Cell Culture 
Anti FITC MicroBeads  Miltenyi Biotec, Bergish Gladbach, Germany 
Calcium chloride  Sigma, Taufkirchen, Germany 
Chloroquine  Sigma, Taufkirchen, Germany 
DMEM (high glucose)  Life Technologies (#21969-035), Karlsruhe, Germany, 
DMSO dimethylsulfoxid  Sigma, Taufkirchen, Germany 
DNase I (RNase-free)  Roche (#776785), Mannheim, Germany 
EasySep® Magnet #18000  Stemcell Technologies, Vancouver, Canada 
EasySep® Mouse Sca-1 Selection Kit #18756  Stemcell Technologies, Vancouver, 
EDTA  Sigma, Taufkirchen, Germany 
Enfluran (2-Chloro-1.1.2-trifluoro-  Abbott, Wiesbaden, Germany 
Ethyldifluoromethylether (Ethrane))   
FACS
 TM Lysing Solution 10x Concentrate  BD Biosciences Pharmigen (#349202), 
Seromed (#S0115), Berlin, Germany  FBS (fetal bovine serum) 
StemCell Technologies (#06400), Vancouver, Canada 
Formaldehyde  Roth, Karlsruhe, Germany 
Glutamine (L-glutamine)  BioWhittaker, Verviers, Belgium 
HBSS (hanks' balanced salt solution)   Sigma (#H6648), Taufkirchen, Germany 
HEPES  Sigma, Taufkirchen, Germany 
HSA (human serum albumin)  DRK-Blutspendedienst, Springe, Germany 
Methocult GF M3434  StemCell Technologies, Vancouver, Canada 
PBS (ohne Ca
2+ und Mg
2+)  BioWhittaker, Verviers, Belgium B. MATERIALS AND METHODS  44 
Dulbecco's Phosphate Buffered Saline  PAA Laboratories GmbH 
Penicillin-Streptomycin #P11-010  PAA Laboratories GmbH 
Polybrene  Sigma, Taufkirchen, Germany 
Poly-L-lysine solution  Sigma, Diagnaostics INC., St. Lous, USA 
Protaminsulfate  Sigma (#2162), Taufkirchen, Germany 
RetroNectin  Takara, Shiga, Japan 
rmIL-3 (recombinant murine interleukin 3)  PeproTech, Frankfurt, Germany 
rmIL-6 (recombinant murine interleukin 6)  PeproTech, Frankfurt, Germany 
rmSCF (recombinant murine stem cell factor)  PeproTech, Frankfurt, Germany 
RPMI 1640   Life Technologies (#31870-025), Karlsruhe, Germany 
(without Glutamine)   
StemSep-Systeme  StemCell Technologies, Vancouver, Canada 
Tris  Roth, Karlsruhe, Germany 
Tuerk Solution  Sigma, Taufkirchen, Germany 
Trypan blue (0,4% solution)  Sigma(#T8154), Taufkirchen, Germany 
Trypsin –EDTA  Life Technologies (#25300-054), Karlsruhe, Germany 
B.5.2  Antibodies for FACS analysis 
Purified  anti-mouse  CD16/CD32  (Fcγ  III/II  Receptor)  BD Biosciences Pharmigen 
Mouse γ1 – APC (x40)  BD Biosciences Pharmigen 
CD45R (B220)-PE Ord.no.130-091-828  Milteny Biotech GmbH 
APC anti-mouse CD117 (c-kit) (2B8) Cat.553356  BD Biosciences Pharmigen 
PE  anti-mouse  CD3  Molecular  Complex  (17A2)  BD Biosciences Pharmigen 
Anti-mouse Ly-6A/E (Sca-1) R-Phycoerythrin Conj. Cat.No.:MSCA04  Caltag Lab 
Simultest 
TM Control γ1/ γ1 Cat.No.349526  BD Biosciences Pharmigen 
PE anti-mouse Ly-6G (Gr-1) and Ly-6C (RB6-8C5) Mat.  BD Biosciences Pharmigen 
PE  anti-mouse  CD11b  (Integrin  αM  chain,  Mac-1  α  BD Biosciences Pharmigen 
PE rat IgG2a,k Cat.No.:553930 (was:11025A)  BD Bioscience Pharmigen 
7-AAD Cat.No.:51-68981E (559925)  BD Biosciences Pharmigen 
Anti-Flavocytochrome b558 moAb (#D162-3)  MoBiTec 
(Nakamura et al., 1987)   
Anti-Flavocytochrome b moAb, FITC Labeled (#D162-4)  MoBiTec  
 
B.5.3  Cell lines 
Name  Description  Reference(s) 
293T  Derived  from  293  cells,  a  continuous  human 
embryonic kidney cell line. 
Transformed by sheared Type 5 Adenovirus DNA 
Graham et al 1977. 
(DuBridge et al., 1987) 
ATCC CRL-1573 
SC-1  Mouse embryonic fibroblasts. 
Exhibit a greater sensitivity than other mouse lines 
to MuMLV. 
(Hartley and Rowe, 
1975) 
PLB-985  Human, diploid, myeloid leukemia cell line. 
Obtained  from  the  peripheral  blood  of  a  patient 
with refractory myeloblastic leukemia. 
With  the  capacity  for  both  granulocytic  and 
monocyte/macrophage  maturation  in  the  presence 
of inducing agents. 
(Tucker et al., 1987)  
DSMZ Cat. Code: ACC 
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X-CGD 
PLB-985 
PLB-985 derivative cell line. 
Based on disruption by homologous recombination 
of the X-linked gp91
phox gene in XO PLB-985 cells. 
Widely used to study functionality, reconstitution 
and structure of the NADPH oxidase. 
(Zhen et al., 1993) 
 
 
B.6  Cell culture methods 
B.6.1  Common cell culture 
All mammalian cells were maintained at 37ºC in an incubator in 5% CO2 and 95% air 
humidity. The adherent 293T cells were used to generate the viral particles and the 
adherent SC1 cells were used for titer determination of ecotropic pseudotyped particles. 
For standard culture, these cell lines were grown in DMEM complemented with 10% 
heat-inactivated fetal bovine serum (FBS), 4 mM L-Glutamine and antibiotic (100 U/ml 
Penicillin  and  100  mg/L  Streptomycin)  in  flasks  of  varying  sizes  depending  on  the 
requirement of cells. The cells were then allowed to grow until confluence of 80-90% 
had been reached, whereupon the cells were subsequently split by trypsinization and 
re-seeded at a lower density. Trypsin treatment of cells was performed by removal of the 
culture medium from the cells, followed by one wash with Ca
2+/ Mg
2+ free PBS. After 
removal of PBS 1-3 ml trypsin, for the T25 and T75 respectively, was applied to the 
cells and the cells incubated at 37ºC until they became detached as observed under a 
low-powered  microscope.  Fresh  medium  was  then  directly  applied  and  the  cells 
re-plated  at  desired  density  in  new  flasks  or  Petri  dishes.  For  the  retroviral  vector 
production  293T  should  be  used  at  low  passage  number  (<p20)  and  kept  as  frozen 
stocks in liquid nitrogen. The non adherent growing cells PLB-985 and its derivatives 
were used for titer determination of GaLV pseudotyped viral particles and for functional 
assays. They were grown in RPMI complemented with 10% heat inactivated FBS, 4 mM 
L-Glutamine and antibiotic (100 U/ml Penicillin and 100 mg/L Streptomycin) in flasks 
of varying sizes depending on the application. The cells were maintained in culture with 
a density between 1x10
5 and 1x10
6 cells/ml with a medium renewal every 3 days. 
B.6.2  Thawing and freezing cells 
To thaw liquid nitrogen frozen cells a fast management is recommended. The cells were 
quickly placed at 37ºC until almost all were thawed. Immediately 1 ml of medium was 
added to the freezing vial and gently transferred to a 15 ml falcon. Further 5 ml of 
medium were added and carefully mixed. The cells were spin down at 1.200 rpm for 
5 min and the supernatant was discarded. This washing step was repeated once again to 
completely remove the freezing medium. Lastly the cells were re-suspended in medium 
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To freeze cells it is recommended that the cells are frozen prior to confluence in order to 
assure the viability of the cell line. The cells were washed and trypsinized as described 
above and transferred to a 15 ml falcon and spin down at 1200 rpm for 5 min. The 
medium  was  discarded  and  1  ml  of  freezing  solution  per  10
6  cells  was  used  to 
re-suspend  the  cells  (90%  heat-inactivated  FBS,  10%  DMSO).  The  mixture  was 
transferred  to  a  cryogenic  vial  and  placed  at  -80ºC  overnight.  Lastly  the  cells  were 
transferred to liquid nitrogen to long-term conservation. 
B.6.3  Assessing cell viability by Trypan Blue exclusion 
The viability of cultured cells was determined by trypan blue exclusion. Trypan blue is a 
vital dye which reactivity is based on the fact that the chromopore is negatively charged 
and does not interact with the cell unless the membrane is damaged. Therefore, all the 
cells which exclude the dye are viable (Freshney, 1987). 
The  cell  suspension  was  diluted  with  trypan  blue  solution  and  set  up  in  a  KOVA 
Glasstic  Slide.  Viable  cells  were  then  counted  under  light  microscope.  The 
concentration of cells per ml is calculated by: 
Cell density [cells/ml] = counted cells x dilution factor x 10
4 
Total cell number = cell density x volume [ml] 
B.6.4  Retroviral  particle  production  via  calcium  phosphate  Ca3(PO4)2  mediated 
transfection 
The  Calcium  Phosphate  transfection  is  a  method  for  introduction  of  DNA  into 
mammalian  cells  based  on  the  formation  of  a  calcium  phosphate-DNA  precipitate 
(Graham and van der Eb, 1973; Wigler et al., 1977). The procedure is routinely used to 
transfect a wide variety of cell types for either transient expression or for the production 
of  stable  transformants.  The  DNA  is  mixed  directly  with  0.25  mM  CaCl2  in 
0.1xTE:dH2O  2:1.  This  is  then  added  dropwise  to  the  same  end  volume  of  2xHBS 
buffer  (50  mM  HEPES  pH  7.05,  280  mM  NaCl,  1.5  mM  Na2HPO4)  where  a 
precipitation of calcium phosphate occurs. Finally, the dispersion is given to the cell 
culture where the calcium phosphate is thought to facilitate the binding of the DNA to 
the cell surface and is believed that then the DNA enters the cell by endocytosis (Welzel 
et al., 2004). 
In the present study HEK 293T cells were seed, 24 hours prior to transfection, at 5x10
6 
cells per 100 mm plate in DMEM 10% FCS to achieve 70-80% confluence at the time 
of transfection. At the day of transfection chloroquine, which is a weak base that inhibits 
fusion of the endosome with the lysosome by buffering the lysosome interior, was added 
to the medium to a final concentration of 10 µM, 5 min prior to transfection (Walker et 
al., 1996). Thereafter, 5 µg transfer vector, 7.5 µg pcDNA3MLVg/p (kindly provided by 
Prof.  Dr.  M.  v.  Laer,  Frankfurt/GSH)  and  2  µg  envelope-containing  plasmid  were B. MATERIALS AND METHODS  47 
cotransfected  using  the  calcium  phosphate  precipitation  method.  The  used  envelope 
depends  on  the  nature  of  the  target  cells.  In  the  present  study  GaLV  pseudotyped 
particles  were  produced  to  infect  human derivative cells, and ecotropic particles for 
mice cells. The medium was changed after 16 hours to avoid cell toxic effects of the 
chloroquine  treatment.  Supernatant  containing  the  viral  particles  was  collected 
48-72 hours after transfection, filtered through a 0.22 µm filter and used immediately 
for transduction or stored at -80ºC until required. Equal transfection efficiencies were 
controlled by immunostaining the cells with FITC labeled Anti-Flavocytochrome b558 
monoclonal antibody and by flow cytometric analysis. 
B.6.5  Titer determination and transduction of target cells 
Titers (transducing units/ml) of the viral supernatants were determined by transducing 
predefined number of X-CGD PLB-985 or SC-1 target cells with serial dilutions of viral 
supernatant. Transduction was performed by spinoculation (90 min at 2.500 rpm and 
32ºC) assisted by adding 4 mg/ml protamine sulfate (Cornetta and Anderson, 1989). 
Cells were grown for 3 days before analysis of the percentage of positive cells by flow 
cytometry with FITC labeled Anti-Flavocytochrome b558 monoclonal antibody which 
recognizes an external epitope of gp91
phox (7D5; (Yamauchi et al., 2001)) or isotype 
control antibody. 
Transducing Units /ml = seeded cells x dilution factor x (% positive cells / 100) 
B.6.6  Flow cytometry 
Also referred to as Fluorescence Activated Cell Sorting (FACS) this technique is used to 
characterize the phenotype of different cell types by analysis of cell surface membrane 
protein.  In  the  present  study  usually  1-2  x  10
5  cells  were  washed  with  PBS.  The 
supernatant was poured off and the cells were incubated with a primary antibody or a 
fluorescent dye bound antibodies for 20 min. Then, one wash step was performed with 
FACS Buffer (1% FBS, 0.1% NaN3 in 1x PBS) and if required a secondary antibody 
added to the cells. After discarding the supernatant of the last wash 200 µl of FACS fix 
solution (1% Formaldehyde in 1x PBS) were added to fix the cells. Control staining 
with appropriate isotype-matched control mAbs was included to establish thresholds for 
positive  staining  and  background  linear  scaled  mean  fluorescence  intensity  (MFI) 
values. The percentage (%) of positive cells was calculated as % of positive cells stained 
with  specific  mAb  -  %  of  background  staining  with  corresponding  isotype  control. 
 MFI was calculated as MFI of cells stained with specific mAb - MFI of cells stained 
with corresponding isotype control. 
B.6.7  Cell differentiation 
For  granulocytic-like  cell  differentiation,  in  the  case  of  PLB-985  and  derivatives, 
logarithmically  growing cells at a density of 2x10
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dimethylsulfoxid (DMSO) for 6 days in the presence of only 2.5% FBS. Flow cytometry 
was  performed  to  ensure  the  differentiation  with  labeled  cells  with  anti-CD11b+ 
antibody. 
B.6.8  Magnetic Cell Sorting 
The Magnetic cell sorting procedure is based in the magnetic beads which are extremely 
small, superparamagnetic particles and in columns containing an optimized matrix to 
generate a strong magnetic field when placed in a permanent magnet. 
In the present study gp91
phox containing cells were selected with this system by the 
MACS MicroBeads, the MS columns and the MiniMACS separator. Up to 2x10
8 cells 
(containing up to 1x10
7 positive cells) were resuspended in 400µl PBS and 400µl 7D5 
antibody against the cytochrome b558 (Nakamura et al., 1987) and incubated for 20 min 
at RT. Then the cells were washed with PBS and resuspended in 1ml PBS. Following 
addition  of  30 l  RAM-IgG1  FITC  Ab  an  incubation  step  of  15  min  at  RT  was 
performed. The cells were washed twice with MACS Buffer (PBS pH 7.2, 0.5% BSA 
and 2 mM EDTA) and lastly incubated with 50 l Anti-FITC MicroBeads for 15 min at 
4°C. One last washing step with MACS buffer was performed prior to apply the cells to 
the column placed in a MiniMACS™ Separator (magnet). Three washing steps were 
performed  to  remove  the  unlabeled  cells  before  removing  the  column  from  the 
separator. To elute labeled cells 1 ml of MACS buffer was loaded onto the column. To 
increase the purity of the magnetically labeled fraction it was passed over a second 
column  following  the  same  protocol.  The  percentage  of  positive  cells  was  finally 
assessed by FACS analysis of the eluted fraction. 
B.6.9  Cytochrome C assay 
A continuous cytochrome c reduction assay is a quantitative method to measure the 
superoxide production by a determined number of cells. In the present study it was used 
to  quantify  the  superoxide  formation  by  granulocyte-differentiated  PLB-985  cells, 
mSca-1
+  cells  and  derivative  cell  lines  (Mayo  and  Curnutte,  1990).  Briefly,  1x10
6 
PLB-985 cells and derivatives, or 2.5x10
6 mSca-1
+ cells and derivatives were washed in 
7.5 mM glucose HBSS
++. Cells were spin down and re-suspended in pre-warmed 250 µl 
HBSS
++ 7.5 mM glucose containing 75 µM cytochrome C and plated in a 96 well plate. 
The  assay  was  performed  at  37  °C  using  a  Spectra  MAX  340  reader  (Molecular 
Devices)  after  cell  stimulation  with  freshly  prepared  PMA  (400  ng/ml).  Superoxide 
production  was  quantified  using  an  extinction  coefficient  of  21.1  mM
-1  cm
-1  for 
cytochrome C based on a light path of 0.6 cm. Data were analyzed using the SOFTmax 
Version 2.02 PRO software to determine Vmax over a 1.8 min interval. B. MATERIALS AND METHODS  49 
B.6.10 DHR assay 
This method describes the functional analysis of the NADPH oxidase and can be used to 
investigate its reconstitution in gp91
phox transduced X-CGD cells. It is also known as 
Burst-Test and uses dihydrorhodamine 123 (DHR 123) as a substrate for the respiratory 
burst reaction in stimulated neutrophils. DHR123 is oxidized by intracellular H2O2 to 
rhodamine 123 which is a fluorescent compound detectable by FACS analysis in the 
first channel. It is really useful since it identifies the carrier phenotype and discerns 
between other pathologies such as complete myeloperoxidase deficiency (Mauch et al., 
2007). 
For  the  PLB-985  cells  ,  mSca-1
+  and  both  derivatives  1x10
6  cells  of  interest  were  
diluted  in  1ml  with  pre-warmed  HBSS  (with  Ca
2+,  Mg
2+,  0.5%  BSA  and  7.5  mM 
glucose) in FACS tubes (preparing two samples for each cell type, 1x non-stimulated 
and 1x stimulated). Then, the cells were incubated at 37°C in the 5% CO2 incubator for 
5 min. 40 µl catalase (1.000 U) were added to both samples and 10 µl of PMA 1mg/ml 
to  the  stimulated  sample.  The  cells  were  then  incubated  at  37°C  in  the  5%  CO2 
incubator for 5 min. 25 µl of the 1mM DHR were then added to both stimulated and the 
non-stimulated  sample.  A  last  incubation  step  was  performed  at  37°C  in  5%  CO2 
incubator for 15 min. The tubes were then placed on ice to stop the reaction and the 
samples were measured in flow cytometer within the next 30 min. 
For the peripheral blood samples obtained from transplanted mice, the Phagoburst® Kit 
from  ORPEGEN  Pharma  was  used.  Briefly  1  ml  peripheral  blood  (preparing  two 
samples, 1x non-stimulated and 1x stimulated) was placed on ice for 10 min. 20 µl of 
PMA  solution  (supplied  with  the  kit)  were  added  to  the  stimulated  sample  and  the 
mixture was incubated for 10 min at 37ºC. Then, 20 µl of DHR solution (supplied with 
the kit) were added to both samples and 10 min incubation was again performed at 
37ºC. Thereafter, 2 ml of lysis buffer (supplied with the kit) were added to the samples 
and incubated 10 min at RT. After washing with the supplied wash buffer, 200 µl of 
DNA staining solution (supplied with the kit) were added to the samples to exclude 
aggregation artifacts of bacteria or cells helping then to identify the granulocytic and 
monocytic  populations  in  the  FACS  analysis  which  was  performed  after  10  min 
incubation on ice. 
B.7  Primary cells and animal experiments 
B.7.1  Breeding of Animals 
All  mice  used  in  the  experiments  were  bred  in  the  animal  centre  of  the 
Georg-Speyer-Haus (Frankfurt, Germany). The health status of the animal centre was 
monitored based on the guidelines of the Federation of European Laboratory Animal 
Science Associations (FELASA). They were bred in standard sterile cages (5 mice/cage) B. MATERIALS AND METHODS  50 
and feed with standard rodent diets and water. For the bone marrow cell preparation, 
mice  of  an  age  between  6-8  weeks  were  chosen.  All  experiments  were  performed 
according to the German Animal Protection Law. 
B.7.2  Preparation of murine Bone Marrow Cells 
The mice chosen for the bone marrow cell preparation were sacrificed after narcosis 
with enfluran. Bone marrow from femurs and tibias of each mouse was isolated by 
flushing  with  a  23-gauge  needle  and  5  ml  RPMI  supplemented  with  antibiotics 
(100 U/ml  Penicillin  and  100  mg/L  Streptomycin).  The  bone  marrow  cells  were 
suspended well and centrifuged at 1200 rpm and 4° C for 5 minutes. The cell pellet was 
resuspended at a concentration of 1 x 10
8
 
cells/ml in PBS supplemented with 1 mM 
EDTA and 2% FBS for further Sca-1
+ magnetic cell sorting. 
B.7.3  mSca-1
+ selection from murine Bone Barrow preparations 
The  mSca-1
+  cells  are  a  subpopulation  of  the  bone  marrow  (BM)  identified  as 
hematopoietic stem (Spangrude et al., 1988; Spangrude, 1989). 
The mSca-1
+ cells were isolated from freshly prepared bone marrow with the EasySep® 
Mouse  SCA1  Selection  Kit  as  indicated  by  the  manufacturer.  Up  to  2x10
8  fresh 
prepared mBM cells were counted with Tuerk solution and suspended at a concentration 
of 1 x 10
8
 
cells/ml in buffer containing 1x PBS, 1 mM EDTA and 2% FBS. Murine FcR 
blocker (supplied with the kit) was added to the cells at a concentration of 10  l/ml. 
Then Sca-1 PE labeling reagent was added at a concentration of 15  l/ml and the sample 
was incubated at 4° C for 15 min. The cells were washed once with 10-fold excess 
buffer  and  resuspended  in  half  of  the  original  volume  and  further  transferred  to  a 
12 x 75 mm polystyrene tube. Thereafter, 100  l/ml PE-selection cocktail was added to 
the sample and incubated at 4° C for 15 min. At last, EasySep
TM Magnet nanoparticles 
were added at 50  l/ml to the sample and the mixture was further incubated at room 
temperature for 10 min. The total sample volume was brought up to 2.5 ml by adding 
buffer. Finally the tube was placed into the magnet and set aside for 5 minutes. Then the 
supernatant fraction was poured off and the magnetically labeled cells remained inside 
the tube. The tube containing the negative sample was removed from the magnet and 
2.5 ml buffer were added to elute the cells. The sample was mixed by gently pipetting 
up and down 2-3 times and placed into the magnet again. This process was repeated 
6 times and at the end the selected cells were suspended in the suitable culture medium 
for further experiments. 
B.7.4  Lineage depeletion 
Lineage negative cells are isolated by depletion of cells expressing so-called “lineage” 
antigens. In the present study the Lineage Cell Depletion Kit (Miltenyi Biotec) was used 
following manufacturer instructions. BM cells were passed through 30µm nylon mesh to B. MATERIALS AND METHODS  51 
remove  cell  clumps.  Thereafter  cells  were  centrifuged  at  300xg  for  10  min  and 
supernatant  was  pipetted  off.  Cells  were  resuspended  in  40µl  of  0.5%  BSA  and 
2 mM EDTA  in  PBS  per  10
7  cells.  10  µl  of  Biotin-Antibody  Cocktail  (CD2,  CD3, 
CD11b, CD14, CD15, CD16, CD19, CD123, and CD235a) per 10
7 cells was added and 
the mixture was incubated for 10 min at 4ºC. Further 30 µl of of 0.5% BSA and 2mM 
EDTA  in  PBS  per  10
7  cells  were  added  to  the  mixture  prior  to  the  Anti-Biotin 
MicroBeads which were added to a concentration of 20 µl per 10
7 cells. Following to a 
15 min incubation step at 4ºC, the cells were washed by adding 1-2 ml of buffer per 
10
7 cells and centrifugation at 300xg for 10 min. The supernatant was pipetted off and 
the cells were then resuspended in 500 µl 0.5% BSA and 2mM EDTA in PBS per 
10
8 cells  prior  to  magnetic  separation  with  the  autoMACS
TM  separator  and  the 
“Deplete” program. The purity of the enriched population was then evaluated by flow 
cytometry. 
B.7.5  Transduction of mSca-1
+ cells 
mSca-1
+  cells  were  pre-stimulated  for  two  days  prior  to  transduction  in  RPMI1640 
complemented  with  10%  heat-inactivated  (FBS),  4mM  L-Glutamine,  antibiotic 
(100 U/ml Penicillin and 100 mg/L Streptomycin) and cytokines (50-100 ng/ml mSCF, 
50 ng/ml mIL-6 and 10 ng/ml mIL-3). Twenty four hours prior to transduction a 24-well 
plate (non-tissue culture) was coated with 10.5 µg/cm
2 RetroNectin and incubated over 
night. At the transduction day RetroNectin solution was replaced by 1 ml of 2% HSA in 
H2O in order to block the plate for 30 min at RT. The HSA solution was discarded and 
the wells were washed with 1 ml HBSS/2.5% (v/v), 1M Hepes and 1 ml 1x PBS. The 
1x PBS  remained  in  the  wells  until  the  viral  supernatant  was  added.  The  ecotropic 
pseudotyped viral supernatant, previously tittered in SC1 cells, was thawed quickly in a 
37°C water bath and added into the RetroNectin coated wells with the required MOI 
(the total volume of the viral supernatant never exceeded 1.5 ml). The virus-loaded plate 
was centrifuged at 3000 rpm for 30 min at 4° C. Then, the supernatant was discarded 
and the viral loading process was repeated as many times as needed to reach the desired 
MOI. Since only about 50% of the infectious particles remain bound to the RetroNectin 
(Li  et  al.,  2003)  the  double  amount  of  infecting  particles  for  the  desired  MOI  was 
preloaded.  In  the  transduction  day  the  cells  were  diluted  to  a  concentration  of 
7.5x10
5
 
cells/ml and 400  l of the cell suspension were added into the prepared wells 
after removing of the last viral supernatant. This process was repeated the next day. 
Twenty four hours after the last transduction cycle the transduced cells were washed 
twice with 1x PBS and used for further studies. 
B.7.6  Bone Marrow transplantation of genetically modified cells 
The recipient mice were lethally irradiated with a total dose of 11 Gy split into two 
doses  of  5.5  Gy  in  two  consecutive  days  from  a  Cs  γ-ray  source  at  the B. MATERIALS AND METHODS  52 
Georg-Speyer-Haus (Frankfurt/Main, Germany). The cells for transplantation with the 
appropriate cell number were washed 3 times with PBS, and then kept on ice until 
transplantation.  2-4 hours  after  irradiation,  transplantation  was  performed  through 
injection of the cells into the tail vein of the recipient mice. From that day on and during 
two weeks, the mice were treated with 1.67 mg/ml Neomycin supplemented H2O as 
preventive  antibiotic.  The  analysis  of  the  mice  was  carried  out  6  weeks  after 
transplantation. 
B.7.7  In vitro differentiation of mSca-1
+ cells 
For in vitro differentiation of mSca-1
+ cells and derivatives, stimulated cells at a density 
of 3x10
5 cells/ml were exposed to 10ng/ml IL-3 and 100ng/ml G-CSF during 9 days. 
The cell density was maintained constant during this time by adding more media or 
splitting the cells into two culture flasks. Differentiation was ensured at day 9 with Gr-1 
and  CD11b  immunolabeling.  The  differentiated  cells  were  then  used  for  functional 
assays such as cytochrome c and DHR assay which are previously described (see B.6.9 
Cytochrome C assay and B.6.10 DHR assay). 
B.7.8  Methylcellulose Based CFU-assay 
This method was used to determine the potential of hematopoietic progenitor cells in 
total bone marrow or peripheral blood to form colonies in semi-solid medium since 
methylcellulose based medium allows cells, derived from the same progenitor cell, to 
build colonies. 6000 mSca-1
+ were diluted in 300 µl IMDM medium supplemented with 
antibiotics (1000 U/ml Penicillin and 1000 mg/L Streptomycin), and then mixed with 
2.7  ml  methylcellulose  in  a  poly  tube.  After  vortexing  the  samples  were  set  aside 
5-10 min until the air bubbles disappeared. Then 1 ml mixtures were dispensed into 
each of two 35 mm culture dishes using a 3 ml syringe and a 16 gauge blunt-end needle. 
The dishes were gently rotated to spread the methylcellulose evenly and placed in a 
100 mm petri dish with a third 35 mm dish containing 3 to 4 ml of sterile water. This 
plate was incubated for 10 days at 37° C in the 5% CO2 incubator. When counting the 
colonies, the cell populations over 50 cells per colony were calculated as one colony. 
B.7.9  NBT assay 
After 10 days in culture hematopoietic colonies were counted and assayed for NADPH 
oxidase activity by the nitroblue tetrazolium (NBT) assay. For this, the cultures were 
overlaid with 0.2% NBT solution in PBS containing 1 mg/ml PMA and kept at 37ºC, 
5% CO2 for 60 min. The NBT reaction was stopped by adding directly to the cultures 
1.5%  paraformaldehyde.  NBT-positive  colonies  were  detected  with  an  inverted 
microscope. B. MATERIALS AND METHODS  53 
B.8  Retroviral vectors - Cloning strategies 
The SIN.11.SF.GFP.pre vector kindly provided by Prof. Dr. C.Baum was used to clone 
in the gp91
phox cDNA from the MSCV.gp91 (Dr. M.Grez). The SIN vector was digested 
with BamHI and then underwent blunt end with Klenow and dephosphorilation with 
Antarctic Phosphatase to avoid religation of the plasmid. The MSCV.gp91 plasmid was 
open at 5’ end of the gp91
phox cDNA with BamHI digestion followed of bunt ending 
with the Klenow polymerase and then excised with EcoRV digestion. Both insert and 
plasmid  were  isolated  and  ligated  originating  the  intermediate  plasmid 
SIN.11.SF.gp91.pre. 
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Fig. 9: Cloning strategy of the gp91
phox expressing SIN gammaretroviral vectors. The gp91
phox cDNA 
was excised from the MSCVgp91 plasmid and cloned in the SIN.11.SF.GFP.pre backbone substituting for 
the GFP sequence. Note that the nomenclature has changed; W is used to define the WPRE element 
instead of pre. 
This plasmid was used to exchange the MESV 5’LTR for the RSV 5’LTR from the 
SRS11.SF.GFP.pre plasmid provided by Prof. Dr. C.Baum (Schambach et al., 2006c). 
To this end both plasmid were excised with NdeI and SacII. Following isolation and 
ligation of the fragments, the resulting plasmid was named SRS11.SF.gp91.W-1. 
This plasmid underwent destruction of the NdeI cleavage site by NdeI digestion, blunt 
ending and religation. It was named SRS11.SF.gp91.W-2. Furthermore, a NotI site was 
introduced upstream of the internal promoter to help with further promoter exchanges. 
Therefore oligonucleotides were designed so that the fragment was amplified containing 
the  NotI  site.  The  PCR  amplification  fragment  was  then  cloned  into  the 
pCR
®2.1-TOPO
® plasmid and then by means of a three fragment ligation transferred to 
the  SRS11.SF.gp91.W-2  plasmid.  The  PCR  fragment  was  excised  from  the 
pCR
®2.1-TOPO
® plasmid with SacII-NheI and the SRS11.SF.gp91.W plasmid was cut 
once with SacII-DraIII and twice with NheI-DraIII. Following isolation of the fragments 
and ligation the resulting plasmid was called SRS11.SF.gp91.W. B. MATERIALS AND METHODS  54 
The SRS11.SF.gp91.W was used to exchange the leader regions always by SacII-NotI 
digestion.  The  leader  71  was  obtained  from  the  SF71gp91
phox  (kindly  provided  by 
Dr. S. Stein) and the leader 110 from the SR110.SF.GFP.pre (Prof. Dr. C.Baum). 
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Fig.  10:  Schematic  representation  of  the  three  different  leaders  in  their  corresponding  initial 
vectors. 
The mutation in the gp91
phox sequence was created as elsewhere explained (see B.3.16 
Site-Directed Mutagenesis and C.1.2 Site-directed mutagenesis of the gp91phox). 
The  intronless  version  of  the  MRP8  promoter  was  obtained  from  the 
pSLMRP8dN-Intgp91b plasmid (Dr. S.Stein). It was excised in a fragment containing 
also a part from the gp91
phox cDNA with SpeI-BspEI. The SRS11.SF.gp91.W-2 plasmid 
digested in two pieces with NheI–XhoI and XhoI–BspEI. After isolation of the three 
fragments a three fragment ligation was performed. The obtained plasmid was named 
SRS11.M8dNdI.W. 
To introduce the MRP8 first intron in the SRS11.M8dNdI.W PCR amplification was 
performed  with  the  pSL1180-MRP8dNGb  plasmid  (Dr.  S.Stein)  as  template  and 
modified oligonucleotides (BM-P1 and BM-P2) so that they introduce an NdeI cleavage 
site at each end of the intron. The PCR fragment was cloned in the pCR
®2.1-TOPO
® 
plasmid  and  then  transferred  by  NdeI  digestion  to  the  SRS11.M8dNdI.gp91m.W 
plasmid also opened with NdeI. After isolation, ligation and analysis of the resulting 
clones, the correct orientation was ensured by sequencing. 
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Fig. 11: Schematic representation of the SIN gammaretroviral constructs containing the MRP8 
promoter and its enhancer 
The c-fes promoter was amplified by PCR cycling from the Topo fes #7 plasmid (cloned 
by Dr. K.Sadler) with modified oligonucleotides so that a 3’SalI and a 5’NotI cleavage 
sites were introduced. This fragment was cloned again in a pCR
®2.1-TOPO
® plasmid B. MATERIALS AND METHODS  55 
from  where  was  later  excised  by  NotI-SalI  digestion.  The  SRS11.SF.gp91m.W  was 
opened also with NotI-SalI to exchange the promoters. The resulting plasmid was called 
SRS11.fes.gp91m.W. 
To clone the reverse cassette plasmid, the SRS11.fes.gp91m.W was used to amplify a 
fragment by PCR with oligonucleotides introducing a HindIII at the 5’ end of the c-fes 
promoter and an NdeI at the 3’ end of the gp91
phoxm cDNA. This fragment was cloned 
into the pCR
®2.1-TOPO
® plasmid and then isolated. The bgh was cut with NdeI–NotI 
from  a  pCR
®2.1-TOPO
®  plasmid  in  the  correct  orientation  (Dr.  S.Stein).  Lastly  the 
SRS11.fes.gp91m.W was opened with NotI-HindIII and a three fragment ligation was 
performed resulting in the SRS11.bgh.gp91m.fes construct. 
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Fig. 12: Schematic representation of SIN gammaretroviral constructs containing the c-fes promoter 
To construct the SERS11.gp91m.W the whole 5’LTR containing the SV40 enhancer 
was  cut  with  NarI-SacII  from  the  SERS11.SF.GFP.pre  (kindly  provided  by 
Prof. Dr. C.Baum). The SRS11.SF.gp91m.W plasmid was then opened with NarI-SacII. 
After isolation and ligation the resulting plasmid was analyzed by sequencing. 
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Fig. 13: Schematic representation of SIN gammaretroviral vectors containing the SV40 enhancer. 
The  SERS11.SF.gp91m.W  was  digested  with  SacII-SalI  and  HindIII-SacII,  and  both 
fragments were isolated after gel separation. The gp91
phoxs was excised by digestion 
with SalI-HindII from the 0600161pPCRscript SK+gp91
phoxs plasmid (Dr. M. Grez). A 
three fragment ligation was set and the obtained plasmid was called SERS11.SF.gp91s. 
This plasmid did not contain the WPRE element. The modified WPRE (WPREm) was 
excised with SalI-SspI from the M661 plasmid (kindly provided by Prof. Dr. M. v. Laer) 
and  introduced  in  the  SERS11.SF.gp91s  opened  with  XhoI-SspI.  After  fragment 
isolation and ligation the resulting plasmid was named SERS11.SF.gp91s.Wm. B. MATERIALS AND METHODS  56 
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Fig.  14:  Schematic  representation  of  the  intermediate  SERS11.SF.gp91s  plasmid  and  the 
SERS11.SF.gp91s.Wm vector. 
 
The four promoters (EFs, SP146, c-fes and MRP8) were cloned by NotI-SalI digestion 
in all the cases in the SERS11.SF.gp91s.Wm also digested with NotI-SalI. The c-fes 
promoter was obtained from the SRS11.fes.gp91m.W plasmid. The M8dN version of 
the  MRP8  promoter  was  NotI-SalI  excised  from  the  pSL1180-MRP8dNGb 
(Dr. S. Stein) and ligated with the NotI-SalI opened SERS11.SF.gp91s.Wm. The EFs 
promoter was obtained from the EF/myc/ER/GFP plasmid (Invitrogen Corporation). It 
was amplified by PCR with modified oligonucleotides (EF1 for and EF1 rev) and cloned 
into the pCR
®2.1-TOPO
® plasmid. Thereafter it was excised from the TOPO plasmid 
with NotI-SalI digestion and ligated with the SERS11.SF.gp91s.Wm opened with the 
same  enzymes.  The  Li  promoter  was  obtained  from  the  lenti  3  107-gp91(K02)#3 
plasmid kindly provided by Dr. S. Li (San Antonio, USA). It was amplified by PCR 
with modified oligonucleotides to introduce NotI (Li NotI for) and SalI (Li SalI rev) 
cleavage sites. The PCR fragment was then cloned into the pCR
®2.1-TOPO
® plasmid. 
Thereafter it was excised from the TOPO plasmid with NotI-SalI digestion and ligated 
with the SERS11.SF.gp91s.Wm opened with the same enzymes (see Fig. 37). 
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C. RESULTS 
C.1  Design of SIN gammaretroviral vectors driving the expression of 
gp91
phox 
C.1.1  Construction of wild-type gp91
phox expressing vectors 
In the present study a series of SIN gammaretroviral vectors driving the expression of 
gp91
phox cDNA was constructed based on the Sin11.SF.eGFP.W vector, kindly provided 
by Prof. Dr. C. Baum (Schambach et al., 2006c) (see B.8 Retroviral vectors - Cloning 
strategies).  The  5’  MPSV  promoter  region  in  the  LTR  of  the  transfer  plasmid  was 
replaced by the promoter of Rous Sarcoma Virus (RSV) since it has been shown to 
overcome  the  promoter  competition  with  the  Spleen  Focus  Forming  Virus  (SFFV) 
promoter as internal promoter. The RSV promoter enables efficient full-length RNA 
expression in packaging cells (Yamamoto et al., 1980; Schambach et al., 2006c). 
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Fig.  15:  Schematic  design  of  SIN  vectors  used  in  this  study.  (a)  Three  different  self-inactivating 
retroviral vectors were cloned differing only in the presence of splicing sites in the leader region. They all 
contain the enhancer-promoter deleted MESV LTR (∆U3), the SFFV U3 promoter (SF), the cDNA of 
gp91
phox as transgene and the WPRE to enhance the nuclear export. Within the leader region the primer 
binding site (Θ), the packaging signal (Ψ), and splice donor (SD) and acceptors (SA) are indicated. The 
provirus form is depicted. (b) The gp91
phox sequence was mutated and cloned into the three different 
vectors generating a second set of vectors. 
 
Moreover, these vectors contained a 3’ LTR from Murine Embryonic Stem cell Virus 
(MESV) in which enhancer-promoter sequences were deleted. This 3’ LTR U3 region 
was fully deleted leaving only the first 22 bp (upstream of the enhancer) and the last 
14 bp (downstream of the TATA box). Such 3’ LTR modifications are automatically 
copied  to  the  5’  LTR  in  the  transduced  cells  thereby  generating  enhancer-deleted 
proviruses  also  called  self-inactivating  vectors.  Hence,  they  required  an  internal 
promoter to drive the expression of the transgene and thus the U3 promoter-enhancer 
sequences  of  SFFV  region  plus  the  adjacent  R  region  stem  loop  (RSL)  was  cloned 
directly upstream of the transgene. This vector was used to insert cDNA coding for C. RESULTS  58 
gp91
phox by replacing the enhanced Green Fluorescent Protein (eGFP) at the position of 
the retroviral gag gene, and followed by the WPRE as a module to increase titer and 
transgene expression (Zufferey et al., 1999). In this first vector series, three different 
gag-deleted leader regions were compared. Leader 11 and 110 were both derived from 
the  MESV.  Leader  11  contained  only  a  splice-donor  site  and  the  leader  110  was  a 
splicing  sites-less  leader  generated  by  enzymatic  restriction  of  leader  11  (Fig.  1). 
Finally,  leader  71  contained  both  splice  donor  and  acceptor  sites  derived  from  the 
Mo-MLV to create a full intron (Hildinger et al., 1999). 
C.1.2  Site-directed mutagenesis of the gp91
phox cDNA 
The presence of cryptic splice sites in the transgene inserted into a retroviral vector is 
likely to cause aberrant transcripts both in packaging cells and in transduced cells. This 
was previously shown to cause a decrease in viral titers and transgene expression. 
In this study the presence of cryptic splice sites in the gp91
phox cDNA was assumed by 
both sequencing analysis and previous experimental observations (data not shown). In 
order to further verify the existence of such sequences, a retroviral vector containing a 
splice donor site upstream of the gp91
phox cDNA was transfected into the producer cell 
line 293T. Total cellular RNA extraction and reverse transcription was performed to 
obtain  cDNA  form.  Oligonucleotides  for  PCR  amplification  were  designed  for  the 
gp91
phox cDNA binding directly upstream of the splice donor site and downstream at the 
3’ end of the gp91
phox cDNA sequence. Following RT-PCR amplification, one band 
corresponding to the designed fragment (~ 2600 bp) would be expected, if no cryptic 
splicing sites are present in the region. However, two bands were detected indicating the 
presence of a cryptic splice acceptor (cSA) in the gp91
phox gene, which was functional in 
the context of packaging cells and might lead to a reduction in the viral titer (Fig. 16a). 
This  band  was  cloned  and  sequenced  to  determine  the  exact  position  of  the  cSA 
(Fig. 16b). This splice site was found at the 5’ end of the gp91
phox cDNA exactly 239 bp 
from the first nucleotide of the gp91
phox cDNA (the gp91
phox cDNA spans 1713 bp), 
matching  the  splice  acceptor  consensus  sequence  with  100%  homology  (Fig.  16c). 
Whether  this  splice  variant  leads  to  the  formation  of  a  truncated  protein  was  not 
investigated. It is believed, though, that truncated and therefore aberrant gp91
phox protein 
is unstable since it is degraded by the cell (Kaneda et al., 1999). 
Since the presence of splice sites might compromise expression of the transgene as well 
as viral particle production due to the generation of incorrect transcripts the gp91
phox 
cDNA was mutated in order to remove the cSA. The most conserved nucleotides at 
intron-exon boundaries in eukaryotic pre-mRNAs are the GU and AG at the 5’ and 
3’ ends of the intron. The cSA found in the gp91
phox cDNA contained these nucleotides. C. RESULTS  59 
Spliced
transcript
Genomic
transcript
pSRS11.SF.gp91.W
wt 293T
H 20
5’xxxxxxxxxxxxxxxxTGGAGGAGGTTCCACCGA
GATTTGGAGACCCCTGCCCAGGGACCACCGA
CCCCCCCGCCGGGAGGGGTTCCAGTGCGTGC
TGCTCA … 3’
Splice Junction Splice Junction
pCR®2.1-TOPO®
a)
b)
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86 87
CCCCGCCGGG AGGTA AGCTGGCCAGCGGTCGTTTCGTGTCTGTCTCTGTCTTTGTGCGTGTTTGTGCCGGCATCTAGTGTTTGCGCCTGCGTCTGTACTAGTTGGCTAACTAGATCTGTATCTGGCGGTC
RSV PROMOTER - 229 bp MESV R region - 69 bp MESV U5 region - 76 bp TGGAGGTTCCACCGAGATTTGGAGACCCCTGCCCAGGGACCACCGACCC
CCGCGGAAGAACTGACGAGTTCGTATTCCCGGCCGCAGCCCCTGGGAGACGTCCCAGCGGCCTCGGGGGCCCGTTTTGTGGCCCATTCTGTATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGCTC
CGCCACTGTCCGAGGGGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGCCCCCGTCTGAATTTTTGCTTTCGGTTTTACGCCGAAACCGCGCCGCGCGTCTTGTCTGCTGCAGCATC
GTTCTGTGTTGTCTCTGTCTGACGTGGTTCTGTATTGTCTGAAAATAGCGGCCGC SFFV INTERNAL PROMOTER (401 bp)
CAGACTGAGT CGGCCGGTCGAATCAAGCTTATCGATACCGTCGACGGATCGATCCTGCCACC ATGGGGAACTGGGCTGTGAATGAGGGGCTCTCCATTTTTGTCATTCTGGTTTGGCTGGGGT
TGAACGTCTTCCTCTTTGTCTGGTATTACCGGGTTTATGATATTCCACCTAAGTTCTTTTACACAAGAAAACTTCTTGGGTCAGCACTGGCACTGGCCAGGGCCCCTGCAGCCTGCCTGAA
TTTCAACTGCATGCTGATTCTCTTGCCAGTCTGTCGAAATCTGCTGTCCTTCCT CAGG GGTTCCAGTGCGTGCTGCTCAACAAGAGTTCGAAGACAACTGGACAGGAATCTCACCTTTCA
TAAAATGGTGGCATGGATGATTGCACTTCACTCTGCGATTCACACCATTGCACATCTATTTAATGTGGAATGGTGTGTGAATGCCCGAGTCAATAATTCTGATCCTTATTCAGTAGCACTCT
CTGAACTTGGAGACAGGCAAAATGAAAGTTATCTCAATTTTGCTCGAAAGAGAATAAAGAACCCTGAAGGAGGCCTGTACCTGGCTGTGACCCTGTTGGCAGGCATCACTGGAGTTGTCAT
CACGCTGTGCCTCATATTAATTATCACTTCCTCCACCAAAACCATCCGGAGGTCTTACTTTGAAGTCTTTTGGTACACACATCATCTCTTTGTGATCTTCTTCATTGGCCTTGCCATCCATGG
AGCTGAACGAATTGTACGTGGGCAGACCGCAGAGAGTTTGGCTGTGCATAATATAACAGTTTGTGAACAAAAAATCTCAGAATGGGGAAAAATAAAGGAATGCCCAATCCCTCAGTTTGCT
GGAAACCCTCCTATGACTTGGAAATGGATAGTGGGTCCCATGTTTCTGTATCTCTGTGAGAGGTTGGTGCGGTTTTGGCGATCTCAACAGAAGGTGGTCATCACCAAGGTGGTCACTCACC
CTTTCAAAACCATCGAGCTACAGATGAAGAAGAAGGGGTTCAAAATGGAAGTGGGACAATACATTTTTGTCAAGTGCCCAAAGGTGTCCAAGCTGGAGTGGCACCCTTTTACACTGACATC
CGCCCCTGAGGAAGACTTCTTTAGTATCCATATCCGCATCGTTGGGGACTGGACAGAGGGGCTGTTCAATGCTTGTGGCTGTGATAAGCAGGAGTTTCAAGATGCGTGGAAACTACCTAAG
ATAGCGGTTGATGGGCCCTTTGGCACTGCCAGTGAAGATGTGTTCAGCTATGAGGTGGTGATGTTAGTGGGAGCAGGGATTGGGGTCACACCCTTCGCATCCATTCTCAAGTCAGTCTGGT
ACAAATATTGCAATAACGCCACCAATCTGAAGCTCAAAAAGATCTACTTCTACTGGCTGTGCCGGGACACACATGCCTTTGAGTGGTTTGCAGATCTGCTGCAACTGCTGGAGAGCCAGAT
GCAGGAAAGGAACAATGCCGGCTTCCTCAGCTACAACATCTACCTCACTGGCTGGGATGAGTCTCAGGCCAATCACTTTGCTGTGCACCATGATGAGGAGAAAGATGTGATCACAGGCCTG
AAACAAAAGACTTTGTATGGACGGCCCAACTGGGATAATGAATTCAAGACAATTGCAAGTCAACACCCTAATACCAGAATAGGAGTTTTCCTCTGTGGACCTGAAGCCTTGGCTGAAACCC
TGAGTAAACAAAGCATCTCCAACTCTGAGTCTGGCCCTCGGGGAGTGCATTTCATTTTCAACAAGGAAAACTTCTAA CTTGTCTCTTCCATGAGGAAATAAATGTGGGTTGTGCTGCCAAATG
WPRE (583 bp) AATT
  SFFV U3 region - 50 bp 47 bp SFFV R region AATAAA
SD
cSA
G GGTTCCAGTGCGTGCTGCTCAACAAGAGTTCGAAGACAACTGGACAGGAATCTCACCTTTCATAAAATGGTGGCATGGATGATTGCACTTCACTCTGCGATTCACAC
CATTGCACATCTATTTAATGTGGAATGGTGTGTGAATGCCCGAGTCAATAATTCTGATCCTTATTCAGTAGCACTCTCTGAACTTGGAGACAGGCAAAATGAAAGTTATCTCAATTTTGCTC
GAAAGAGAATAAAGAACCCTGAAGGAGGCCTGTACCTGGCTGTGACCCTGTTGGCAGGCATCACTGGAGTTGTCATCACGCTGTGCCTCATATTAATTATCACTTCCTCCACCAAAACCAT
CCGGAGGTCTTACTTTGAAGTCTTTTGGTACACACATCATCTCTTTGTGATCTTCTTCATTGGCCTTGCCATCCATGGAGCTGAACGAATTGTACGTGGGCAGACCGCAGAGAGTTTGGCT
GTGCATAATATAACAGTTTGTGAACAAAAAATCTCAGAATGGGGAAAAATAAAGGAATGCCCAATCCCTCAGTTTGCTGGAAACCCTCCTATGACTTGGAAATGGATAGTGGGTCCCATGT
TTCTGTATCTCTGTGAGAGGTTGGTGCGGTTTTGGCGATCTCAACAGAAGGTGGTCATCACCAAGGTGGTCACTCACCCTTTCAAAACCATCGAGCTACAGATGAAGAAGAAGGGGTTCAA
AATGGAAGTGGGACAATACATTTTTGTCAAGTGCCCAAAGGTGTCCAAGCTGGAGTGGCACCCTTTTACACTGACATCCGCCCCTGAGGAAGACTTCTTTAGTATCCATATCCGCATCGTT
GGGGACTGGACAGAGGGGCTGTTCAATGCTTGTGGCTGTGATAAGCAGGAGTTTCAAGATGCGTGGAAACTACCTAAGATAGCGGTTGATGGGCCCTTTGGCACTGCCAGTGAAGATGTG
TTCAGCTATGAGGTGGTGATGTTAGTGGGAGCAGGGATTGGGGTCACACCCTTCGCATCCATTCTCAAGTCAGTCTGGTACAAATATTGCAATAACGCCACCAATCTGAAGCTCAAAAAGA
TCTACTTCTACTGGCTGTGCCGGGACACACATGCCTTTGAGTGGTTTGCAGATCTGCTGCAACTGCTGGAGAGCCAGATGCAGGAAAGGAACAATGCCGGCTTCCTCAGCTACAACATCT
ACCTCACTGGCTGGGATGAGTCTCAGGCCAATCACTTTGCTGTGCACCATGATGAGGAGAAAGATGTGATCACAGGCCTGAAACAAAAGACTTTGTATGGACGGCCCAACTGGGATAATG
AATTCAAGACAATTGCAAGTCAACACCCTAATACCAGAATAGGAGTTTTCCTCTGTGGACCTGAAGCCTTGGCTGAAACCCTGAGTAAACAAAGCATCTCCAACTCTGAGTCTGGCCCTCG
GGGAGTGCATTTCATTTTCAACAAGGAAAACTTCTAAT CTTGTCTCTTCCATGAGGAAATAAATGTGGGTTGTGCTGCCAAATGCTCAAATAATGCTAATTGATAATATAAATACCCCCTGCTTAA
CTCAAATAATGCTAATTGATAATATAAATACCCCCTGCTTAAAAATGGACAAAAAGAAACTATAATGTAATGGTTTTCCCTTAAAGGAATGTCAAAGATTGTTTGATAGTGATAAGTTACATTTATGTG
GAGCTCGCCGGCAGAATTCGATATCCCCCGGGCTGCAGGAATT
AATTCGATATCAAGCTTAACACGAGCCATAGATAGAATAAAAGATTTTATTTAGTCTCCAGAAAAAGGGGGG
RSV PROMOTER - 229 bp MESV R region - 69 bp MESV U5 region - 76 bp TGGAGGTTCCACCGAGATTTGGAGACCCCTGCCCAGGGACCACCGACCC
CCCCGCCGGG AG
AAATGGACAAAAAGAAACTATAATGTAATGGTTTTCCCTTAAAGGAATGTCAAAGATTGTTTGATAGTGATAAGTTACATTTATGTGGAGCTCGCCGGCAGAATTCGATATCCCCCGGGCTGCAGGAA
TT WPRE (583 bp) AATTAATTCGATATCAAGCTTAACACGAGCCATAGATAGAATAA
AAGATTTTATTTAGTCTCCAGAAAAAGGGGGG   SFFV U3 region - 50 bp 47 bp SFFV R region AATAAA
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Fig. 16: The cDNA of the gp91
phox bears a cryptic splice acceptor (cSA). (a) Products obtained after 
RT-PCR amplification with primer P1 and R8 of total cDNA from pSRS11.SF.gp91.W transfected cells 
revealed the presence of the full-length transcript and an additional band due to an alternative splicing 
event. (b) The obtained band was cloned into pCR2.1-TOPO vector and sequenced. This fragment is 
shown and the position of the cSA is indicated. Amino acid positions of gp91
phox are indicated below the 
sequence.  (c) Sequence  of  the  pSRS11.SF.gp91.W  plasmid  showing  between  the  promoter  and  the 
polyadenylation  signal.  The  transcription  start  site  is  marked  by  an  arrow.  The  gp91
phox  sequence  is 
presented  in  bold  letters.  The  consensus  sequences  in  the  splice  sites  are  underlined  and  the  100% 
conserved sites are indicated in red. (d) The splice variant expressed by the viral construct is shown. The 
fusion of the SD and cSA sites is boxed. 
 
Therefore, mutation of one of the nucleotides was believed to reduce or even abolish 
splicing  events  at  that  particular  site.  However,  the  gp91
phox  gene  appears  to  be 
extremely sensitive to mutations, especially to missense and nonsense mutations (60% 
of  all  described  mutations)  (Rezvani  et  al.,  2005).  Consequently,  it  was  of  crucial C. RESULTS  60 
importance to maintain not only the open reading frame but also the encoded amino acid 
sequence.  The  only  possible  mutation  of  the  cSA-site  was  to  introduce  a  cytosine 
instead  of  the  invariable  adenosine,  thereby  changing  the  coding  AGG  into  a  CGG 
codon, which both translate into the same amin oacid, arginine (see Fig. 17). 
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ATG        CTG TCC TTC CTC AG G GGT TCC AGT GCG     stop Gp91phox cDNA
ATG        CTG TCC TTC CTC CG G GGT TCC AGT GCG     stop
Mutated gp91phox
cDNA
Arg
Arg
a)
b)
Site Directed 
Mutagenesis
 
Fig. 17: Consensus sequences around 5’ and 3’ intron splice sites in vertebrate pre-mRNAs. (a) The 
frecuency of the bases found at the indicated position is given. (b) Strategy used to mutate the cryptic 
splice acceptor site (cSA) by site-directed mutagenesis. The adenosine of the consensus AG at the cSA 
located in an Arg codifying triplet was mutated to cytosine by site directed mutagenesis. 
 
Mutated primers were designed to amplify the whole gp91
phox containing plasmid and to 
introduce the mutation. After verifying the occurrence of the mutation by sequencing the 
PCR  product,  the  new  gp91
phox  variant  was  cloned  in  the  three  different  retroviral 
vectors obtaining thus a 2 series of 3 constructs (Fig. 15b). 
C.1.3  Transduction efficiency of X-CGD PLB-985 cells 
One of the most limiting factors for therapeutical applications of retroviral vectors is the 
viral  titer.  To  investigate  this  issue,  GaLV  pseudotyped  retroviral  particles  were 
generated by calcium phosphate transfection into 293T cells. The number of infecting 
units  per  ml  of  the  viral  supernatant  was  assessed  by  transduction  of  human 
X-CGD PLB-985  cells,  a  myelomonocytic  cell  line  in  which  the  gp91
phox  gene  was 
knocked out (Zhen et al., 1993). Transduction efficiencies were measured three days 
post-transduction  to  avoid  pseudotransduction  phenomena  and  false  positives.  False 
positive cells express the transgene transiently from non-integrated viral genomes which 
could  lead  to  overestimation  of  the  transduction  efficiency  (Haas  et  al.,  2000).  The 
percentage  of  gp91
phox  expressing  cells  was  determined  by  FACS  analysis  of  cells 
immunostained  with  a  7D5  moAb,  which  recognizes  an  extracellular  epitope  of  the C. RESULTS  61 
flavocytochrome b558  (Yamauchi  et  al.,  2001).  Additionally,  genomic  DNA  of 
transduced  cells  was  isolated  to  quantify  the  number  of  viral  integrants  per  cell  by 
semi-quantitative  PCR  amplification.  Genomic  DNA  isolated  from  a  cell  clone 
containing 1 proviral copy per cell (previously determined using LM-PCR by C. Preiss) 
was used as reference for quantification (Fig. 18). 
A high variability between the measurements was observed. Titers quantified by PCR 
reached from 2.0 to 3.0 x10
6 t.u./ml whereas up to 1.2 x10
6 t.u./ml were obtained by 
FACS  determination.  The  lowest  titers  of  3.3x10
5  t.u./ml  and  7.1x10
5  t.u./ml  were 
obtained with the SRS110.SF.gp91.W vector by FACS or PCR analysis, respectively. 
Moreover,  differences  from  up  to  3-fold  in  titer  were  observed  between  the 
semi-quantitative  PCR  measurements  and  FACS  determinations,  which  might  be 
explained by the presence of integrated proviruses that do not express the transgene. 
When  comparing  the  three  different  leaders  present  in  the  constructs,  vectors  with 
leader 11 appear to have slightly higher titers than other vectors both in FACS and PCR 
analysis. Only in one case leader 71 showed better titers than leader 11 using FACS 
analysis  of  wild-type  gp91
phox  containing  constructs;  however,  the  data  had  high 
standard  deviation  levels.  Between  wild-type  and  mutated  gp91
phox  cDNA  therefore 
were no significant differences. However, a 3.4-fold higher PCR-titer was observed for 
the  SRS110.SF.gp91m.W  when  compared  to  the  SRS110.SF.gp91.W.  The  FACS 
measurements also showed differences in the titers reached by both vectors containing 
the  leader  71  but  again  the  levels  of  standard  deviation  reached  doubts  about  the 
significance of this difference. 
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Fig. 18: Determination of vector titers by transduction of X-CGD PLB-985 cells. FACS analysis and 
semi-quantitative  PCR  were  used  to  determine  the  titers  of  GaLV  pseudotyped  SIN  gammaretroviral 
particles after transduction of X-CGD PLB-985 cells with serial dilutions of the viral supernatants. The 
titer is indicated in transducing units (t.u.) observed per ml viral supernatant used for transduction. Bars 
represent  mean  values  ±  standard  deviations  of  at  least  three  independent  transfection/transduction 
procedures. 
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Overall, these results indicate that between the six constructs the leaders 11 and 71 
performed slightly better than the leader 110 containing vectors and that, although high 
standard deviations were calculated, all these vectors reached titers that are high enough 
to their use in therapeutic applications. 
C.1.4  Magnetic cell sorting of gp91
phox positive cells 
Together with the capacity of generating high titers, the most important characteristic of 
a gene transfer vector for the treatment of CGD is the ability to reconstitute the oxidase 
activity to physiological levels. In order to be able to compare the performance of the six 
different  retroviral  vectors,  populations  of  100%  positive  cells  harboring  the  same 
amounts of integrants per cell were required. Consequently, a selection procedure of 
gp91
phox  positive  cells  was  set  up  by  which  populations  of  5  to  15%  positive 
(7D5 positive)  cells  were  enriched  to  up  to  95%.  It  was  desirable  to  start  with 
populations  with  5  to  15%  gp91
phox  expressing  cells  since  the  aim  was  to  obtain 
populations with one integrated viral genome per cell. Previous studies have shown that 
an exponential increase in integration numbers correlates with a linear increase of gene 
transfer  rates  (percentage  of  positive  cells  after  transduction  as  measured  by  FACS 
analysis of transgene expressing cells), defined as Poisson-like distribution (Kustikova 
et  al.,  2003).  Therefore,  transduced  cell  populations  for  each  vector  were 
immunostained  with  antibodies  against  gp91
phox  coupled  to  magnetic  beads  prior  to 
selection  by  passing  the  labeled  cells  through  a  magnetic  field.  After  washing  and 
eluting, the gp91
phox positive cell enrichment was assessed by FACS analysis. 
As shown in Fig. 19 all transduced populations were efficiently sorted by the MACS 
procedure,  reaching  about  98%  for  almost  all  constructs.  Note  that  the  mean 
fluorescence  intensity  ( MFI)  of  transduced  cells  prior  to  selection  was  higher  in 
wild-type gp91
phox-expressing cells than in cells expressing the mutated gp91
phox protein, 
but reached equivalent levels after sorting. 
Additionally,  the  mean  copy  number  was  analyzed  by  semi-quantitative  PCR 
amplification  again  using  a  population  with  a  known  copy  number  as  a  standard 
reference.  This  analysis  revealed  a  uniform  1  copy  per  cell  for  all  the  enriched 
populations (data not shown). C. RESULTS  63 
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Fig. 19: Magnetic cell sorting allows purification of gp91
phox expressing cells by positive selection. 
X-CGD PLB-985 cells were transduced with the two series of SIN gammaretroviral vectors. They were 
then labeled with antibodies against gp91
phox coupled to magnetic beads prior to selection by passing the 
labeled cells through a magnetic field. FACS analysis data of gp91
phox expressing cells (7D5 positive) 
before, left panel, and after, right panel, cell sorting are shown. 
 
C.1.5  Functional analysis of the gp91
phox transduced cells 
The  NADPH  oxidase  activity  has  been  shown  to  be  restricted  to  terminally 
differentiated  granulocytes,  monocytes  and  B  lymphocytes.  Upon  stimulation 
granulocytes promote assembly and activation of the oxidase enabeling the generation of 
high  amounts  of  superoxide.  PLB-985  cells  have  the  ability  to  differentiate  to 
granulocyte-like cells, thus providing an excellent model to test the performance of the 
retrovirally  transferred  gp91
phox  to  reconstitute  the  activity  of  the  oxidase.  Several 
protocols are being used to induce differentiation of myeloid cell lines. DMSO, DMF, 
Vit.  D3  or  phorbol  myristate  acetate  (PMA)  stimulation  are  most  commonly  used 
(Rovera et al., 1979).  C. RESULTS  64 
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Fig.  20:  Granulocyte-like  cell  differentiation  of  the  sorted  cell  populations  transduced  with 
gp91
phox-viral particles. PLB-985 cells and transduced derivatives described in Fig. 19 were incubated 
with 1.25% DMSO for 6 days. The expression of the CD11b monocyte/macrophage differentiation marker 
was ensured by FACS analysis. 
 
In the present study incubation with 1.25% DMSO for 6 days was used to stimulate 
maturation of the MACS-selected cell populations. The CD11b surface marker was used 
to ensure the differentiation of the transduced cells by flow cytometry. In all the cases, 
about 80-90% of the cells were positive for CD11b (Fig. 20). 
Since  it  was  possible  to  differentiate  the  transduced  cell  populations,  it  was  then 
possible to investigate the ability of SIN gammaretroviral vectors to reconstitute the 
NADPH oxidase activity. The cytochrome c assay was used, which is a quantitative 
method  to  measure  the  cellular  superoxide  anion  production.  DMSO  differentiated 
populations  were  stimulated  with  PMA,  a  powerful  stimulant  that  triggers  O2
  
production.  The  superoxide  production  per  cell  was  measured  by  reduction  of 
ferricytochrome c over time. Differentiated wild-type PLB-985 cells were always used 
as a reference value. C. RESULTS  65 
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Fig. 21: Percentage of superoxide production in X-CGD PLB-985 cells after SIN gammaretrovirus-
mediated gene transfer. Transduced cells were immunomagnetically sorted, expanded, and cultivated for 
6 days in the presence of 1.25% DMSO to induce granulocyte-like cell differentiation. The total amount 
of superoxide production was measured by a continuous cytochrome c assay after PMA stimulation. Data 
are  shown  in  percent  superoxide  production  relative  to  the  amount  of  superoxide  produced  by 
differentiated  wild-type  PLB-985  cells.  The  mean  values  ±  standard  deviations  of  at  least  three 
independent experiments are represented. 
 
As shown in Fig. 21 all constructs were able to reconstitute the oxidase activity to high 
extents reaching in some cases the same levels than wild-type PLB-985 cells. Although 
the standard deviation is high, the 11 leader-containing vectors SRS11.SF.gp91.W and 
SRS11.SF.gp91m.W showed the best preformance. By using the SRS110.SF.gp91.W 
construct only 60% of the wild-type activity could be reached. 
The levels of oxidase reconstitution reached by all these vectors might be enough to 
ensure  adequate  microbicidal  activity,  since  female  X-CGD  carriers  with  as  few  as 
5-10% oxidase-positive neutrophils often display a symptom-less disease (Johnston et 
al., 1985; Woodman et al., 1995). 
C.1.6  Analysis  of  myeloid-specific  promoters  for  targeted  expression  of  retroviral 
vectors 
Since the activity of the NADPH oxidase is required mainly in phagocytic cells, the 
restriction of the expression of the retrovirally introduced gp91
phox to myeloid cells is of 
great  interest.  The  SIN  vectors  represent  an  excellent  model  to  test  cell-specific 
promoters, since in these vectors the transgene expression in transduced cells is under 
the control of an internal promoter. Various promoters can be used for this purpose. 
Since the gp91
phox is transferred into deficient cells of CGD patients, the use of the 
gp91
phox  promoter  itself  would  be  the  best  option.  However,  additional  studies  are 
required  to  identify  all  the  required  sequences  of  the  gp91
phox  promoter  for  proper 
transgene expression. Currently, different fragments of the gp91
phox proximal promoter 
are  being  analyzed  to  elucidate  all  the  regulatory  factors  affecting  the  gp91
phox 
expression (Samuelson et al., 2001; Islam et al., 2002).  C. RESULTS  66 
Therefore,  two  human  myeloid-specific  MRP8  and  c-fes  promoters  were  chosen  as 
alternative. They were tested in the SRS11.SF.gp91m.W vector configuration, since it 
showed the best performance regarding titer and reconstitution of the NADPH oxidase 
activity in the previous experiments. 
C.1.6.1  The MRP8 promoter 
The MRP8 promoter drives the expression of the myeloid related protein 8, which has 
been  shown  to  be  involved  in  several  cellular  processes  during  transendothelial 
migration of phagocytes such as, inter alia, microtubule reorganization and arachidonic 
acid transport but also during differentiation of myeloid cells (Kerkhoff et al., 1999; 
Vogl et al., 2004). Moreover, recent studies have shown that MRP8, in a hetero-dimeric 
form with MRP14, are also implicated in the activation of the NADPH oxidase complex 
(Berthier et al., 2003; Paclet et al., 2007). The MRP8 protein is tightly regulated during 
differentiation  of  myeloid  cells.  Its  expression  level  is  low  in  common  myeloid 
progenitors and their granulocyte/monocyte progenitors whereas MRP8 expression can 
reach up to 45% and 1% of the cytosolic protein content in neutrophils and monocytes, 
respectively  (Edgeworth  et  al.,  1991;  Hessian  et  al.,  1993).  Thus,  due  to  this 
characteristic, the MRP8 promoter has been used to drive the expression of different 
transgenes in several myeloid leukemia transgenic mouse models (Yuan et al., 2001; 
Jaiswal et al., 2003). 
In the present study, a fragment containing 1176 bp, from -1159 to +17, of the MRP8 
upstream regulatory sequence was used. It spann 17 bp of the first exon of the gene, but 
contained a mutated ATG triplet. It was changed to ACT by PCR amplification with 
oligonucleotides  containing  the  mutation.  This  was  important  to  avoid  translation 
initiation (Dr. S. Stein, pers. commun.). Since this sequence was able to drive efficiently 
the expression of eGFP after transduction of X-CGD cells in the context of a lentiviral 
backbone (Dr. S. Stein; pers. commun.), it was cloned in both the wild-type and mutated 
gp91
phox cDNA-containing vectors and is labeled as M8dNdI (Fig. 22 and Fig. 23a). 
TGAGTGCATGCACTCAAAATGATGCATTCAACTTCAATTCAGTTTCAGGGATGTATGGCCTGACCACCAATGCAGGGGATTAGCAATCGCAATAGTGGAG
AATGGATATAGCCCTTGGCAACAACACATTTCCCCACAAAGCACCCACCCAAAAGAACAACAACGATAGTTTTAGTTTTTAGTAATGAGAACAATAGTTC
GTGCCGAGGGACCCCAAGCAGCCTCCATCTCCCAGGGCATGGTCCATCCCCAGCTTCACAGAACAGGAAAGCTGTGGAGGAGTGTGGGCAGCAGGGTAGG
CTCTTCAGCCAGTGATCCTGGGGTCCCAGACACAATAATTAACCAAGAGAGGGTGAAAGGCTCCCTGCTGTGTTTATGCAATGGCTCAGGCCCTTGTGAA
TCCTGGGGAATTGGCCACCTCCTCTTCTCCTCTTAGGCATGAAGCGCGTCTGGCTTCTCCAAAGAACTCTTCCCCTCCACTACCTCAGAGTTAGCTTCCT
TTTGTAACAACAGAAACACACCACAGTCTTCAAGGTTGGAAGCCAGTTAATCTGAGTAGCATTTTGTTAGTGGTGGGGAGAGGATTTGTTCCTCCTGAAA
TTTTTGATTGGTTTGTTTGTTTTTTGTTGTTGAGTTGTAGGGATTCTTTTATATTCTGGATATTAATCCCTTATCAGATATTTGTTTTACAAATATTTTC
TATGCTTATTGACCATTTGTATATCTTCTTCGGAGAAGTGTCTATTTGAGTCTTTTCCCCAA
ACGTCTCTTGTCAGCTG 
Exon 1
GTAGCAACTCTGGCAGGGAGAAGCTGTCTCTGATGGCCTGAAGCTGTGGGCAGCTGGCCAAGCCTAACCGCTATAAAAAGGAGCTGCCTCTCAGCCCTGC
TCATGACTAAAAGCCATCAGCCAGGACACGTGTTCTCAACCCTTTTGCGGTCTTTGGACCCTTTGAAACTCTGACAGAAGCCATGGAGGAATGTTCTCAC
AGGGCATGGGAGTGGGAATCTGGCTGGATCAAGCAAGTGGATGCCAGCAGCCCAGAAAAAGAGCCCCCCTACCTGCTTTTTCCTTCTGGGCACTATTGCC
CAGCAAATGCCTTCCTCTTTCCGCTTCTCCTACCTCCCCACCCAAAATTTTCATTCTGCACAGTGATTGCCACATTCACCTGGTTGAGAAACCAGAGACT
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Fig. 22: Nucleotide sequence of the MRP8 promoter used in this study. The exon sequence is boxed 
and  conserved  promoter  elements  are  overlined.  Nucleotides  are  numbered  according  to  the  cap  site 
(position +1). 
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Following  transduction  of  X-CGD  PLB-985  cells  with  GaLV  pseudotyped  particles 
gp91
phox expression was almost undetectable with the MRP8 containing-vectors (less 
than 4% gp91
phox positive cells), whereas expected levels were achieved if gp91
phox is 
under the control of the SF promoter (30%). Under the caveat that the obtained levels of 
positive  cells  were  close  to  the  non-specific  binding  of  the  antibody  in  the  assay 
(background), a slightly higher percentage of gene transfer was seen by the combination 
of MRP8 and mutated gp91
phox (Fig. 23b). 
Previous studies have shown that immature human myeloid cell lines (such as HL60, 
U937  and  TPH-1)  increase  the  expression  of  the  MRP8  protein  when  myeloid 
differentiation is induced (Lagasse and Clerc, 1988). To investigate whether X-CGD 
PLB-985  cells  equally  transduced  cells  with  the  SRS11.M8dNdI.gp91.W  or  the 
SRS11.M8dNdI.gp91m.W  construct  also  experienced  an  increase  in  transgene 
expression,  these  cell  populations  were  used  to  assess  for  gp91
phox  expression  after 
granulocyte-like  cell  differentiation.  However,  again  no  gp91
phox  expression  was 
observed in the transduced populations, neither with the wild-type gp91
phox nor with the 
mutated  sequence.  The  obtained  levels  of  positive  cells  were  similar  to  the  values 
generated by non-specific binding (background levels) assessed by FACS analysis of 
differentiated X-CGD PLB-985 cells (Fig. 23c). 
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Fig.  23:  The  MRP8  myeloid-specific  promoter  driving  the  expression  of  gp91
phox  in  a  SIN 
gammaretroviral  vector.  (a) Schematic  presentation  of  the  MRP8  promoter-containing  SIN 
gammaretroviral vector (b) GaLV pseudotyped particles were used to transduce X-CGD PLB-985 cells 
with serial viral dilutions and FACS analysis was performed to analyze the expression of gp91
phox. Cells 
transduced with a 10-fold dilution of viral supernatant of both MRP8-containing constructs and the SF as 
control are shown. (c) The increase in transgene expression of transduced cell populations was assessed 
after DMSO differentiation by FACS analysis. 
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To analyze whether the absence of transgene expression in transduced cells was due to 
the lack of integrated proviruses, genomic DNA of transduced cells was prepared and 
PCR  amplification  was  performed  with  oligonucleotides  binding  in  the  gp91
phox 
sequence (Fig. 24a). Amplification of β-actin was used as a control for DNA quality. A 
band  indicating  the  presence  of  the  transgene  was  detected  for  both  transduced 
populations indicating that the viral particles were indeed produced and able to properly 
infect the target cells. Therefore, it was presumed that either absent or wrong processing 
of the transgene could be the cause of the extremely low expression level. To assess this 
possibility Northern Blot analysis of total RNA from transduced cell populations was 
performed to investigate the presence or absence of the internal transcript. Although the 
loaded amount of total RNA was higher than in the positive control sample, gp91
phox 
mRNA was not detectable for any of the MRP8-containing vectors (Fig. 24b). 
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Fig. 24: Molecular analyses of gammaretroviral vectors containing an internal MRP8 promoter. 
(a) PCR reaction of genomic DNA of transduced X-CGD PLB-985 cells using primers gp-for-01 and 
gp-rev-02 to amplify the gp91
phox gene and primers ACT5’ and ACT3’ to amplify β-actin as a control was 
performed  to  ensure  the  presence  of  transgene.  (b) Northern  blot  analysis  of  3  µg  total  RNA  from 
transduced cells. 
32P-labelled specific probe against gp91
phox sequence was used and the 28S rRNA band 
is shown as loading control. 
 
The absence of transcription could be related to the lack of enhancer modules present in 
the  genomic  configuration  of  the  endogenous  MRP8  protein.  Previous  studies  have 
shown  the  existence  of  an  enhancer  in  the  first  intron  of  the  MRP14  sequence 
(Melkonyan  et  al.,  1998).  This  cis-acting  element  has  been  shown  to  increase 
transcriptional  efficiency  up  to  9.8-fold  in  Mono  Mac  6  cells  when  cloned  to  a 
heterologous promoter. This sequence functions independently of its position and shares 
a high homology with the first intron of MRP8. 
Therefore,  to  further  investigate  the  effect  of  the  enhancer  in  the  MRP8  driven 
expression, a 392 bp fragment containing the intron of the MRP8 gene (+575 to +967) 
was placed upstream of the promoter into the retroviral vectors (Fig. 25). C. RESULTS  69 
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Fig. 25: The first intron of MRP8 as possible cis-acting activator of transgene expression. Schematic 
presentation of the SIN gammaretroviral vector containing the MRP8 promoter and intron sequences. 392 
bp of the first intron (position +575 to +967) of MRP8 gene were cloned upstream of the promoter in the 
SIN gammaretroviral constructs in direct orientation. 
 
X-CGD PLB-985 cells were transduced and the percentage of gp91
phox expressing cells 
was assessed by flow cytometry of 7D5 antibody stained cells. As shown in Fig. 26a 
there was again less than 5% gp91
phox positive cells three days post-transduction as well 
as  after  granulocyte-like  cell  differentiation.  The  differentiation  of  these  cells  was 
successful since FACS analysis revealed between 75 and 90% of CD11b positive cells 
(Fig. 26b). 
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Fig. 26: MRP8 enhancer as possible cis-acting activator of transgene expression. (a) Transduction of 
X-CGD PLB-985 cells was performed with GaLV pseudotyped particles. FACS analysis assessing the 
presence of gp91
phox positive cells in transduced population with a 10-fold viral dilution is shown. The 
SF-containing  vector  is  also  shown  as  control.  (b)  Changes  in  transgene  expression  were  analyzed 
following 1.25% DMSO granulocyte-like cell differentiation of transduced cells. Immunostaining with 
anti-CD11b  surface  marker  to  verify  successful  differentiation  is  also  shown.  (c)  The  presence  of 
integrated proviruses was analyzed by PCR amplification of genomic DNA isolated from transduced cells. 
PCR amplification of β-actin was used as loading control. C. RESULTS  70 
Further investigations were performed in order to assess whether the transduced cells 
contained  detectable  numbers  of  proviral  integrations.  Therefore  gp91
phox  PCR 
amplification of genomic DNA of equally transduced cells was performed. The analysis 
of the obtained band revealed the presence of proviral integrations in cells transduced 
with the MRP8-containing construct. Proviral integrations were not detectable for the 
intron-containing construct as shown by the absence of a band in the corresponding PCR 
lane (Fig. 26c).  
C.1.6.2  The c-fes promoter 
The c-fes gene encodes a cytoplasmic protein tyrosine-kinase that has been detected in 
hematopoietic cells, predominantly in immature myeloid progenitors, in differentiated 
granulocytes and macrophages, and in vascular endothelial cells. Fes expression is also 
evident in leukemia cell lines, which can be differentiated in vitro along the granulocyte 
and monocyte pathways, but is absent in cell lines resistant to myeloid differentiation 
(Carlson  et  al.,  2005).  The  c-fes  promoter  in  combination  with  untranslated  gene 
sequences have been used in some transgenic mice models to uncover roles for this 
kinase in hematopoiesis, innate immunity, inflammation and angiogenesis. It has also 
been  shown  to  be  involved  in  regulation  of  the  tubulin  cytoskeleton  as  a  process 
implicated in proliferation and differentiation (Laurent et al., 2004). Furthermore, c-fes 
plays a role in signal transduction pathways for several hematopoietic cytokines such as 
IL-3,  IL-4,  IL-6,  granulocyte-macrophage  colony-stimulating  factor  (GM-CSF)  and 
erythropoietin (Smithgall et al., 1998). 
Analysis  of  upstream  regulatory  sequences  of  the  endogenous  expression  of  c-fes 
revealed  binding  sites  for  several  transcription  factors,  such  as  PU.1  and  Sp1. 
(Heydemann et al., 1996). Moreover, it was also shown that the locus control region 
(LCR), a cis-acting DNA element that enhances expression of the linked gene, present 
in  the  c-fes  gene  is  an  important  element  in  the  regulation  of  appropriate  gene 
expression. Additionally, a minimal 446 bp promoter cassette was shown to efficiently 
direct expression of luciferase reporter gene towards myeloid cells (Greer et al., 1990; 
Heydemann et al., 2000). 
TTCTGCGGTGGCCCTGGCCTGGTGCTAGGACTGCGCGCCTCCCCTCAGTACCCGCGGACACCCTGGGCTTCCCTGGGCCCAGCATCTGCCTGGGGCCTCG
ACTGGCCGGGGTCCGCACCGGGCCTGAGTCGGTCCGAGGCCGTCCCAGGAGCAGCGCCCG
GGGGCGGTCGGGCCGGTCCCGCCCGCCCCTTCCCCTCCACAGGCCCGCCCCGGGGCCTGGGCCAACTGAAACCGCGGGAGGAGGAAGCGCGGAATCAGGA
GAATTCCGTGAGGTGGGGAGGGCTGGGACCAGGGTTCCCTCTTTCTC
CCCTGGGCTCCCCCTCCTGACCCCCACCTTGCGCCCCTTCCCGGTGTTCCCGGGGCGCTGCCGGGCCCTGGGGCCTGCGGGGCGCGGGCGGCTCTTGGCT
GGGCCATTCTTTCCCGGCCCCCTCCTCCCTTCCGTTTCCGTGGCCGTGCGGCCGGCTAGAGGCTGCGGCCCAGCGCGGAGCAGGGGGGCTGGCAGGCGTC
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Fig. 27: Nucleotide sequence of the c-fes promoter used in this study. Consensus sites for Sp1 and 
PU.1/Elf-1 are overlined. Nucleotides are numbered according to the cap site (position +1). 
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In the present study, the c-fes promoter was cloned in the SRS11.SF.gp91m.W construct 
substituting the SF promoter to test its performance in the X-CGD PLB-985 cell model 
(Fig. 27). 
The gene transfer efficiency was evaluated by FACS analysis of transduced cells three 
days  post-infection.  As  shown  in  Fig.  28b  the  c-fes  construct  efficiently  drove  the 
expression  of  the  gp91
phox  although  to  slightly  lower  levels  than  the  SF-containing 
construct. About 11.4% of positive cells were detected after transduction with a 10-fold 
dilution of viral supernatant with the SRS11.fes.gp91m.W vector whereas 26.5% were 
obtained with the SF construct. Moreover, analysis of the  MFI revealed a 2.3-fold 
lower level of gp91
phox expression in the c-fes transduced population compared to the 
SF  transduced  cells.  Further  investigation  of  these  cells  following  1.25%  DMSO 
differentiation showed minimal changes in the transgene expression level by the c-fes 
promoter  since  the   MFI  after  differentiation  was  1.2-fold  higher  for  the  cells 
transduced with the SF-containing construct (i.e. around non-specific binding levels) 
and 1.5 for the fes-promoter transduced population. 
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Fig. 28: Testing the c-fes promoter as internal promoter for a SIN vector. (a) The c-fes promoter was 
cloned into the SRS11.SF.gp91m.W vector replacing the SFFV promoter and the map of the transfer 
vector is depicted. (b) GaLV pseudotyped viral particles were produced by transient transfection of 293T 
cells.  Transduction  of  X-CGD  PLB-985  cells  with  a  10-fold  dilution  of  supernatant  is  shown.  The 
SF-containing vector was used as control. The increase of transgene expression was evaluated by FACS 
analysis after differentiation with 1.25% DMSO. (c) The presence of proviral integrations was assessed by 
genomic DNA PCR of transduced cells. β-actin was used as loading control. (d) MACS selection starting 
with a population of 11.4% gp91
phox positive cells was performed and FACS analysis was used to analyze 
the outcome of the sorting.  MFI values are indicated. 
 
Further genomic DNA analysis revealed that the lower percentage of gp91
phox positive 
cells reached by the c-fes construct compared to SF was possibly due to a lower number C. RESULTS  72 
of integrants detected by PCR as shown in Fig. 28c. Therefore the lower titer reached by 
the fes-containing construct, which was half the SF construct titer, could be caused by 
less integration events. 
A  population  of  transduced  cells  with  the  c-fes  promoter-containing  construct  was 
enriched by magnetic cell sorting for further functional analysis. As shown in Fig. 28d, a 
population transduced with a 10-fold dilution of viral supernatants underwent positive 
selection  and  about  72%  of  gp91
phox  expressing  cells  were  obtained  as  assessed  by 
FACS analysis.This sorted population, as well as X-CGD PLB-985 and MACS selected 
SRS11.SF.gp91m.W,  were  induced  to  differentiate  by  DMSO  incubation.  CD11b 
immunostaining  was  performed  to  analyze  the  differentiation  degree  at  day  6,  and 
positive cells were measured by flow cytometry. As shown in Fig. 29a, about 90% of 
granulocytic cells were detected in each population. 
Further  investigations  of  the  MACS  selected  populations  after  differentiation  were 
performed by protein analysis. In granulocytes, gp91
phox normally present in different 
forms, generating multiple bands with a wide range of molecular mass (76-90 kDa) in 
Western Blots as shown for the control lysate of granulocytes in Fig. 29b. However, the 
bands detected in lysates of the studied populations showed a different pattern. In the 
SF-vector containing cells a band of about 90-100 kDa was detected by the gp91
phox 
antibody  (moAB  48).  This  band  is  almost  invisible  in  cells  transduced  with  the 
fes-construct.  Additionally,  the  65  kDa  high-mannose  glycoprotein  precursor  of  the 
gp91
phox was clearly detected in both populations by the gp91
phox antibody. A decrease 
in the content of the precursor was observed in both MACS selected populations if 
lysated  between  before  and  after  differentiation  are  compared.  This  observation 
correlates  with  the  above  mentioned  description  of  this  precursor,  which  is  an 
intermediate form that needs association with p22
phox to complete the maturation. The 
decrease in 65 kDa precursor amounts indicated completion of the maturation process of 
the flavocytochrome b558, which goes parallel with granulocytic differentiation. Another 
additional band of about 55 kDa was detected on the blot, which might correspond to 
the protein core of gp91
phox and was described in previous studies (Porter et al., 1993). 
A  strong  decrease  in  the  55 kDa  band  was  observed  after  differentiation  of  both 
populations. 
The cytochrome c assay was used as functional study to analyze the reconstitution of 
superoxide  activity  in  the  selected  populations.  The  MACS  selected  populations 
containing the c-fes construct did reach only half the O2
  levels as detected for the cells 
transduced with the SF construct. Even after 24 min of PMA stimulation the superoxide 
levels only reached 60% (Fig. 29c). Moreover, the amount of superoxide produced by 
these  populations  reached  only  about  10%  related  to  the  wild-type  PLB-985  cells, 
although this population contained 72% positive cells (Fig. 29d). C. RESULTS  73 
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Fig. 29: Reconstitution of the NAPDH oxidase activity by the c-fes promoter-containing vector. 
(a) Myeloid differentiation of the sorted population assessed by FACS analysis of CD11b positive cells. 
(b)  Protein  extracts  obtained  from  sorted  cells  comparing  proliferating  cells  (-  DMSO)  and 
granulocytic-like cells (+ DMSO) were subjected to electrophoresis on a 10% SDS-polyacrylamide gel. 
Immunoblotting was performed using the moAB48 antibody (1:400) against gp91
phox. β-actin was used to 
ensure  equal  loading  of  total  protein.  (c)  Kinetics  of  superoxide  production  by  DMSO-differentiated 
MACS-selected cells was elicited by PMA induction. Reduction of ferri cytochrome C to its ferrous form 
over  time  was  measured.  (d)  Percentage  of  superoxide  anion  production  of  PMA-stimulated  cells 
expressed in percent relativ to the wild-type PLB-985 cells for which the O2¯ production was set to 100%. 
 
Another  variant  of  the  c-fes  promoter  containing  construct  was  cloned 
(SRS11.bgh.gp91
phoxm.fes).  This  construct  contained  the  expression  cassette  in  the 
inverse  orientation  and  a  polyadenylation  signal  of  the  bovine  growth  hormone 
downstream of gp91
phox (Fig. 30a). Previous studies showed that this expression cassette 
cloned in a lentiviral backbone, achieved significant restoration of the oxidase activity in 
vitro with myeloid-lineage specific expression (Dr. S. Stein, pers. commun.). 
As previously described GaLV pseudotyped retroviral particles were produced in the 
packaging cell line and were used to transduce X-CGD PLB-985 cells. As shown in 
Fig. 30b, there were no gp91
phox positive cells detectable when measured three days 
post-transduction although the SF- and fes- containing constructs did reach the expected 
levels. 
To further analyze whether this lack in transgene expression was due to a defect in 
transgene  transcription  of  integrated  viruses,  genomic  DNA  of  transduced  cells  was 
prepared  and  investigated  for  the  presence  of  the  gp91
phox  sequences  by  PCR 
amplification. There was no detectable transgene in the population of transduced cells C. RESULTS  74 
neither with 1:2 nor 1:50 viral supernatant dilution, which indicated a failure in the viral 
particle production (Fig. 30c). 
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Fig. 30: Performance of a reverse expression cassette. (a) The c-fes promoter followed by the mutated 
gp91
phox  and  the  polyadenylation  signal  of  the  bovine  growth  hormone  gene  were  cloned  in  a  SIN 
gammaretroviral  vector  in  reverse  orientation.  The  structure  of  this  vector  is  represented  (b)  GaLV 
pseudotyped viral particles and X-CGD PLB-985 transduction were performed as described above. FACS 
analysis of the cells transduced with the 1:10 viral dilution is shown. (c) PCR amplification from genomic 
DNA obtained from transduced cells with 1:2 and 1:50 viral supernatant dilutions is shown. β-actin PCR 
amplification was used to check for equal loaded quantities. 
 
C.2  Codon optimization of gp91
phox sequence
 
C.2.1  Synthetic sequence and SV40 enhancer improve the performance of SIN vectors 
Previous  attempts  to  generate  a  SIN  gammaretroviral  vector  expressing  either  the 
wild-type  or  the  mutated  gp91
phox  under  the  control  of  a  myeloid-specific  promoter 
(MRP8 or c-fes promoters) failed because the titer of the virus produced by transient 
transfection  protocols  were  very  low  (<5x10
5  t.u./ml)  and  because  low  transgene 
expression levels. Various modifications including the addition of enhancer elements or 
reversion  of  the  expression  cassette  neither  improved  titer  values  nor  increased  the 
transgene expression level. Therefore, a codon optimization of the gp91
phox cDNA was C. RESULTS  75 
considered as an alternative. Codon optimization is a strategy that is used to improve 
heterologous gene expression of genes introduced in foreign genomes. All codons of a 
protein are adjusted to the optimal codon usage pattern of the targeted organism. This 
methodology has already been used for widely known reporter proteins like GFP and 
luciferase (Cubitt et al., 1995; Heim et al., 1995; Yang et al., 1996) and has shown to 
overcome  poor  transgene  expression  in  several  organisms  (Kanekiyo  et  al.,  2005; 
Patterson et al., 2005). 
The company GeneArt (Regensburg, Germany) analyzed the gp91
phox wild-type mRNA 
sequence and improved the codon content by substituting codons with lower frequency 
of utilization with the preferred ones as represented by the respective tRNA content in 
the  cell.  The  codon  adaptation  index  (CAI),  which  indicates  the  relative  number  of 
matches  between  the  given  sequence  and  the  codon  preference  of  a  determined 
organism, was optimized from originally 0.77 to 0.99. Additionally, several motifs were 
found which might interfere with either gene expression or virus production. Internal 
polyadenylation  sites,  additional  cryptic  splice  sites  and  RNA  instability  motifs  as 
AU-rich elements were then deleted. 
The  synthetic  gp91
phox  gene  was  used  to  replace  the  eGFP  cDNA  in  the 
SERS11.SF.GFP.Wm backbone (kindly provided by Prof. Dr. C. Baum) (Schambach et 
al., 2006c). This backbone contains an additional 233 bp SV40 enhancer (E) placed 
upstream of the RSV promoter as shown in Fig. 31a. For the SV40 enhancer it is known 
that it significantly increases gene expression in a wide variety of tissues and species 
(Schirm  et  al.,  1987).  It  also  enhances  the  expression  of  the  genomic  transcript  in 
packaging cells, thereby overcoming the promoter competition for the transcriptional 
machinery  (Schambach  et  al.,  2006c).  Moreover,  previous  data  obtained  from 
WHV-associated  hepatocellular  carcinomas  suggest  a  relation  between  sequences 
overlapping  with  the  PRE  and  tumorigenesis,  especially  if  encoding  a  C-terminally 
truncated version of the WHV X protein. Although a role of the PRE remained suspect, 
to minimize potentially harmful effects of the PRE, a mutated version, which is devoid 
of  the  X  protein  promoter  and  any  remnant  open  reading  frame  (ORF)  larger  than 
25 amino acids by mutating residual ATGs (Wm), was introduced (Schambach et al., 
2006a). For comparison, a vector containing the gp91
phoxm cDNA in combination with 
the SV40 enhancer was also constructed. 
GaLV  pseudotyped  particles  were  produced  in  293T  packaging  cells  and  used  to 
transduced  X-CGD  PLB-985  cells.  Synthetic  gp91
phox-containing  vectors  showed  a 
2.7-fold increase in gene transfer rate by FACS analysis (Fig. 31b) which correlates with 
a corresponding increase in titer (Fig. 31c). Moreover, the amount of surface protein 
detected  on  the  transduced  cells  was  markedly  higher  with  the  synthetic 
gp91
phox-containing construct as compared to gp91
phoxm-construct. This was shown by 
the fact that the  MFI value increased from 6.4 to 8.6 (Fig. 31b). C. RESULTS  76 
To further investigate the correlation between the amount of genomic RNA and the 
increase in titer, Northern Blot analysis of total RNA content of 293T packaging cells 
was performed (Fig. 31d). Transfection was carried out with an ecotropic envelope to 
avoid  re-infection  and  RNA  production  from  integrated  proviruses.  Finally,  the 
intensities of the obtained bands in the blots were evaluated by densitometry. Indeed a 
higher production (1.1-fold) of genomic transcripts derived from the vector containing 
the synthetic gp91
phox sequence was observed, and this correlates with the higher titers. 
Moreover, an increase in the amount of internal transcripts (starting at the SF promoter) 
of about 1.4-fold was also detected when the synthetic gp91
phox was compared with the 
mutated gp91
phox transcript levels in transfected cells (Fig. 31d). 
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Fig. 31: Codon optimized gp91
phox increases vector titers and its gene expression level. (a) Schematic 
drawing of the SIN vector backbone used to evaluate the mutated or synthetic gp91
phox versions. The 
plasmid form contains a SV40 enhancer upstream of the RSV promoter. (b) Expression of gp91
phox in 
X-CGD PLB-985 cells after transduction with the same viral supernatant dilution (10-fold). FACS data of 
one  representative  experiment  is  shown  with  the  corresponding   MFI  value.  Note  the  improved 
separation  of  the  transduced  cell  population  from  the  non-transduced  cells  in  case  of  the  gp91
phoxs 
construct (c) Titers were determined as described above. The mean values ± standard deviations (SD) of 
at least three independent experiments are shown. (d) Northern blot analysis of 3 µg total RNA of 293T 
packaging cells. The expected RNA products are named on the right side of the blot. A specific WPREm 
probe was used to detect the gp91
phox transcript and an 18S rRNA probe to assess equal loading of the 
samples. The relative counts for the genomic and internal transcripts (normalized according to 18S rRNA 
levels) are given. C. RESULTS  77 
In order to compare the functional performance of both vectors, MACS selection of 
transduced  cells  was  performed  prior  to  vector  copy  number  (VCN)  analysis  by 
semi-quantitative PCR amplification. To generate standard curves, genetically modified 
X-CGD  PLB-985  cell  populations  containing  1  copy  of  gp91
phox  transgene  per  cell 
(SF71gp#1  and  Lenti  MM5  transduced  cells  for  the  native  and  synthetic  sequence, 
respectively) were used. Three different amounts (25, 50 and 100 ng) of genomic DNA 
were included in the PCR reaction amplifying gp91
phox and GAPDH, thereby ensuring 
maximal primer efficiency (Fig. 32). 
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Fig.  32:  Determination  of  the  vector  copy  number  (VCN)  by  semi-quantitative  PCR. 
(a) Oligonucleotides gp91S-2for and gp91S-2rev for synthetic gp91
phox and GAPDH/5 and GAPDH/3 for 
GAPDH  (loading  control)  were  used  to  amplify  genomic  DNA  of  the  sorted  population.  Different 
mixtures of DNA from a known population with one copy of transgene per cell (SF71gp#1) and X-CGD 
cells  were  used  as  standard.  Analysis  of  band intensities of the standards allows the generation of a 
mathematic correlation which can be used to calculate the vector copy number in the samples. Linear 
regression and R-square values are shown. (b) Analysis of the VCN of the sorted SERS11.SF.gp91m.Wm 
transduced population using the Lenti MM5 cell population as standard. Primers gp-for-01 and gp-rev-02 
were used in this case. PCR amplification and band intensity analysis was performed as described in (a). 
 
Band intensity quantification and comparison with the standard values revealed similar 
numbers  of  integrations  for  both  populations.  The  mutated  gp91
phox-containing 
population had a mean of 1.5 proviral integrations per cell, whereas for the synthetic 
gp91
phox 1.3 copies were detected in the transduced population. FACS analysis of the 
sorted populations revealed a 2.2-fold increase in the expression level of the transgene 
with the synthetic sequence (Fig. 33). Additionally no changes were observed in the C. RESULTS  78 
transgene  expression  levels  ( MFI)  after  1.25%  DMSO  granulocyte-like  cell 
differentiation, as expected for SF driven gene expression. 
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Fig. 33: Surface expression of gp91
phox in MACS-selected populations. Sorted populations underwent 
granulocytic-like cell differentiation by incubating the cells for 6 days with 1.25% DMSO. FACS analyses 
of gp91
phox (=7D5) and CD11b expressing cells are shown. Data of one representative experiment are 
shown with the corresponding  MFI. 
 
C.2.2  Molecular and functional analyses 
Northern Blot analysis performed as described above revealed marked differences in the 
expression level of the gp91
phoxm and gp91
phoxs-containing constructs. All cells of the 
sorted populations expressed the full length transcript initiated at the internal promoter 
and  terminating  at  the  3’LTR.  However,  densitometry  analysis  showed  hardly  any 
change in transgene expression after DMSO differentiation for both constructs. Only a 
slight, non-significant decrease in transcription was observed for both constructs after 
differentiation. However, when comparing both gp91
phox versions, either proliferating or 
differentiated  cells,  higher  transgene  expression  was  detected  for  the  synthetic 
gp91
phox-containing  cells,  corresponding  to  4.7-  and  15-fold  increase,  respectively 
(Fig. 34a).  Note  that  the  low  intensity  of  the  SERS11.SF.gp91m.Wm  differentiated 
sample could be responsible for an underestimation of the values, thereby erroneously 
magnifying the differences in gp91
phox transcript amount between both differentiated 
populations. 
To assess whether these differences correlated also with the protein levels of these cells, 
western blotting analysis was performed. Unfortunately, due to the differences in the 
amount  of  loaded  proteins  (as  detected  with  β-actin)  between  undifferentitated  and 
differentiated populations, it was not possible to study the changes in protein amounts C. RESULTS  79 
after granulocyte-like cell maturation. Nevertheless, as shown in Fig. 34b, when levels 
of  gp91
phox  protein  obtained  with  the  synthetic  sequence  were  compared  with  the 
amount  achieved  by  the  mutated  gene,  a  2-fold  increase  in  the  protein  content  of 
differentiated cells was detected for the synthetic gp91
phox gene and a 5.5-fold increase 
when compared to differentiated wild-type PLB-985 cells. 
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Fig.  34:  The  synthetic  gp91
phox  cDNA  promotes  higher  expression  and  higher  superoxide 
production. (a) Northern blot analysis of total RNA from MACS-selected population before (- DMSO) 
and after (+ DMSO) granulocytic-like cell differentiation. The analysis of the gp91
phox band intensity 
(normalized according to 18S rRNA) is shown. (b) Western blot analysis of 30 µg of total protein from 
sorted cells before (- DMSO) and after (+ DMSO) differentiation. The samples were loaded onto a 10% 
SDS-polyacrylamide gel and subjected to electrophoresis. Immunoblotting was performed as previously 
described,  using  a  monoclonal  antibody  against  gp91
phox.  Quantification  of  the  gp91
phox  content 
(normalized to β-actin) for each sample is shown as percentage values related to the PLB-985 value. 
(c) DMSO-induced cells were used to analyze the superoxide production in a cytochrome C assay. The 
nanomols of superoxide produced per one million of cells, per min and per ml were measured after PMA. 
The means and standard deviations of at least three experiments are shown. The proviral VCN of the 
corresponding population is also indicated. 
 
The functionality of the synthetic gp91
phox-containing construct was also assessed by the 
cytochrome c assay as previously described. The superoxide production was measured 
in 1.25% DMSO differentiated cells stimulated with PMA. As shown in Fig. 34c, a 
1.7-fold  increase  in  superoxide  production  was  achieved  with  the  synthetic 
gp91
phox-containing  cells  when  compared  to  the  wild-type  PLB-985  and  mutated 
gp91
phox-containing  populations.  This  1.7-fold  increase  in  superoxide  production 
correlated  with  the  higher  amounts  of  protein  detected  in  these  cells  (Fig.  34b). 
However,  no  correlation  was  found  when  the  wild-type  cells  were  compared  to  the 
mutated  gp91
phox-transduced  cells  since  half  the  levels  of  protein  were  observed  in 
PLB-985 cells although reached the same levels of superoxide production. C. RESULTS  80 
C.3  Transcriptional targeting with SIN gammaretroviral vectors 
Targeting the transgene expression towards granulocytes would be a major improvement 
for the gene therapy of CGD. To this end several tissue-specific internal promoters were 
tested to drive the transgene expression. 
Based on the SERS11.SF.gp91s.Wm vector as a backbone, the performance of three 
myeloid-specific  promoters  was  assessed;  c-fes,  MRP8  and  SP146.  Beside  the  SF 
promoter and the already described c-fes promoter, an alternative version of the MRP8 
promoter  was  used  which  comprises  1.7  kb  of  the  upstream  human  MRP8  region, 
including exon 1 and intron 1 (from –1162 bp to +535 bp). The SP146 promoter is a 
synthetic promoter constructed by random ligation of several short sequences identified 
as  binding  sites  for  myeloid/macrophage  transcription  factors  (Fig.  35b  and  c).  The 
functionality of this promoter was previously tested in several cells lines, such as human 
myeloid/monocytic THP-1 cells and Mono Mac-1 cells, and was tested in an apoE
-/-
 mouse model. This promoter spans 423 bp and is comprised of 14 cis-acting modules 
(He et al., 2006). 
TGAGTGCATGCACTCAAAATGATGCATTCAACTTCAATTCAGTTTCAGGGATGTATGGCCTGACCACCAATGCAGGGGATTAGCAATCGCAATAGTGGAG
AATGGATATAGCCCTTGGCAACAACACATTTCCCCACAAAGCACCCACCCAAAAGAACAACAACGATAGTTTTAGTTTTTAGTAATGAGAACAATAGTTC
GTGCCGAGGGACCCCAAGCAGCCTCCATCTCCCAGGGCATGGTCCATCCCCAGCTTCACAGAACAGGAAAGCTGTGGAGGAGTGTGGGCAGCAGGGTAGG
CTCTTCAGCCAGTGATCCTGGGGTCCCAGACACAATAATTAACCAAGAGAGGGTGAAAGGCTCCCTGCTGTGTTTATGCAATGGCTCAGGCCCTTGTGAA
TCCTGGGGAATTGGCCACCTCCTCTTCTCCTCTTAGGCATGAAGCGCGTCTGGCTTCTCCAAAGAACTCTTCCCCTCCACTACCTCAGAGTTAGCTTCCT
TTTGTAACAACAGAAACACACCACAGTCTTCAAGGTTGGAAGCCAGTTAATCTGAGTAGCATTTTGTTAGTGGTGGGGAGAGGATTTGTTCCTCCTGAAA
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Fig.  35:  MRP8  and  SP146  promoters.  a)  Nucleotide  sequence  of  the  MRP8  promoter  used  in  the 
targeted SIN gammaretroviral vector backbone. The exon sequence is boxed and the intron is underlined. 
Conserved DNA motifs are overlined. Nucleotides are numbered according to the cap site (position +1). 
(b) Nucleotide sequence of the SP146 promoter cloned in the SIN gammaretroviral vectors. (c) Order and 
orientation of the randomly ligated SP DNA fragments in the SP146 promoter (modified after He et al., 
2006). 
 C. RESULTS  81 
In addition a eukaryotic constitutive promoter was also tested. The Elongation Factor 1α 
short (EFs) promoter is a eukaryotic ubiquitous promoter that drives the expression of 
translation elongation factor 1 alpha (eEF1A) (Negrutskii and El'skaya, 1998). In this 
study a short intronless version of the promoter (244 bp) was used (Woods et al., 2001; 
Schambach et al., 2006b). This promoter was chosen since promoters with relatively 
low activity in hematopoietic stem and progenitor cells are expected to be less likely to 
upregulate proto-oncogenes in these cell fractions, which might lead to the initiation of 
leukemia  (Dick,  2003).  Therefore  the  EFs  promoter  might  also  be  an  alternative  to 
replace the strong viral SF sequence. 
C.3.1  Performance of the targeted SIN vectors in X-CGD PLB-985 cells 
Titers (transducing units per ml) of SIN gammaretroviral vectors bearing the SF, EFs, 
c-fes, SP146 and MRP8 promoters were determined as above by GaLV pseudotyped 
particles production and following transduction of X-CGD PLB-985 cells with serial 
dilutions  of  the  viral  supernatant.  Three  days  post-transduction  the  cells  were 
immunolabeled with a FITC coupled antibody against gp91
phox and the percentage of 
positive cells was analyzed by flow cytometry. 
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Fig. 36: Evaluation of the performance of several promoters in the SIN vector backbone. (a) Five 
different promoters driving the expression of synthetic gp91
phox were cloned in the SIN vector backbone 
and analyzed. Titer analysis of the constructs was performed by transduction of X-CGD PLB-985 cells as 
described previously. Mean and standard deviation of at least three independent transfection/transduction 
experiments are depicted (b) Northern blot analysis of total RNA of packaging 293T cells. A specific 
32P-labeled probe against WPREm was used to detect the gp91
phox transcripts. An 18S rRNA probe was 
used  to  verify  equal  loading  of  the  samples. (c) Densitometry analysis. On the x-axis, the signals in 
relative counts for the genomic viral RNA normalized to 18s rRNA levels obtained in the Northern Blot 
analysis, plotted against the corresponding titers (y axis) with the standard deviations. 
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As shown in Fig. 36a, titers range around 1x10
6 infectious units per ml, with the cellular 
promoters  displaying  a  ~3-fold  reduction  in  titer  when  compared  to  the  SF  internal 
promoter.  The  fes.gp91s  construct  showed  the  best  performance,  with  titers  up  to 
1.8x10
6  t.u./ml,  and  the  lowest  titers  were  obtained  with  the  MRP8  and  SP146 
promoter-containing constructs. 
To  further  analyze  whether  this  variability  was  due  to  differences  in  viral  particle 
production or transgene expression levels in packaging cells, Northern blot analysis of 
total  RNA  from  transfected  293T  cells  was  performed.  As  shown  in  Fig.  36b  the 
transcripts obtained matched with the expected size for both the genomic and internal 
transcripts.  Interestingly,  the  internal  transcript  was  not  detected  in  packaging  cells 
transfected  with  the  c-fes  promoter-containing  vector.  In  the  case  of  the  MRP8 
promoter-containing construct the obtained genomic RNA represented the non-spliced 
sequence, still including the MRP8 intron. Additionally, intensity analysis of the bands 
revealed  a  positive  correlation  between  the  titer  and  genomic  RNA  content  for  the 
constitutive  promoters,  SF  and  EFs.  In  contrast  the  myeloid-specific 
promoter-containing  constructs  showed  slightly  higher  genomic  RNA  contents 
(normalized to 18S rRNA) but lower titers than those obtained with the constitutive 
promoter-containing  constructs  (Fig.  36c).  Thus,  the  lower  titers  obtained  by  these 
vectors cannot be due to the lack in genomic RNA production, but possibly because of 
problems associated with thepackaging of these molecules or with the lack of transgene 
expression in the transduced populations. 
Further molecular analysis of these constructs included the study of the proper proviral 
size  in  transduced  cells  as  assessed  by  Southern  Blot  analysis  of  genomic  DNA. 
Following enzymatic digestion with restriction enzymes (Kpn I and EcoR V) that only 
cut at both ends of the provirus, the DNA underwent electrophoresis and blotting on a 
membrane.  The band obtained after hybridization with a 
32P-labeled WPREm probe 
should  represent  the  size  of  the  provirus.  As  shown  in  Fig.  37a  and  Fig.  37b,  all 
proviruses  were  detected  in  the  correct  size  on  the  blot  except  for  the  SP146 
promoter-containing vector. In that particular case an additional unexpected band was 
observed with a slightly lower size than the proviral one. This indicated the presence of 
an  alternative  form  of  provirus  which  contained  the  packaging  signal  and  the  LTR 
sequences required for integration. Whether this proviral form contained and expressed 
gp91
phox was subjected to further investigations (see chapter C.3.2 Functionality of the 
targeted SIN vectors in sorted populations). 
The expression of the gp91
phox transgene expression in transduced cells was analyzed by 
Northern blot analysis of total RNA. Only one transcript is expected for the transduced 
cells with SIN vectors. It should start at the transcription start site (TSS) in the internal 
promoter and finish at the polyadenylation signal in the R region of the 5’LTR. The 
approximate  expected  size  of  this  transcript  for  the  constructs  used  in  this  study  is C. RESULTS  83 
2535 bp  with  little  variations  (+/-  10  bp)  due  to  the  position  of  the  TSS  in  each 
promoter. As shown by the Fig. 37c only one band was detected which matched the 
expected  size  for  all  constructs.  No  unexpected  forms  of  internal  transcripts  were 
detected thus indicating the proper elimination of transcription from the viral LTR in the 
transduced  cells.  The  differences  in  the  amounts  of  transcripts  are  in  this  analysis 
irrelevant because the used cells were from cells transduced with a high MOI with no 
comparable proviral copy numbers. 
3521bp
3318bp EFs
3497bp SP146
3623bp fes
4849bp
sd
WPREm
∆
∆
∆
∆
U
3
R U5 P P gp91phoxs R U5
∆
∆
∆
∆
U
3
KpnI EcoRV KpnI EcoRV
Ψ Ψ Ψ Ψ
SF
M8dN
a)
Internal transcript
(~2535bp)
18S rRNA
SF.gp91s
EFs.gp91s
SP146.gp91s
M8dN.gp91s
fes.gp91s
PLB-985
X-CGD 
PLB-985 c)
Internal transcript
(~2535bp)
18S rRNA
SF.gp91s
EFs.gp91s
SP146.gp91s
M8dN.gp91s
fes.gp91s
SF.gp91s
EFs.gp91s
SP146.gp91s
M8dN.gp91s
fes.gp91s
PLB-985
X-CGD 
PLB-985 c)
PLB-985
X-CGD 
PLB-985 c)
SF.gp91s
EFs.gp91s
SP146.gp91s
M8dN.gp91s
fes.gp91s
5 kb
4 kb
3 kb
b)
SF.gp91s
EFs.gp91s
SP146.gp91s
M8dN.gp91s
fes.gp91s
5 kb
4 kb
3 kb
b)
NotI SalI
 
Fig.  37:  Molecular  analysis  of  X-CGD  PLB-985  transduced  cells  with  five  different constructs. 
(a) Schematic presentation of five constructs differing in the internal promoter. For details see text and 
B. Materials and methods. (b) Southern blot analysis of transduced cells was performed by digesting 
genomic DNA with restriction enzymes that cut at both ends of the provirus (KpnI and EcoRV). Cleavage 
sites  are  indicated.  For  detection  of  the  blotted  fragments  a 
32P-labeled  WPREm  probe  was  used. 
(c) Northern blot analysis was performed with total RNA of transduced cells. The same WPREm fragment 
as above was used to probe the membrane and a 
32P-labeled 18S rRNA probe was used to assess for 
equivalent loading quantities. 
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C.3.2  Functionality of the targeted SIN vectors in sorted populations 
For further molecular and functional analysis, comparable transgene copy numbers were 
desired  and  therefore  transduced  populations  of about 10% positive cells underwent 
positive selection as previously described (Fig. 38). 
 
 
Fig. 38: Myeloid differentiation of the MACS-selected populations. X-CGD cells were transduced 
with five different constructs, sorted and induced to differentiate by incubation with 1.25% DMSO for six 
days. Cells were immunostained for CD11b and 7D5. The FACS analysis profile of a representative 
experiment with the corresponding percentage values for each gate. The  MFI is shown below the figures. 
 
Further analysis showed changes in  MFI of DMSO differentiated populations. A 2.4-, 
2.2-  and  1.1-fold  increase  in  expression  of  gp91
phox  in  the  SP146,  c-fes  and  MRP8 
promoter-containing  cells  was  observed,  respectively.  Furthermore,  no  changes  were 
detected with any of the ubiquitous promoter-containing constructs (Fig. 38). 
Vector copy number analysis of these MACS selected cells by semi-quantitative PCR 
amplification revealed a similar mean of integrants per cell for all populations. The 
mean values varied between 1.1 copies per cell for the c-fes construct transduced cells 
and 1.4 for the MRP8 construct-containing cells (Fig. 39a). 
Southern blot analysis of sorted cells confirmed the appropriate size of the provirus for 
all constructs except for the SP146-containing construct (Fig. 39b). The second proviral 
form of the SP146 vector detected with the WPRE probe was also previously found in 
non-selected cells (Fig. 37b). Thus, this band should be caused by a rearrangement event 
or by a mistake that occurred during production of the viral genomes leading to the 
formation of an alternative form of gp91
phox-containing provirus capable to be packaged 
and inserted. 
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Fig.  39:  Vector  copy  number  (VCN)  and  proviral  integrity  analysis.  (a)  Semi-quantitative  PCR 
analysis of the proviral copy number in the MACS sorted populations. Genomic DNA was obtained from 
sorted  cells  and  PCR  amplification  of  a  gp91
phox  fragment  (and  the  corresponding  GAPDH  loading 
control) was performed. A standard curve was prepared with serial dilutions of DNA from a genetically 
modified X-CGD PLB-985 population with 1 copy per cell. With the obtained R square value and linear 
regression the number of integrated provirus in the samples were calculated. (b) Southern blot analysis of 
sorted cells. Genomic DNA was isolated and digested with enzymes cutting at both ends of the provirus 
and  blotted  onto  a  nylon  membrane  as  described  above.  DNA  fragments  containing  proviral  DNA 
fragments were detected after hybridization with a 
32P-labeled WPREm specific probe. 
 
To analyze whether the increase in expression of gp91
phox after DMSO differentiation 
could also be detected in RNA and protein levels, Northern and Western blotting of 
MACS sorted cells was performed. The RNA blot revealed an increase in transcription 
with all constructs following DMSO differentiation, ranging from 1.3-fold with the SF 
promoter up to 2.3-fold with the c-fes promoter. The SP146 led to a 2.0-fold increase in 
internal transcript expression, and showed the highest transcript production, whereas the 
MRP8 promoter only led to a 1.7-fold increase being the second less active promoter. C. RESULTS  86 
The  EFs  also  achieved  a  2.0-fold  increase  although  being  a  ubiquitous  promoter 
(Fig. 40a).  
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Fig. 40: Transgene expression levels of MACS-selected populations. (a) Northern blot analysis of 
7.5 µg total RNA obtained from sorted cells before (- DMSO) and after (+ DMSO) granulocyte-like cell 
differentiation. 
32P-labeled probes against WPREm and 18S rRNA (as loading control) were used and the 
band  intensity  analysis  is  shown.  The  vector  copy  number  in  MACS-selected  populations  is  shown 
(b) Western blot analysis of MACS-selected cells. Sorted populations were induced to differentiate with 
1.25% DMSO and total protein extracts were prepared. 10% SDS-polyacrylamide gel, electrophoresis and 
Immunoblotting were performed as previously described, using the moAB48 antibody against gp91
phox. 
Quantification of the gp91
phox content (normalized to β-actin) for each sample is shown as percentage 
values related to the PLB-985 value. 
 
When the protein levels were assessed by Western blotting surprising higher amounts of 
beta actin were seen in the differentiated populations. The extensive difference in the 
amounts of β-actin before and after granulocyte-like cell differentiation complicated the 
analisis. Thus, it is unclear whether there was a correlating increase in protein levels. 
Nevertheless,  when  comparing  the  differentiated  populations  with  the  wild  type 
PLB-985 cells higher protein levels were detected in all cases. The highest amount was 
seen with the SF promoter (3.3-fold) followed by the SP146 (3.0-fold) when compared 
to the wild-type PLB-985 cells. The c-fes and MRP8 led to 2.4- and 1.4-fold higher 
values of protein which were the lowest values obtained between the myeloid-specific 
promoters. These results correlate with the mRNA levels detected in Fig. 40a. In the 
case of the EFs.gp91s construct a 1.7-fold higher amount of gp91
phox compared to the 
levels  in  wild-type  PLB-985  cells  was  observed,  which  might  indicate  that  an C. RESULTS  87 
overestimation of the RNA values occurred since this is the only value that does not 
follow the correlation observed between RNA and protein. 
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Fig. 41: Reconstitution of respiratory burst activity in PLB-985 cells and derivatives. The amounts 
of produced superoxide per million of cells, min and ml following PMA stimulation of granulocytic-like 
cells  were  measured  by  the  cytochrome  c  assay.  The  mean  and  standard  deviation  of  at  least  three 
independent experiments are shown. Additionally, the mean copy numbers of the used populations are 
indicated. 
 
When reconstitution of the NADPH oxidase was assessed by the cytochrome c assay 
(Fig.  41)  all  constructs  showed  higher  levels  of  superoxide  production  than  those 
obtained by the wild-type PLB-985 cells. The MRP8 promoter produced the highest 
rate,  more  than  2-fold  higher  than  PLB-985  cells.  The  SP146  promoter  showed  the 
lowest value of superoxide production; however, they still were 1.5-fold higher than for 
the wild-type PLB-985 cells. Furthermore, by relating these results to the mean copy 
number of the cells, the c-fes containing construct showed the best performance, since it 
reached the best superoxide production levels per copy of integrated provirus. 
Additional functional analysis of differentiated populations included the DHR assay. 
This  assay  was  first described by (Vowells et al., 1995) and is used to identify the 
superoxide producing cells as well as the amount of products (by the mean fluorescence 
intensity) evaluated by flow cytometry. Furthermore, this is the most common test used 
in the clinic. It is used due to its high reliability, small sample requirement, sensitivity 
and efficiency (between the available flow cytometric probes) (Jirapongsananuruk et al., 
2003); and is specific for H2O2 accumulation (Walrand et al., 2003). 
As shown in Fig. 42 the granulocyte-like cell differentiated populations were up to 98% 
Rhodamine  positive  cells  as  expected  for  sorted  populations.  Furthermore,  the  SF 
promoter  led  to  a  superoxide  production  similar  to  wild-type  cells.  The  rest  of  the 
constructs achieved lower levels, with the MRP8 promoter showing the lowest ones. 
These data did not correlate with the results obtained by the cytochrome c assay where 
the MRP8 promoter showed the best performance. These differences might be due to the 
assay itself since the cytochrome c assay measures the generation of extracellular O2
- C. RESULTS  88 
and  the  DHR  is  a  membrane  permeable  probe  which  reacts  intracellularly  with  the 
superoxide anion (Henderson and Chappell, 1993). 
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Fig. 42: DHR assay of MACS-selected populations. Dot blots of flow cytometry assays of oxidant 
production by PMA stimulation in DMSO-induced cells. A representative unstimulated sample and the 
stimulated  measurements  for  PLB-985  cells  and  transduced  derivatives  are  shown.  The  “positive 
threshold” is set so that at least 95% of stimulated X-CGD PLB-985 cells are to the left of that line. The 
data shown are of a single experiment. 
 
C.4  Vector testing in primary murine cells 
Since  the  five  SIN  gammaretroviral  vectors  were  able  to  generate  high  titers  after 
transient  transfection  of  293T  packaging  cells,  to  efficiently  transduce  the  X-CGD 
PLB-985 cell line and to reconstitute the NADPH oxidase activity to a high degree, it 
was decided to assess the performance of these constructs in primary mouse cells. The 
stem cell antigen 1 (Sca-1) was used as a marker to select hematopoietic stem/progenitor C. RESULTS  89 
cells by FACS and to enrich this population from X-CGD mouse bone marrow (mBM). 
After  positive  selection,  the  percentage  of  positive  cells  was  about  95%  Sca-1
+  as 
assessed by flow cytometry (Fig. 43). 
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Fig. 43: Selection of Sca-1
+ cells. FACS plots of unseparated 
(left)  and  Sca-1
+  (right)  mouse  bone  marrow  (mBM)  cells 
after positive selection. 
 
C.4.1  Ex vivo analysis 
Ecotropic  retroviral  supernatants  were  produced  from  all  different  vectors  and  titers 
were  assessed  by  SC1  transduction  as  previously  described.  Sorted  murine  X-CGD 
Sca-1
+ cells were stimulated for 48 hours in the presence of mouse Stem Cell Factor 
(mSCF) (100 ng/ml), mIL-6 (100 ng/ml) and mIL-3 (10 ng/ml). Then the cells were 
transduced  with  similar  multiplicities  of  infection  (MOI).  The  transduction  was 
performed  on  RetroNectin  coated  plates  with  preloading  of  the  viral  particles  and 
posterior addition of the target cells. Transduction was further enhanced by the use of 
spinoculation  to  bring  cells  and  viruses  closer  together.  Two  or  three  rounds  of 
transduction, depending on the desired MOI, were performed over a period of 48 or 72 
hours. Three independent analyses (with MOI 5, 5 and 3) were performed and the cells 
were analyzed 4 days after the last round of infection. The gene transfer rate of each 
population  was  assessed  by  FACS  analysis  and  VCN  was  determined  by  semi-
quantitative PCR amplification, respectively, as previously described (Fig. 44a). The 
percentage of gp91
phox expressing cells related to the VCN ranged from 45.5% with the 
SF.gp91s  vector  to  10%  with  the  M8dN.gp91s.  The  c-fes  promoter  drove  high 
expression  of  the  transgene,  up  to  30%,  which  is  in  accordance  with  previous 
observations  showing  high  c-fes  protein  expression  levels  in  mouse  and  human 
undifferentiated progenitor cells purified from different sources (Care et al., 1994). The 
SP146 reached with 39.4% the highest value, and it was similar to the data obtained 
with the EFs promoter. C. RESULTS  90 
Thereafter, the transduced cells were induced to differentiate by incubating the cells 
with IL-3 (10 ng/ml) and G-CSF (100 ng/ml) for eight days. The differentiation progress 
was monitored by co-immunostaining of the surface markers Gr-1 and CD11b. Around 
80-90% of the cells stained positively in all three experiments (data not shown). If the 
gp91
phox expression level was related to the copy number in differentiated cells slightly 
higher  values  for  all  constructs  compared  to  those  of  before  differentiation  were 
obtained. With the constitutive promoters, a slight increase was also observed except for 
the SF in one of the assays. The SP146 promoter showed the highest increase although it 
also  exhibited  also  the  highest  variability.  The  lowest  inducibility  of  the  gp91
phox 
expression  after  myeloid-differentiation  was  shown  by  the  MRP8  promoter.  This 
promoter  also  showed  the  lowest  levels  of  transgene  expression  before  and  after 
differentiaion (Fig. 44a). 
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Fig. 44: Performance of the SIN gammaretroviral vectors in sorted murine X-CGD Sca-1
+ cells. 
(a) mSca-1
+  cells  were  selected  by  magnetic  cell  sorting  and  transduced  with  similar  MOIs  for  all 
constructs.  FACS  analysis  of  gp91
phox  positive  cells  was  performed  prior  and  after  ex  vivo  myeloid 
differentiation with IL-3 (10 ng/ml) and G-CSF (100 ng/ml). (b) DHR assay of differentiated cells was 
performed eight days post-differentiation as previously described. Both gp91
phox and DHR positive cells 
are represented normalized to their respective VCN. Results of three independent experiments are shown. C. RESULTS  91 
Superoxide production of transduced cells after differentiation was assessed by the DHR 
assay.  The  values  were  normalized  to  the  levels  measured  for  the  wild-type  cells 
(Fig. 44b). When this ratio was further normalized to the VCN, the SF.gp91s showed 
almost 1.2-fold higher DHR positive cells (*) than the wild-type control cells in one of 
the  assays  which  displayed  also  the  highest  level  of  gp91
phox  expression  (**)  after 
differentiation (Fig. 44a). However, when the mean values for the three experiments 
were calculated this construct showed also the highest variability in the percentage of 
DHR positive cells per copy of integrated provirus (71 ± 46%). Although the EFs.gp91s 
showed more constant levels of DHR reactive cells related to the wild-type and VCN, 
these  were  lower  than  those  obtained  with  the  SF  promoter  (21  ±  16%).  The  three 
myeloid-specific promoters showed more constant levels of reactive cells (Fig. 44b). 
The SP146.gp91s construct was found to be the best myeloid promoter reaching more 
than 50% of the levels observed in wild-type cells (68 ± 12%), and was followed by the 
M8dN.gp91s and fes.gp91s which showed only 24 ± 4% and 21% ± 2% of the levels 
observed in wild-type cells, respectively (Fig. 44b). 
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Fig.  45:  Cytochrome  c  assays  were  performed  after  nine  days  of  myeloid  differentiation.  The 
percentages of superoxide production related to wild-type cells and to the VCN of three independent 
experiments are depicted. 
 
The measurement of superoxide production by the cytochrome c assay showed the same 
tendency  as  the  DHR  assay  (Fig.  45).  The  SF.gp91s  construct  led  to  the  highest 
percentage of superoxide production per copy number relative to the wild-type cells 
reaching, in two of the three experiments, more than 100% of the wild-type activity. Of 
the three myeloid-specific promoters the SP146 promoter reached again here the highest 
values although showing the greater variability between the measurements. Finally, as 
already observed in the DHR assay, the most constant but lowest results were obtained 
with the c-fes promoter with about 30% in all the cases (Fig. 45). 
The  results  described  above  showed  that  sorted  Sca-1
+  murine  X-CGD  cells  were 
efficiently transduced by these vectors and that reconstitution of the NADPH oxidase C. RESULTS  92 
activity  was  achieved  in  liquid  culture  media  with  these  cells.  Subsequently,  the 
presence of transduced murine hematopoietic progenitor cells with functional NADPH 
oxidase  in  the  sorted  population  was  assessed  by  the  methylcellulose  based  colony 
forming  unit  (CFU)  assay.  Mouse  Sca-1
+  cells  transduced  with  the  five  different 
constructs as well as the control cells were plated in a semi-solid medium containing the 
appropriate  cytokines  and  were  grown  for  10  days.  After  that  time,  the  number  of 
colonies was determined by counting all cell clusters of more than 50 cells. 
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Fig.  46:  Restoration  of  superoxide  production  (NBT  assay)  in  CFU-GM  colonies  derived  from 
transduced  mSca-1
+  cells.  (a)  An  example  of  NBT  negative  (upper)  and  a  positive  (down)  colony. 
(b) Percentages of NBT
+ colonies of two independent experiments related to the corresponding vector 
copy number are depicted. 
 
The  colonies  in  the  methylcellulose  plates  were  assessed  for  reconstitution  of  the 
NADPH  oxidase  activity  by  the  nitroblue  tetrazolium  (NBT)  test  (see  B.7.9.  NBT 
assay). Two independent experiments are shown in Fig. 46 where an MOI of 5 was used 
to  transduce  the  cells  with  the  different  viral  particles.  All  constructs  were  able  to 
transduce progenitor cells, and to reconstitute NADPH oxidase activity after myeloid 
differentiation  although  with  variable  levels.  The  SP146.gp91s  was  again  the  most 
efficient promoter, since with this promoter the highest percentages of NBT positive 
(NBT
+)  CFUs  were  observed  in  both  assays  (33%  and  55%).  This  construct  was 
followed by SF.gp91s and fes.gp91s with similar numbers in both assays, about 25% 
NBT
+ colonies. Finally, with the EFs and MRP8 promoter-containing constructs only 
low percentages of NBT
+ colonies were counted. 
C.4.2  Transplantation of genetically modified gp91
phox 
-/- mSca-1
+ progenitors 
To  further  analyze  the  performance  of  these  five  vectors  an  X-CGD  mouse  model 
(Pollock  et  al.,  1995)  was  chosen  for  a  transplantation  procedure  following  ex  vivo 
transduction of mSca-1
+ cells. C. RESULTS  93 
Mouse Sca-1
+ cells were enriched up to 92% positive cells (see Fig. 43) and stimulated 
for 48 hours in presence of mSCF (100 ng/ml), mIL-6 (50 ng/ml) and mIL-3 (10 ng/ml). 
Transduction was preformed as previously described with a final MOI of 3. Twenty-four 
hours after the last round of infection and prior to transplantation, a small sample of the 
cells was used to analyze the gene transfer rate by FACS and semi-quantitative PCR 
amplification. As shown in Fig. 47, the percentage of gp91
phox positive cells within the 
Sca-1
+ subpopulation related to the number of integrated viruses reached up to 45.7% 
with the EFs.gp91s construct. The M8dN.gp91s vector showed the lowest values, as 
expected for a myeloid-specific promoter. The SF, c-fes and SP146 promoter-containing 
constructs achieved intermediate levels, with 30-45% gp91
phox positive cells. 
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Fig. 47: Transduction efficiency of SIN gammaretroviral vectors in mSca-1
+ cells. Sorted cells were 
transduced  as  previously  described  and  were  analyzed  one  day  post-transduction.  FACS  analysis  of 
gp91
phox positive cells by 7D5 staining related to the respective VCN determined by sq-PCR is shown. 
 
To confirm gene transfer efficiencies, transduced cells were also plated in semi-solid 
medium  and  all  GM/G  colonies  arising  at  day  10  were  assayed  for  generation  of 
superoxide by the NBT assay. When the values of NBT positive (NBT
+) colonies were 
related to the number of integrated provirus, the tendency observed in the percentages of 
transduced  cells  prior  to  transplantation  correlated  with  the  functionality  of  the 
transduced  hematopoietic  precursor  cells  (Fig.  48).  In  both  analyses  (Fig.  47  and 
Fig. 48), the EFs.gp91s construct reached the highest levels of expressing cells (46% 
gp91
phox positive cells and 95% NBT
+ colonies). The lowest numbers were obtained for 
the SF.gp91s, 29% and 44% respectively, and for the M8dN.gp91s (15.5% and 64%). 
The  numbers  of  NBT
+  colonies  were  about  2-fold  higher  the  number  of  gp91
phox 
positive Sca-1
+ cells after transduction with all the contructs except for the M8dN.gp91s 
which  showed  4-fold  higher  levels.  However,  the  performance  of  the  M8dN.gp91s 
construct in the NBT colony assay was not efficienrbest since it showed lower levels of 
gp91
phox  positive  colonies  than  the  EFs.gp91s  vector  (1.5-fold).  In  contrast  the  data 
obtained with the SP146 and c-fes constructs were promising.These myeloid-specific 
constructs gave rose to a high percentage of positive cells as well as a high number of 
NBT
+ colonies. C. RESULTS  94 
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Fig.  48:  Analysis  of  NADPH  oxidase  activity  in  reconstituted  murine  X-CGD  Sca-1
+  cells. 
Percentage  of  colonies  scoring  positive  with  NBT.  Percentages  of  positive  colonies  related  to  copy 
number are shown. 
 
To assess the in vivo performance of these constructs, four X-CGD mice per construct 
were lethally irradiated with two doses of 5.5 Gy prior to receive 1x10
6 transduced cells 
by intravenously tail injection. Unfortunately, two mice which received the EFs.gp91s 
transduced cells and one receiving the SP146.gp91s gene modified cells died before 
being  analyzed.  Six  weeks  after  transplantation  the  surviving  recipient  mice  were 
sacrificed and bone marrow as well as peripheral blood populations were analyzed by 
flow  cytometry  to  verify  multi-lineage  reconstitution  and  functional  rescue  of  the 
NADPH oxidase activity. 
The expression of the gp91
phox transgene was assessed by flow cytometry analysis of the 
different bone marrow lineages from the transplanted mice. Marrow myeloid cells were 
identified using Gr-1 and CD11b (Mac-1) specific antigens which are mainly expressed 
at variable levels on monocytes/macrophages, granulocytes and their precursors. The 
antigen B220 (CD45R) was used to identify B lymphocyte precursor cells, because this 
marker  is  almost  exclusively  expressed  on  cells  of  the  B  lineage  in  bone  marrow. 
Murine hematopoietic precursor cells were labeled with a Sca-1 antibody as described 
above. Data were related to the copy number of integrated provirus measured 24 hours 
post-transduction in the transduced and transplanted cells. 
With  all  the  constructs  gp91
phox  positive  cells  were  detected  in  the  mSca-1
+ 
subpopulation  with  levels  ranging  between  30%  and  84%  except  for  the  MRP8 
construct,  which  showed  again  lower  levels  of  gp91
phox  positive  cells  (up  to  14%) 
(Fig. 49). 
The percentage of gp91
phox expressing cells per integrated provirus within the marrow 
myeloid  subpopulation  was  similar  to  those  observed  for  positive  gp91
phox  cells  in 
Sca-1
+.  The  highest  difference  in  gp91
phox  expression  between  Sca-1
+  and  marrow 
myeloid  subpopulation  was  observed  with  the  SP146  promoter,  which  showed  an 
increase  of  1.15  ±  0.24-fold  towards  myeloid  commitment.  The  c-fes  and  MRP8 C. RESULTS  95 
promoters  showed  the  lowest  differences  between  these  populations.  The  MRP8 
construct showed in all mice almost the same percentage of gp91
phox positive cells in the 
Sca-1
+ and myeloid marrow subpopulations (Fig. 49). 
When  comparing  the  gp91
phox  expression  between  the  HSC  precursor  and  the 
B lymphoid subpopulation a marked decrease was observed regardless of the type of 
promoter. This decrease ranged from 1.9-fold with the SP146 promoter to up to 2.4-fold 
with  the  MRP8  promoter.  Also  a  2.3-fold  decrease  in  gp91
phox  positive  cells  was 
observed for the SFFV promoter, which is actually a constitutive regulatory element. 
To assess whether there were changes in gp91
phox expression after maturation of the 
myeloid and B lymphoid lineages a sample of peripheral blood cells was analyzed by 
flow  cytometric  analysis  using  the  markers  previously  described.  The  differences  in 
gp91
phox expression between myeloid and B lymphoid circulating cells were lower than 
those  of  bone  marrow,  except  for  the  M8dN.gp91s  construct.  In  the  case  of  the 
SF.gp91s, the smaller differences between the two peripheral blood lineages were due to 
an increased percentage of gp91
phox in B lymphocytes (from 13-28% to 25-55%) and a 
decrease of this in granulocytes when compared to the bone marrow percentages (from 
43-58%  to  24-42%).  The  two  EFs.gp91s  mice  revealed  a  decrease  in  transgene 
expression in both peripheral blood lineages (myeloid and B lymphoid) but being more 
pronounced in the commitment towards granulocytes. Moreover, the levels of gp91
phox 
detected in peripheral blood granulocytes and B lymphocytes of the EFs.gp91s mice 
reached  only  very  low  levels,  6-20%  and  11-17%  respectively.  The  SP146.gp91s 
construct  showed  similar  results,  although  with  a  smaller  difference  in  the  decrease 
ratios of both subpopulations. With this construct only 7 to 19% of granulocytes and 6 
to  14%  of  B  lymphocytes  respectively  were  positive  for  gp91
phox  expression, which 
represented  approximately  3-  and  2.2-fold  lower  expression  than  that  of  the 
corresponding  marrow  subpopulation.  In  the  case  of  the  c-fes  construct,  there  were 
almost no differences in the transgene expression levels of the myeloid and B-lymphoid 
lineages  in  the  two  compartments.  The  granulocytes  reached  24-36%  and  19-33% 
gp91
phox positive cells in bone marrow and peripheral blood respectively, whereas the 
B lymphocytes reached 12-16% in bone marrow and 9-22% in peripheral blood. The 
M8dN.gp91s mice showed a high variability in transgene expression in peripheral blood 
achieving up to 15% in granulocytes and 5% in B lymphocytes. In the rest of the cases, 
the  levels  of  gp91
phox  positive  B  lymphocytes  were  almost  undetectable,  with  the 
granulocytes ranging from 2 to 7%. 
Reconstitution of the oxidase activity was measured in peripheral blood granulocytes by 
the DHR assay. Unfortunately; this assay could not be performed with all the samples 
due to technical problems. When the DHR values were related to the wild-type and the 
vector copy number, one of the MRP8 blood samples showed a maximum of 2-fold 
higher  levels  of  oxidase  positive  cells  although  previously  only  7%  of  gp91
phox C. RESULTS  96 
granulocytes were detected (Fig. 49b). In the rest of the MRP8 blood samples 0 to 80% 
DHR positive cells compared to the wild-type blood samples with up to 15% gp91
phox 
positive  peripheral  granulocytes.  The  most  constant  levels  were  achieved  by  the 
SF.gp91s construct with a 1.1 ± 0.2-fold increase in DHR positive cells when related to 
the  wild-type  and  34.9  ±  7.5%  of  transgene  expressing  cells.  In  the  case  of  the 
EFs.gp91s, only one mouse could be analyzed which reached 64% rhodamine positive 
cells although only 6.9% gp91
phox positive granulocytes were detected. In the two SP146 
samples similar oxidase levels as in EFs.gp91s mice were detected, although in this case 
more than 2-fold higher numbers of gp91
phox expressing granulocytes were found. The 
fes.gp91s construct achieved intermediate DHR levels (around 49 ± 18%), while having 
almost the same percentage of gp91
phox cells as the SF.gp91s mice (Fig. 49b). 
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Fig. 49: In vivo multilineage reconstitution ability and restoration of the NADPH oxidase activity of 
transduced  mSca-1
+  cells.  (a)  Percentage  of  gp91
phox  expressing  cells  in  bone  marrow  lineages  of 
reconstituted  X-CGD  mice  per  VCN.  Bone  marrow  cells  from  transplanted  mice  were  analyzed  for 
gp91
phox  expression  within  the  myeloid  lineage  (Gr-1
+  &  CD11b
+),  B  lymphoid  lineage  (B220
+)  and 
hematopoietic stem cell subpopulation (Sca-1
+). (b) Percentage of gp91
phox peripheral blood expressing 
cells per VCN and DHR reactive cells related to the wild-type sample and the VCN. Peripheral blood 
cells  were  immunostained  and  analyzed  for  gp91
phox  positive  cells  in  the  myeloid  and  B  lymphoid 
subpopulations. The percentage of DHR positive cells related to the wild-type sample and the VCN in 
peripheral blood of the indicated mice is also depicted.  
  
Table 2: Overwiew summarizing the reconstitution of NADPH oxidase activity in vivo using SIN viral vectors 
           
  Transduced mSca-1
+ cells    Bone Marrow  Peripheral blood  % DHR   
% 7D5  % 7D5 positive cells   % 7D5 positive cells   positive cells   
Vector 
positive cells 
VCN 
Mouse 
Nr. 
in Gr-1
+ and CD11b
+ 
in 
B220
+  in Sca-1
+  in Gr-1
+ and CD11b
+  in B220
+  12.0  Positive Control 
SF.1  38.8  11.7  34.4  30.0  21.9  11.7   
SF.2  38.0  16.7  35.9  21.6  25.6  9.7   
SF.3  50.3  20.0  41.1  33.5  27.3  10.0   
SF.gp91s  25.1  0.87 
SF.4  51.2  24.8  54.2  36.6  48.6  13.8   
                     27.6  Positive Control 
EFs.1  41.3  27.0  38.0  4.5  7.6  11.6   
EFs.gp91s  29.7  0.65 
EFs.2  54.9  19.5  54.1  13.3  11.5  ND   
SP.1  18.8  8.0  21.5  5.6  4.5  ND   
SP.2  43.6  22.0  33.0  14.2  7.9  10.7    SP146.gp91s  26.3  0.72 
SP.3  40.6  20.2  31.9  10.3  10.5  6.4   
                     34.3  Positive Control 
f.1  26.1  13.1  33.1  22.7  11.1  12.6   
f.2  24.5  13.7  28.0  20.2  23.4  ND   
f.3  35.2  16.7  37.4  35.1  19.7  24.9   
fes.gp91s  35.2  1.03 
f.4  37.4  12.7  34.0  25.0  8.9  14.9   
                     14.0  Positive Control 
M.1  13.0  3.6  14.5  7.0  1.3  28.4   
M.2  8.0  4.8  9.2  1.9  0.0  11.8   
M.3  10.9  7.5  9.6  4.1  0.0  9.8   
M8dN.gp91s  15.2  0.98 
M.4  11.7  4.4  12.2  15.0  5.1  6.8   
ND: not determined                 C. RESULTS  98 
C.4.3  Transplantation of genetically modified gp91
phox 
-/- Lin
Neg progenitors 
To further investigate the performance of the different gammaretroviral vectors a second 
in  vivo  experiment  was  performed.  In  this  case  the  vectors  containing  two  of  the 
investigated promoters were not included. First, the SF promoter, because it might still 
elicit transactivation events following proviral integration due to its strength. Second, 
the SP146 was disclosed since it showed genomic rearrangements phenomenon leading 
to the formation of aberrant proviral species. 
In  this  second  study,  mice  bone  marrow  preparations  were  used  to  isolate  lineage 
uncommitted  cells,  which  were  separated  from  lineage  specific  cells  up  to  >  95% 
(Dr. L. Chen, pers. commun.). The cells were stimulated for 48 hours in growth media 
containing  mSCF  (50  ng/ml),  mIL-6  (50  ng/ml)  and  mIL-3  (10  ng/ml).  After 
prestimulation, lineage antigen-negative (Lin
Neg) cells were transduced with the three 
different  retroviral  vectors  at  a  final  MOI  of  3  on  RetroNectin-coated  plates  as 
previously  described.  After  the  last  round  of  transduction,  cells  were  maintained  in 
culture under the same cytokine and media conditions for four days. Then the gene 
transfer efficiencies were assessed by flow cytometry. 
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Fig. 50: Ex vivo transduction efficiency in mouse bone marrow Lin
Neg cells isolated from murine 
bone  marrow.  Sorted  cells  were  transduced  with  the  indicated  viral  constructs  and  analyzed 4 days 
post-transduction. Histograms show the distribution of gp91
phox positive cell among Sca-1
+ and Gr-1
+ and 
CD11b
+ subpopulations. 
 
As shown in the Fig. 50, transduction efficiencies of ecotropic virus into murine HSCs, 
as scored by the percentage of 7D5 positive cells in the Sca-1
+ subpopulation, was high 
for all the constructs (ranging from 72 to 89%). In addition, the percentage of gp91
phox 
positive cells within the myeloid progenitor cell fraction showed almost the same values 
for all the constructs (ranging from 35.9 to 38.2%). When the MFI was analyzed, the 
EFs.gp91s  vector  generated  the  highest   MFI  among  all  the  constructs  both  in  the C. RESULTS  99 
Sca-1
+ (EFs.gp91s, 6.5; fes.gp91s, 5.7; M8dN.gp91s, 5.5) as well as in the myeloid 
subpopulation (EFs.gp91s, 5.3; fes.gp91s, 5.0; M8dN.gp91s, 3.1). 
Groups of eight X-CGD mice per construct were lethally irradiated with two doses of 
5.5 Gy prior to transplantation. For this the mice were injected intravenously in the tail 
vein  with  around  1.8x10
6  transduced  cells.  Unfortunately,  two  M8dN.gp91s 
transplanted  mice  died  before  being  analyzed.  Six  weeks  after  transplantation,  the 
recipient  mice  were  sacrificed  and  the  gp91
phox  expression  in  bone  marrow  and 
peripheral  blood  lineages,  as  well  as  the  NADPH  oxidase  activity  reconstitution  in 
peripheral blood granulocytes, was investigated. 
Gp91
phox expression in marrow myeloid and lymphoid lineages of transplanted mice was 
analyzed by flow cytometry and the results are summarized in the Fig. 51a. In this study 
the  antibodies  used  for  cell  marking  were  the  same  as  in  the  previously  described 
experiment. Additionally, T lymphocytes were labeled with a CD3 antibody to analyze 
transgene expression in these cells as well. 
The  results  show,  that  mice  transplanted  with  EFs.gp91s  and  fes.gp91s  transduced 
Lin
Neg cells showed extensive mouse-to-mouse variability in gp91
phox expression in the 
different lineajes. When comparing the percentages of gp91
phox positive cells within the 
marrow  myeloid  subpopulation,  the  EFs.gp91s  mice  showed  the  highest  intragroup 
variability. Levels of gp91
phox positive cells ranged from 13.4 to 64.6% (29.9 ± 18.9%). 
For  the  c-fes  mice  the  values  ranged  from  15.3  to  60.5%  (35.7  ±  15.2%).  The 
M8dN.gp91s  mice  showed  the  lowest  levels  of  gp91
phox  expression  in  all  marrow 
lineages. In the myeloid marrow subpopulation M8dN.gp91s values ranged from 4.4 to 
22.4% (11.6 ± 6.1%). Interestingly, in six out of eight fes.gp91s mice gp91
phox was 
expressed in at least 30% of the cells, whereas only three of the EFs.gp91s and none of 
the M8dN.gp91s mice reached this level. The proportion of gp91
phox expressing cells 
within the myeloid subpopulation was in most cases, and notably in all the M8dN.gp91s 
transplanted mice, higher than those of gp91
phox in marrow B cells. As expected, the 
expression of gp91
phox in marrow T lymphocytes was for the M8dN construct almost 
invariably below that of Gr-1
+ and CD11b
+ and B220
+ populations. In effect was also 
observed in the EFs mice. In contrast, in three fes.gp91s mice gp91
phox expressing T 
cells reached unexpected higher values than in myeloid cells (f9, f15 and f16) (Fig. 51a). 
To assess whether the gp91
phox expression levels detected in the bone marrow correlated 
with that of circulating cells, a sample of peripheral blood from each mice was analyzed 
by flow cytometry. The percentages of gp91
phox positive cells in the blood samples are 
shown in the Fig. 51b. 
When comparing the bone marrow and peripheral blood samples from the EFs.gp91s 
and  fes.gp91s  mice,  the  percentages  of  gp91
phox  positive  cells  within  myeloid 
subpopulations did not reveal any clear tendency. Half of the mice population showed C. RESULTS  100 
an increase in gp91
phox expression in the cells of the blood samples whereas the other 
half rather showed a decrease compared to the bone marrow specimen. In contrast, for 
the  M8dN.gp91s  mice  the  percentage  of  transgene  positive  cells  increased  through 
maturation  although  the  gp91
phox  level  was  still  low.  Only  one  M8dN.gp91s  mice 
reached the 30% threshold line whereas for the EFs.gp91s and fes.gp91s constructs 5 
and 6 out of 8 mice, respectively, reached this threshold. 
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Fig. 51: In vivo multilineage reconstitution ability of transduced Lin
Neg marrow cells. (a) Percentage 
of gp91
phox expressing cells in bone marrow lineages of irradiated and transplanted X-CGD mice. Bone 
marrow  cells  from transplanted mice were analyzed after 6 weeks for gp91
phox expression within the 
different hematopoietic lineages (myeloid-specific markers: Gr-1 and CD11b, B lymphoid marker: B220 
and  T  lymphoid  marker:  CD3).  (b) Percentage  of  gp91
phox  expressing  cells  in  peripheral  blood 
populations.  Peripheral  blood  cells  were  immunostained  and  analyzed  for  gp91
phox  expression  in  the 
myeloid and lymphoid lineages as described in (a). 
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Almost the same pattern in bone marrow and peripheral blood populations was observed 
for the changes in transgene expression in T cells. Extensive variability was observed in 
mice  transplanted  with  the  EFs.gp91s  and  fes.gp91s  transduced  cells,  while  the 
M8dN.gp91s did not show significant changes, only one mouse (M21) showed no (0%) 
gp91
phox  positive  cells  in marrow T lymphocytes and reached 7.6% in circulating T 
cells. It is important to mention that the percentages of gp91
phox expressing cells in both 
T cell sources were generally low, even in the case of the constitutive EFs promoter. In 
peripheral blood, the fes.gp91s mice showed lower values of transgene expressing T 
cells than the EFs mices. The lowest values were obtained with the M8dN.gp91s mice, 
which confirms the myeloid specificity of this promoter. 
The  differences  in  gp91
phox  expression in B cell populations isolated from the bone 
marrow or the peripheral blood followed clear tendencies. An increase in the expression 
of gp91
phox was detected in all EFs.gp91s and fes.gp91s mice, with only one exception 
(E8,  f16).  In  contrast,  a  decrease  was  observed  in  most  of  the  M8dN.gp91s  mice 
although to a very low extent (apart from the M21 mouse which showed an 8.2-fold 
increase in gp91
phox expression through maturation). Moreover, without taking the mice 
which showed a decrease in gp91
phox expression (E8, f16) into account, the increase 
observed with the EFs.gp91s construct was higher and not as variable as the increase in 
the fes.gp91s mice (2.6 ± 0.8-fold compared to 2.0 ± 1.3-fold, respectively). 
To  quantify  the  number  of  proviral  integrations  per  cell,  semiquantitative  PCR  was 
performed with the bone marrow and peripheral blood samples of the transplanted mice. 
However,  due  to  technical  problems  it  was  not  possible  to  analyze  all  mice.  The 
obtained values are depicted in the Fig. 52. There was a high variability in the vector 
copy number (VCN) observed in all mice, both in bone marrow and peripheral blood 
samples. Numbers ranged from 0.4 to 1.9 integrated proviruses per bone marrow cell, 
and from 0.4 to 4 in peripheral blood cells. 
The  VCN  was  compared  and  related  to  the  gp91
phox  expression  in  the  myeloid 
subpopulation  (Gr-1
+  &  CD11b
+)  of  the  corresponding  bone  marrow  and  peripheral 
blood mice samples. A clear tendency for a better performance was observed with the 
fes.gp91s construct (mainly when comparing both myeloid promoters) (Fig. 53a). The 
fes.gp91s  construct  showed  slightly  higher  and  more  constant  levels  of  transgene 
expression per copy number than the EFs.gp91s in the bone marrow (50.9 ± 4.8% and 
44.3  ±  8.8%  gp91
phox  positive  cells  per  integrated  vector,  respectively).  With  these 
promoters almost 4-fold higher levels were obtained than for the M8dN.gp91s construct 
(13.1 ± 3.6% gp91
phox positive cells per integrated vector). C. RESULTS  102 
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Fig. 52: VCN analysis of bone marrow and blood samples of the reconstituted X-CGD mice by 
semi-quantitative PCR. (a) Genomic DNA was obtained from bone marrow samples of recipient mice 
and PCR amplification of a gp91
phox fragment was performed. Amplification of the β-actin was used as 
loading control. A standard curve was prepared by serial dilution of mouse DNA from a genetically 
modified population with 1 copy of provirus per cell (m#3), and the linear regression and correlation 
coefficient R
2 were obtained to calculate the VCN of the samples. (b) DNA from a peripheral blood 
sample of each mouse was used to VCN determination by PCR amplification. A standard curve was 
prepared as described for the bone marrow analysis in (a). 
 
The  number  of  integrated  proviruses  was  also  assessed  in  the  peripheral  blood  of 
transplanted mice (Fig. 53b), but again not all mice could be analyzed due to technical 
problems (only two fes.gp91s mice could be tested). When the percentage of transgene 
expressing peripheral granulocytes was related to the VCN, a higher mouse-to-mouse 
variability than for bone marrow was observed (Fig. 53b). Nevertheless, EFs.gp91s and 
fes.gp91s  constructs  showed  higher  levels  of  gp91
phox  expression  per  integrated 
provirus, than M8dN.gp91s in almost all the cases (except for the mouse M21, which 
showed  up  to  10-fold  higher  transgene  expression  per  copy  number  than  the  other 
M8dN.gp91s  mice).  Most  of  the  M8dN.gp91s  mice  reached  markedly  low  levels, 
ranging from 5.1 to 14.4% gp91
phox positive circulating myeloid cells per integrated 
proviruses. The EFs.gp91s and fes.gp91s mice displayed a minimum of 20% transgene 
expressing cells per VCN in the myeloid peripheral blood compartment (except for the 
E2 mice which due to the low percentage of gp91
phox expressing peripheral Gr 1
+ and 
CD11b
+ cells (5.6%) only reached 6.3% of expressing cells per integrated provirus). C. RESULTS  103 
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Fig. 53: Gp91
phox expression per copy of integrated provirus. The percentage of gp91
phox expression in 
the Gr-1
+ & CD11b
+ subpopulation of bone marrow (a) and peripheral blood (b) from recipient X-CGD 
mice related to the corresponding VCN is represented. 
 
Finally, in vivo correction of the enzymatic defect was evaluated in peripheral blood 
granulocytes by the DHR assay in combination with Gr-1 & CD11b immunostaining 
and also in vitro with clonogenic progenitors using the NBT dye reduction assay. 
The  percentage  of  DHR  positive  cells  (normalized  according  to  the  wild-type)  is 
represented in histogram shown in Fig. 54. Though a high intragroup variability, the 
fes.gp91s construct showed the highest proportion of mice going beyond the threshold 
line  of  40%  DHR  positive  cells.  Six  fes.gp91s  mice  showed  more  than  40%  DHR 
positive cells and four out of these six even reached 80% whereas only four mice for 
EFs and two M8dN.gp91s mice reached 40% of DHR positive cells. C. RESULTS  104 
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Fig. 54: Reconstitution of the NADPH oxidase activity in irradiated and repopulated X-CGD mice. 
The  percentage  of  positive  cells  in  the  functional  DHR  analysis  of  peripheral  blood  samples  from 
transplanted mice is shown. 
 
When the flow cytometry DHR assay was analyzed in a dot blot form (Fig. 55) an 
evident shift with the PMA-stimulated wild-type peripheral blood granulocytes could be 
observed  indicating  robust  oxidase  activation  upon  stimulation.  The  analysis  of  the 
PMA-stimulated granulocytes from transplanted mice resulted in a 3- to 6-fold lower 
∆MFI  indicating  a  lower  superoxide  production  in  gene  modified  peripheral 
granulocytes.  Moreover,  when  comparing  the  ∆MFI  values  between  the  different 
constructs the M8dN.gp91s seemed to show a slightly better performance (6.9 ± 2.0; 
6.6 ±  0.6  and  6.5  ±  1.6  with  the  M8dN,  EFs  and  c-fes  promoters,  respectively). 
However,  this  promoter  was  also  shown  to  have  more  integrated  proviruses  in 
circulating granulocytes. Therefore, when the ∆MFI values were related to the number 
of integrated proviruses the best results were obtained with the EFs.gp91s (9.1 ± 3.3) 
followed by the fes.gp91s (6.7 ± 0.8) and finally the M8dN.gp91s construct, which also 
showed the highest mouse-to-mouse variability (5.9 ± 5.0). Of note, although only two 
fes.gp91s mice could be analyzed for the VCN, this construct showed a markedly lower 
intragroup variability in the DHR assay (if related to the VCN) than the other groups. 
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Fig. 55: Correction of oxidase activity in genetically-modified peripheral blood granulocytes of transplanted mice. Dot blot analysis of the flow cytometry DHR assay. 
Shown are analyses of non-stimulated and stimulated wild-type mouse peripheral granulocytes for comparison, and samples of transplanted mice show the results of stimulated 
peripheral granulocytes. C. RESULTS  106 
In addition to the DHR analysis of the blood cell, myeloid progenitor populations in the 
bone marrow of transplanted mice and non-transduced control mice were assayed for the 
ability to reconstitute the NADPH oxidase activity. For this purpose, bone marrow cells 
from transplanted mice were cultivated in semi-solid collagen-based medium containing 
mSCF  (50  ng/ml),  mGM-CSF  (10  ng/ml)  and  mIL-3  (10  ng/ml)  to  stimulate 
proliferation and colony formation. After 12 days of incubation, the number of colonies 
was assessed by counting every cell cluster of more than 50 cells as one colony. The 
enzymatic correction of the NADPH oxidase was evaluated using the NBT reduction 
assay (Dr. L. Chen). 
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Fig. 56: Analysis of NADPH oxidase activity in clonogenic progenitors of reconstituted X-CGD 
mice.  Percentage  of  colonies  scoring  positive  with  NBT  after  growth  in  semi-solid  culture  medium 
containing mSCF, mGM-CSF and mIL-3 for 12 days. 
 
As shown in the Fig. 56 a higher percentage of NBT
+ colonies was detected for the 
clonogenic  progenitors  of  the  fes.gp91s  transplanted  mice  than  those  of  the  other 
constructs  (about  4.9-  and  7.2-fold  increase  in  percentage  of  NBT
+  colonies  when 
compared to EFs.gp91s and M8dN.gp91s mice, respectively). 
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D. DISCUSSION 
To date, bone marrow transplantation is the most recommended therapy for the CGD, 
but  only  if  a  matched  donor  is  available.  However,  such  ideal  match  is  extremely 
infrequent and, in addition, several severe side effects may occur after transplantation 
which might lead to a fatal outcome. Therefore, this treatment possibility should be 
studied thoroughly before proceeding (Barese et al., 2004). 
Gene therapy offers an interesting alternative to BMT, which implies a less invasive 
treatment and possibly represents a possibly unique curative option for patients with not 
suitable donor. Gammaretroviral vector were already used in some gene therapy trials 
for  CGD  and  other  immunodeficiencies  showing  relevant  clinical  benefit.  However, 
these trials uncovered also mutagenic side effects, which occurred as a direct result of 
vector  integration  into  the  host  genome  leading  to  the  development  of  malignant 
processes (Hacein-Bey-Abina et al., 2003a) or to a selective advantage of affected target 
cells resulting in a monoclonal repopulation (Deichmann et al., 2007). Therefore there 
was  a  need  to  further  improve  the  safety  of  these  vectors  and  to  this  end  the 
self-inactivating gammaretroviral vectors were engineered. Non essential sequences for 
virus  infectivity  and  integration,  which  might  influence  the  surrounding  gene 
expression,  were  deleted  in  these  vectors.  Although,  these  vectors  showed  low 
efficiency in virus production, the requirement for an internal promoter was a major 
advantage. These vectors offer the opportunity to test the performance of tissue-specific 
promoters driving transgene expression towards the desired cells. 
In the present study the suitability and performance of self-inactivating gammaretroviral 
vectors for the treatment of the CGD was investigated, focusing on improvements of the 
therapy based on findings obtained with previous clinical studies. The improvements 
included production of the virus in high titers as well as the selection of an efficient 
tissue-specific promoter for expression of the transgene. 
D.1  Improving retroviral vectors driving gp91
phox expression 
In  the  first  set  of  experiments,  a  series  of  SIN  gammaretroviral  vectors  was  cloned 
driving  the  expression  of  the  wild-type  gp91
phox  cDNA  under  the  control  of  a  viral 
constitutive SFFV promoter. These vectors contained an RSV promoter to drive the 
expression  of  the  genomic  viral  transcript  in  the  packaging  cells  and  the  WPRE 
sequence  to  enhance  the  export  of  the  intronless  RNAs  from  the  nucleus  into  the 
cytoplasm. These changes resulted in a substantial increase in the titers of this vectors, 
which was one major drawback of the former gammaretroviral SIN vectors (Schambach 
et al., 2006a). Additionally three different leader conformations were design based on 
the presence or absence of donor and acceptor splicing sites: leader 11 which contains 
only splice donor site, leader 71 with both splice donor and acceptor, and leader 110 D. DISCUSSION  108 
without  splicing  sites.  Previous  studies  with  retroviral  vectors  have  shown  that  the 
presence of an intron at the 5’UTR favored the transgene expression in transduced cells 
likely due to the fact that the mRNA nuclear export process is coupled to the cellular 
splicing (Kraunus et al., 2004). This idea is supported by studies showing enhanced 
nuclear  export  of  cellular  genes  by  splicing  (Luo  and  Reed,  1999).  Moreover,  the 
presence of the packaging signal in the transcript of the integrated proviral genome was 
found to reduce transgene expression. This phenomenon might be due to the cellular 
inhibition  of  retroviral  RNA  export  or  caused  by  its  complex  secondary  structure 
(Kraunus et al., 2004). Therefore, the effect of a packaging signal placed within an 
intron, and upstream of the internal promoter was studied. 
In  addition  to  the  leader  modifications  in  the  first  series  of  vectors,  an  alternative 
version of the gp91
phox gene, which contains a mutated cryptic splice acceptor (cSA) 
sequence, was tested. The presence of the cSA within the wild-type gp91
phox cDNA was 
revealed by analyzing the mRNA species produced by pSRS11.SF.gp91.W-transfected 
293T cells (Fig. 16), and it was likely to reduce viral titers due to the generation of 
incorrect  transcripts.  Therefore,  a  point  mutation  was  introduced  in  the  consensus 
sequence of the cSA and its effect on the virus production in combination with the three 
different  leader  sequences  was  studied  (Fig.  17).  Titer  analysis  of  the  six  different 
vectors  showed  about  1x10
6  t.u./ml  as  measured  by  FACS  analysis  and  about 
2.5x10
6 t.u./ml  by  PCR  amplification  (Fig.  18).  The  differences  between  FACS  and 
PCR measurements were likely caused by the failure in transgene expression of some 
integrated vectors, which is dependent on the chromosomal integration site. Between the 
three different leader sequences no big differences were observed. Also the mutation 
introduced to avoid aberrant splicing occurring within the gp91
phox mRNA did not show 
significant differences. This indicated that the cSA had no detrimental effect on virus 
production,  probably  because  the  splicing  machinery  of  the  producer  cells  did  not 
efficiently use it. The surprising 3.4-fold increase in titer observed with the mutated 
versus wild-type gp91
phox in combination with leader 110 could not be explained by the 
avoidance of a splicing event, since this leader has no splice sites able to interact with 
the  cSA  of  the  wild-type  gp91
phox  cDNA.  Mostly  important,  all  constructs  tested 
achieved enhanced titers (previously <5x10
5 t.u./ml) which is an important requirement 
for large-scale retroviral vector production and a prerequisite for clinical applications 
(Schambach and Baum, 2007). 
The  level  of  transgene  expression  within  individual  cells  is  an  additional  critical 
parameter for functional correction in the gene therapy of the CGD. Previous molecular 
studies of X-CGD patients showed that low amounts of superoxide production are still 
related  to  severe  symptoms  (Bu-Ghanim  et  al.,  1995;  Goebel  and  Dinauer,  2002). 
Therefore, studying the efficacy (maximal therapeutic effect with minimal vector copy 
number) of an improved gene therapy vector is of great interest. D. DISCUSSION  109 
To assess this question, a selection procedure for gp91
phox positive cells with a vector 
copy number of 1 integrant per cell was set up (in order to compare between equally 
transduced cells). However, the selection process caused changes in the  MFI values of 
the  populations  transduced  with  vectors  containing  the  mutated  gp91
phox  sequence. 
These constructs reached values of about 5 prior to selection and shifted to about 7 after 
sorting  (Fig.  19).  These  differences  might  be  due  to  the  selection  process,  but  also 
caused  by  imprecise  measurements  prior  to  sorting.  The  pre-selected  populations 
contained only a few positive cells, which might not be representative for the whole 
population. To additionally determine differences in the superoxide production levels 
between  the  sorted  populations,  the  cytochrome  c  assay  was  performed  after 
granulocyte-like  cell  differentiation  (Fig.  20).  This  assay  is  an  accurate  test,  which 
measures  the  extracellular  O2
-  production  of  cells  upon  stimulation,  but  is  also 
extremely  sensitive  giving  rise  to  variations  between  measurements.  However, 
regardless  of  the  high  standard  deviations,  the  obtained  superoxide  levels  reached 
between 60 to 90% of the wild-type PLB-985 cells (Fig. 21), which might be enough to 
ensure a stable follow-through of the disease. Furthermore, these values are comparable 
to those obtained in a previous study where X-CGD PLB-985 cells were transduced 
with a full-length LTR murine stem cell virus-based vector (MSCV vector) expressing 
the wild-type gp91
phox gene. In this case, superoxide production levels of 57 to 119% 
related to the wild-type PLB-985 cells were detectable in derivative clonal populations 
(Ding et al., 1996). The cytochrome c assay also revealed that vectors containing the 
mutated sequence reached slightly higher values of oxidase activity than those harboring 
the wild-type cDNA. This increase might not be due to the mutation in the cSA of the 
gp91
phox gene itself. In the SIN gammaretroviral vector configuration the splice sites are 
present  in  the  leader  sequence  situated  upstream  of  the  internal  promoter,  and  thus 
should not have any influence on the cSA of the transgene. Therefore, the increased 
values  in  superoxide  production  by  the  mutated  sequence  might  indicate  a  better 
performance in transcription or protein processing although the reason is still unknown. 
In addition, both vectors containing the leader 11 showed the best titers, whereas the 
highest levels of superoxide production were obtained in combination with the mutated 
gp91
phox cDNA. Therefore, the SRS11.SF.gp91m.W was selected as basal backbone for 
further modifications such as transcriptional targeting by the use of myeloid-specific 
promoters. 
D.2  Introduction of myeloid cell specificity in retroviral vectors 
D.2.1  Evaluation of the MRP8 promoter 
The  NADPH  oxidase  is  mainly  required  in  phagocytic  cells,  thus,  it  would  be  a 
desirable and powerful strategy to target the transgene expression towards myeloid cells 
by the usage of tissue-specific promoter such as the MRP8 and c-fes promoters. D. DISCUSSION  110 
The MRP8 promoter has been widely used to drive the expression of several transgenes, 
such as bcl-2 or AML-ETO, towards myeloid and neutrophil cells including common 
myeloid  progenitors  in  transgenic  leukemia  mouse  models  (Lagasse  and  Weissman, 
1994; Yuan et al., 2001). Moreover, it has been shown in our group that a fragment of 
1176  bp  of  the  MRP8  promoter  containing  upstream  regulatory  elements  efficiently 
drives  the  expression  of  GFP  when  cloned  in  a  lentiviral  construct  (Dr.  S.  Stein, 
pers. commun.). Therefore, to test the performance of this sequence, it was cloned into 
the SRS11.SF.gp91m.W gammaretroviral construct, which previously showed the best 
results  in  the  cytochrome  c  assays  (Fig.  22).  It  was  shown  that  viral  particles  were 
produced  by  the  packaging  cells  since  gp91
phox  cDNA  could  be  detected  by  PCR 
amplification  of  genomic  DNA  of  the  SRS11.M8dNdI.gp91m.W  transduced  cells 
indicating the presence of integrated viral genomes (Fig. 24a). However, when X-CGD 
PLB-985 cells were transduced with this vector, there was no detectable expression of 
gp91
phox neither prior nor after granulocyte-like cell differentiation (Fig. 23). The absent 
or inefficient transcription as well as aberrant mRNA products generated by erroneous 
transcription  of  the  transgene  are  both  possible  causes  for  undetectable  levels  of 
gp91
phox glycoprotein in the cellular membrane. Therefore, Northern blot analysis was 
performed to investigate the presence of gp91
phox transcripts in the transduced cells. A 
total  lack  of  gp91
phox  RNA  was  shown confirming absent transgene transcription as 
responsible for the missing expression of the integrated gp91
phox cDNA (Fig. 24b). The 
loss of expression using this vector might be caused by the cloning strategy. In the 
previous  lentiviral  construct  the  expression  cassette  (MRP8-GFP)  was  cloned in the 
inverse  orientation,  whereas  the  direct  orientation  was  used  for  the  gammaretroviral 
construct. Whether changing the orientation of the expression cassette would have led to 
an enhancement in the transgene expression was not further studied. Instead, a cis-acting 
regulatory element was introduced to improve the transgene expression (Fig. 25). 
Melkonyan and colleagues revealed the existence of a myeloid-specific enhancer in the 
first intron of the MRP14 gene, which encodes a Ca
2+-binding protein of the S-100 
family to which the MRP8 protein also belongs to (Rammes et al., 1997). This MRP14 
intronic sequence showed enhancing effects (with up to 37-fold increase in transgene 
expression) and position independent characteristics when cloned, either upstream or 
downstream of an heterologous promoter, such as the TK promoter (Melkonyan et al., 
1998). Furthermore, this is a highly conserved sequence in the human MRP genes, and 
thus it shares also a high degree of homology with the first intron of the MRP8 gene. 
Therefore, to assess if this element is able to increase transgene expression, the enhancer 
sequence located at the first intron of the MRP8 gene was PCR amplified and cloned 
upstream  of  the  internal  MRP8  promoter  in  the  gammaretroviral  vectors.  However, 
when virus treated cells were analyzed for transgene expression gp91
phox positive cells 
could  not  be  detected  after  transduction  neither  after  granulocytic-like  cell 
differentiation (Fig. 26a and b). Moreover, when the presence of integrated proviruses D. DISCUSSION  111 
was  investigated  in  transduced  cells  gp91
phox-containing  sequences  could  not  be 
detected (Fig. 26c). This lack of proviral integrations might be due to absent or defective 
virus production in the producer cells because of either a transcriptional or a packaging 
failure,  respectively.  The  large  size  (~5  kb)  of  the  expression  cassette  may  not  be 
responsible  for  detrimental  packaging  of  the  genomic  viral  RNA,  since  it  has  been 
previously  shown  that  gammaretroviral  vectors  are  able  to  package  heterologous 
sequences up to 8 kb in length (O'Connor and Crystal, 2006). 
D.2.2  Evaluation of the c-fes promoter 
Another  myeloid  promoter  was  chosen  to  test  its performance in the context of the 
gp91
phox–containing gammaretroviral vectors, the c-fes promoter. This promoter drives 
the expression of a non-receptor tyrosine kinase (p92
c-fes protein) involved in several 
cellular processes including differentiation and proliferation of myeloid cells. Moreover, 
the  c-fes  promoter  is  constantly  active  during  myeloid  differentiation,  but  becomes 
silenced upon erythroid maturation (Care et al., 1994). The PU.1, a transcription factor 
required for c-fes promoter activity in myeloid cells, interacts with GATA-1, a zinc 
finger  transcription  factor  required  for  erythroid  differentiation,  thereby  blocking 
erythroid differentiation (Heydemann et al., 1996; Stopka et al., 2005). Previous studies 
showed that this promoter is influenced by the locus control region (LCR), a cis-acting 
DNA  element  that  enhances  expression  of  the  linked  gene,  driving  a  copy  number 
dependent  expression.  However,  they  also  showed  that  a  446  bp  fragment  of  the 
promoter was able to ensure a transgene tissue-specific expression (Heydemann et al., 
2000). Therefore, in the present study this short sequence of the c-fes promoter was 
PCR amplified and placed in the selected viral vector for further testing in X-CGD 
PLB-985 cells. In contrast to the MRP8 promoter, the c-fes promoter clearly activated 
detectable gp91
phox expression when X-CGD PLB-985 cells were transduced with these 
viral  particles.  Nevertheless,  the  transgene  expression  of  the  c-fes  promoter  showed 
moderate  transcriptional  levels  since  the   MFI  analysis  of  SRS11.fes.gp91m.W 
transduced cells reached only around 50% of gp91
phox expression of cells transduced 
with the SF promoter-containing construct (Fig. 28a). Moreover, titer analysis revealed a 
reduced virus production possibly caused by transcriptional interference between the 
c-fes promoter and the RSV promoter located in the plasmid 5’LTR. Titers obtained 
with the SRS11.SF.gp91m.W construct were twice as high as titers obtained with the 
c-fes  construct.  These  data  correlated  with  previous  studies  from  Schambach  and 
colleagues  also  showing  that  the  SF  internal  enhancer  promoter  influenced  the 
expression  from  the  RSV  5’LTR  (Schambach  et  al.,  2006c).  Additional  studies  on 
transduced cells, such as genomic detection of integrated provirus, corroborated this 
observation  since  lower  amounts  of  integrants  were  detectable  in  the 
SRS11.fes.gp91m.W  transduced  cells  (Fig. 28c). In addition to the low titer only, a 
slightly increase of the transgene expression was observed after granulocyte-like cell 
differentiation with the c-fes construct (Fig. 28b). This was also observed in a previous D. DISCUSSION  112 
study showing that the c-fes driven expression did not experience any significant change 
through differentiation (Haigh et al., 1996). Thus, it can be concluded that in contrast to 
previous observations, the c-fes is a weak promoter when compared to the SF viral 
promoter,  and  that  it  is  not  inducible  through  differentiation.  Nevertheless,  the 
transcriptional activity of the c-fes promoter should not be considered as defective. The 
desired  transgene  expression  should  not  be  necessarily  compared  to  the  high  levels 
produced by the SF viral promoter, which might produce an excess of protein compared 
to the endogenous levels in wild-type cells. Therefore, the functionality of the c-fes 
promoter-containing  construct  was  further  investigated  in  sorted  transduced  cell 
populations  containing  similar  VCN  per  cell.  The  purity  of  the  c-fes  transduced 
population  reached  only  72%  of  positive  cells  likely  due  to  the  lower  amounts  of 
gp91
phox  expressed  by  the  c-fes  promoter,  leading  to  a  less  efficient  labeling  and 
enrichment (Fig. 28d). The NADPH functionality was assessed by the cytochrome c 
assay in these cell populations after granulocyte-like cell differentiation showing that the 
c-fes  promoter  did  not  reach  the  wild-type  kinetic  level  even  after  25  min  of 
measurement (Fig. 29a and c). In accordance, when comparing the values of superoxide 
production between both constructs, 5 times lower levels were obtained by the c-fes 
promoter and only 10% of superoxide production of the wild-type levels were obtained 
(Fig.  29d).  These  results  were  also  confirmed  by  the  observation  that  the  gp91
phox 
glycoprotein  was  almost  undetectable  in  Western  blot  analysis  of  the  sorted  cell 
population  containing  the  SRS11.fes.gp91m.W  construct  (Fig.  29b).  Overall,  these 
results ruled out this construct for development of an efficient and effective viral vector 
for X-CGD gene therapy. For this purpose not only the percentage of positive cells, but 
also the total amounts of superoxide produced by each individual cell has been shown to 
be crucial for effective treatment of the disease (Johnston et al., 1985). 
Previous studies with lentiviral backbones showed an optimal performance (NADPH 
oxidase reconstitution ability with myeloid-specific expression) of a c-fes construct, in 
which the expression cassette (gp91
phox and bgh polyadenylation signal) was cloned in 
the inverse orientation (Dr. S. Stein, pers. commun.). Therefore a similar cassette was 
placed in the SIN gammaretroviral backbone also in the inverse orientation (Fig. 30a). 
In  this  gammaretroviral  vector  the  WPRE  sequence  was  deleted  since  the  bgh 
polyadenylation  signal  was  included  in  the  cassette.  The  bgh  signal  is  a  strong  and 
specialized polyadenylation signal from the bovine growth hormone gene that ensures 
transcriptional termination. This element was placed downstream of the transgene to 
avoid possible read-through events from the internal c-fes promoter (Schambach et al., 
2007). 
Although in the lentiviral context this cassette showed a good performance, the c-fes 
promoter again failed to induce gp91
phox expression in the gammaretroviral backbone 
(Fig. 30b). No gp91
phox positive cells were detected after transduction of target cells and 
PCR analysis revealed that the provirus didn’t integrate in the genome of cells treated D. DISCUSSION  113 
with  viral  supernatants  indicating  that  no  infecting  particles  were  released  by  the 
packaging cells (Fig. 30c). The failure to produce infectious particles with this construct 
might be due to several reasons e.g. the formation of antisense transcripts hybridizing 
with the sense RNA molecules. This may down regulate gene expression by inhibiting 
sense mRNA transcription and/or translation (Kumar and Carmichael, 1998). Whether 
this occurs requires further studies e.g. Northern blot analysis of RNA from transfected 
cells. Since the c-fes construct (with the expression cassette in the direct orientation) 
showed a low but detectable transgene expression and a transgene-dependent effect in 
the  efficacy  of  the  vector  can  not  be  excluded.  Therefore  subsequent  studies  were 
focused  on  improving  the  transgene  expression  levels  by  codon  optimizing  of  the 
gp91
phox wild-type sequence. 
D.3  Synthetic gp91
phox 
D.3.1  Improvements of viral titer and transgene expression 
Replacement  of  the  viral  internal  constitutive  promoter  of  the  SIN  gammaretroviral 
constructs by myeloid-specific elements caused a reduction in both titer and transgene 
expression. Further modifications in the leader region, in the gp91
phox cDNA itself or in 
the content of cis-acting elements did not improved the performance of these vectors. 
Therefore, a complete codon optimization of the native gp91
phox cDNA was performed. 
The codon optimization process requires the knowledge of the codon usage of the target 
cell. Usage is defined by the relative amounts of the 20 tRNAs available in the cell and 
the percentage of utilization of each tRNA by the ribosomes. To optimize a sequence, its 
codon content is evaluated, and each codon for which a better codon is available is 
exchanged.  This  technique  has  multiple  applications  (e.g.  optimize  transgene 
expression, increase genetic stability of vector constructs, reduce homology to wild-type 
sequences  counteracting the risk of homologous recombination events, etc.) and has 
already shown to increase viral titer and improve transgene expression levels in vectors 
designed for further gene therapy applications (Radcliffe et al., 2008). 
In the present study, the wild-type gp91
phox cDNA was optimized (gp91s) for translation 
in human cells. Additionally, sequences such as internal polyadenylation sites, cryptic 
splice sites and RNA instability motifs were also detected and eliminated, since they 
might lead to undesirable and aberrant transcripts thereby exerting a negative influence 
on viral genome production. 
The synthetic gp91
phox and the mutated version were then cloned in a new construct 
based  in  the  SERS11.SF.GFP.W  backbone  kindly  provided  by  Prof.  Dr.  C.  Baum 
(Fig. 31a). This construct contained a SV40 enhancer (E) upstream of the LTR plasmid 
promoter shown to enhance viral particle production of SIN gammaretroviral vectors 
(Schambach et al., 2006c). Moreover, a X protein promoterless, ORFs deleted WPRE 
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Indeed, when assessing the performance of the synthetic gp91
phox sequence cloned into 
the  new  SIN  gammaretroviral  backbone  (SERS11.SF.gp91s.Wm  vector),  a  2.7-fold 
increase in titer was observed when compared to the SERS11.SF.gp91m.W construct 
(Fig.  31c).  The  higher  virus  production  was  assumed  to  be  due  to  an  improved 
translation of this construct in transfected and transduced cells. This hypothesis was first 
assessed by Northern blot analysis of the viral transcripts in transfected cells which 
revealed correlating higher amounts of genomic transcripts with the codon optimized 
vector (Fig. 31d). Moreover, the better transcription of the transgene in transduced cells 
might  have  helped  also  to  ensure  detection  of  the  integrated  proviruses.  This 
phenomenon was assumed to occur since higher amounts of the internal transcript were 
also observed in SERS11.SF.gp91s.Wm transduced cells with similar VCN (Fig. 34a). 
The  transcriptional  enhancement  of  the  synthetic  transgene  led  to  a  higher  protein 
expression since an increase in  MFI, when compared to the mutated gp91
phox, was 
observed  in  transduced  X-CGD  PLB-985  cells  (1.3-fold)  and  MACS  selected 
populations  (2.2-fold)  with  similar  VCN  per  cell  (Fig.  32).  Furthermore,  after 
granulocyte-like cell differentiation of sorted synthetic and mutated gp91
phox transduced 
populations no changes in  MFI were detected (Fig. 33), which is consistent with the 
previously described, constitutive transcriptional activity of the SF promoter (Tumas et 
al.,  1996).  Additional  analysis  revealed  that  the  differences  in   MFI  between 
undifferentiated  and  differentiated  sorted  populations  did  not  correlate  with  those 
observed  in  internal  transcript  amounts  (Fig.  34a).  The  transcriptional  increase  was 
higher  than  the   MFI  change  thereby  showing  the  beneficial  effect  of  deleting  the 
polyadenylation and RNA instability motifs. However, these differences in transcript 
and  protein  amounts  have  already  been  shown  by  previous  studies  where  primary 
hCD34
+  cells  were  transduced  with  a  gp91
phox-containing  retroviral  construct  and 
analyzed  after  granulocyte-like  cell  differentiation  in  vitro  (Grez  et  al.,  2000). 
Nevertheless,  the  analysis  of  protein  amount  revealed  a  correlation  with  the  higher 
 MFI values when comparing both differentiated populations which indicates that the 
protein  amount  was  directly  proportional  with  its  incorporation  into  the  membrane 
(Fig. 34b). Additionally, there was also an increase in the protein content of transduced 
cells when compared to the wild-type PLB-985 cells, 2.7- and 5.5-fold increase were 
achieved by the mutated and synthetic gp91
phox sequence respectively. 
D.3.2  Enhanced superoxide generation by the synthetic gp91
phox 
When  the  restoration  of  superoxide  generation  was  assessed,  the  synthetic 
gp91
phox-containing  cells  showed  higher  superoxide  production  (1.7-fold)  than  the 
mutated gp91
phox transduced cells and even higher levels of O2¯ than those produced by 
the  wild-type  cells  (Fig.  34c).  The  functional  difference  between  both  transduced 
populations correlated with that of protein and  MFI levels, which indicated that the 
augmented superoxide production was likely due to the increase in the protein content 
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gp91
phox transduced cells compared to wild-type cells, although here the cytochrome c 
assay did not show differences in the reconstitution of the NADPH oxidase between 
these populations. Since the amino acid sequence, and thus the structure of the gp91
phox 
protein,  was  conserved,  regardless  of  the  codon  optimization,  the  1.7-fold  higher 
superoxide  production  observed  with  the  synthetic  gp91
phox  sequence  cannot  be  the 
result  of  just  higher  protein  content.  Therefore,  the  higher  superoxide  production 
observed might be explained by an underlying effect of the codon optimization process, 
by the sensitivity of the assay, or by non-significant differences. 
D.3.3  The EFs promoter 
Previous molecular studies in patients as well as gene therapy pre-clinical investigations 
have shown that the level of NADPH oxidase activity per cell can be an important factor 
in determining the outcome to certain microorganisms’ infection when small numbers of 
O2¯ neutrophils are present (Dinauer et al., 2001). In the present study it is shown that 
the  use  of  the  synthetic  gp91
phox  sequence  in  the  context  of  a SIN gammaretroviral 
vector  represents  an  excellent  alternative  to  those  former  constructs  expressing  the 
mutated or native gp91
phox transgene. 
Therefore,  the  SERS11.SF.gp91s.Wm  was  chosen  to  investigate  the  performance  of 
non-viral  promoters,  since  it  was  postulated  that  the  SF  promoter  could  still  cause 
transactivation of neighboring genes due to its strength (Modlich et al., 2006). One of 
the tested promoters is the EF-1α promoter, a ubiquitous promoter that efficiently drives 
the transgene expression in myeloid and lymphoid progeny of engrafting cells (Woods 
et al., 2001). A short, intron-deleted version of the EF-1α promoter, known as EFs, has 
already been tested in both gammaretroviral and lentiviral SIN vectors, and it showed a 
moderate transcriptional activity with acceptable titer (Schambach et al., 2006b). 
In the present study, this short EFs sequence was used to analyze the expression of 
synthetic gp91
phox in a SIN gammaretroviral vector. When the EFs promoter was tested 
in X-CGD PLB-985 cells, a 3-fold lower titer was obtained when compared to the SF 
promoter (Fig. 36a). This effect might be due to the lower trans-activation potential of 
the EFs promoter on transcription from the LTR promoter as already seen for the c-fes 
promoter in the previous constructs of this study. This was confirmed by the fact that the 
amounts of genomic viral RNA assessed by Northern blot was lower as compared to the 
transcript amounts achieved by the SF promoter, which indicated a lower transcriptional 
rate from the LTR promoter (Fig. 36b). 
Further  investigations  showed  that  the  EFs  promoter  has  also  less  transcriptional 
strenght  than  the  SF  promoter,  since  the   MFI  and  protein  levels  in  differentiated 
X-CGD  PLB-985  transduced  cells  showed  1.4-  and  2-fold  lower  values  (Fig.  38). 
Nevertheless,  the  cytochrome  c  assay  revealed  that  higher  values  of  superoxide 
production  were  reached  in  the  DMSO  differentiated  transduced  cells  with  the  EFs D. DISCUSSION  116 
promoter than the wild-type PLB-985 cells (Fig. 41). When measured in a DHR assay, a 
slight 1.5-fold lower  MFI was observed (Fig. 42). The lack of correlation between the 
results  from  these  two  assays  is  caused  by  the  fact  that  these  methods measure the 
external superoxide release or the cytoplasmatic superoxide production, respectively. 
Furthermore, DHR is oxidized to rhodamine by hydrogen peroxide, whereas cytochrome 
c  is  directly  reduced  by  superoxide  ions  produced  by the activation of the NADPH 
oxidase at the beginning of the reaction (Henderson and Chappell, 1993; Krause et al., 
2001). Although these differences were observed, the levels of superoxide production 
obtained with the EFs.gp91s construct in both assays were high enough to ensure a 
stable follow-through of the disease. Therefore further investigations using ex vivo and 
in vivo models were performed with this promoter. 
The EFs promoter-containing vector reached up to 85% gp91
phox positive cells within 
the Sca-1
+ subpopulation when mouse Lin
Neg sorted cells were transduced with a final 
MOI of 3 (Fig. 50). When the gene transfer efficiency was related to the copy number of 
integrated proviruses, up to 45.7% positive cells were detected following transduction of 
mouse Sca-1
+ cells using the same final MOI (Fig. 47). It remains to be tested whether 
the cell source influenced the gene transfer ratio, since the VCN in the Lin
Neg cells was 
not monitored after transduction. However, titers obtained with the SIN constructs were 
assessed  following  limiting  dilution  transduction  of  murine  SC-1  fibroblasts,  and 
although marrow stem cells were subjected to prestimulation, it might be assumed that 
the transduction of murine Sca-1
+ cells might be less efficient owing to their quiescence, 
as retroviral transduction requires that the target cells be cycling (Miller et al., 1990). 
This idea was confirmed by the VCN analysis of the mSca-1
+ transduced cells, in which 
only 0.65 to 1.03 copies per cell could be monitored although a MOI of 3 was used 
(Table 2). Additionally, if it is assumed that the VCN per cell is similar for both assays 
(regardless of the cell source) the fact that the gene transfer efficiency in the mSca-1
+ 
sorted cells was investigated 24 hours after the last round of transduction might have 
lead to an underestimation of the gene transfer rate. Further data obtained with the NBT 
assay in CFUs showing similar ratio of transduction efficiencies for the mSca-1
+ cells 
and the Lin
Neg cells were consistent with the hypothesis that more time is required to 
achieve full transgene expression levels (Fig. 48). 
When the changes in transgene expression were assessed slightly higher percentages, 
1.4 ±  0.3-fold,  of  gp91
phox  expressing  cells  were  detected  after  ex  vivo  myeloid 
differentiaion  (Fig.  44a).  In  Sca-1
+  transplantation  analyses  the  level  of  gp91
phox 
expressing  cells  was  almost  identical  in  Sca-1
+  and  Gr-1
+&CD11b
+  bone  marrow 
subpopulations six weeks after transplantation, which decreased when maturation was 
completed  (from  63%-84%  in  bone  marrow  to  6%-20%  in  peripheral  blood  of  two 
mice) (Fig. 49a and b). Moreover, in Lin
Neg transplantation experiments the transgene 
expression  level  measured  in  Sca-1
+  ex  vivo  transduced  cells  decreased  after 
differentiation into myeloid bone marrow derivatives (Fig. 51a). Then 50% of the mice D. DISCUSSION  117 
experienced  an  increase  and  in  the  other  half  a  decrease  was  observed  after 
differentiation  into  myeloid  peripheral  blood  cells  (Fig.  51b).  It  is  clear  that  the 
engraftment potential of each individual transduced stem cell is different, due to the 
natural-  or  retroviral  vector-mediated  fitness  (Baum, 2007a). This might explain the 
differences in the patterns of transgene expression from engrafted stem cells to myeloid 
precursors  and  those  from  ex  vivo  transduced  Sca-1
+  cells  to  myeloid  marrow 
derivatives. 
When the performance of the EFs.gp91s construct was assessed in vivo in marrow B 
lymphoid cells the level of gp91
phox positive cells was lower than in granulocytic and 
stem cell marrow subpopulations in the two mSca-1
+ transplanted mice (Fig. 49a). In 
contrast mice transplanted with transduced Lin
Neg cells showed low and constant levels 
of gp91
phox positive cells (between 10-25%) regardless of the expression in granulocytes 
(Fig.  51a).  Moreover,  there  was  no  correlation  in  the  change  of  expression  towards 
maturation of B lymphocytes, since for the mSca-1
+ experiments a decrease and for the 
Lin
Neg  transplantations  a  increase  in  percentage  of  gp91
phox  expressing  cells  was 
detected (Fig. 49b and Fig. 51b). 
Although the EF-1alpha promoter has been shown to be expressed in almost all kinds of 
mammalian cells in a constitutively manner, the results obtained in this study show that 
short, intron-deleted EFs promoter did not confirm a constant and constitutive transgene 
expression in the different lineages analyzed (Mizushima and Nagata, 1990). 
Despite  this  discrepancy,  the  reconstitution  of  the  oxidase  activity  in  pimary  mouse 
transduced cells was assessed. In two of the three experiments the ex vivo differentiated 
cells did not reached 20% DHR positive cells compared to the wild-type cells although 
22% and 40% gp91
phox positive Gr-1
+ & CD11b
+ cells were detected (Fig. 44b and a). 
Correlation  of  these  data  with  the  results  of  the  mouse  Sca-1
+  transplantation 
experiment could not be assessed, since only one mouse could be analyzed with the 
DHR assay. In this mouse 50% of the cells were reactive to DHR, related to the wild 
type control, although only 7% of gp91
phox positive peripheral blood granulocytes were 
detectable  (Fig.  49b).  The  DHR  assay  performed  in  the  Lin
Neg  transplantation 
experiments was combined with Gr-1
+ & CD11b
+ immunostaining and in this case four 
out of eight EFs.gp91s mice reached about 40% DHR positive cells and six out of eight 
had values above 20% (Fig. 54). The ex vivo differentiation conditions or the limited 
number of assays in comparison to the in vivo experiments might explain the fact that 
higher numbers of DHR reactive cells were detected in the transplantation experiments. 
Mostly important, the numbers of superoxide producing cells obtained by the in vivo 
studies with the EFs.gp91s construct were similar than those observed in the clinical 
X-CGD trial conducted by the groups of Dr. M. Grez and Prof. R. A. Seger (over 35% 
in  one  patient  and  ~15%  in  the  second),  which  led  to  the  eradication  of  therapy 
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the  DHR  assay  of  gene-modified  granulocytes  from  Lin
Neg  transplanted  mice  were 
constantly lower than those of wild-type granulocytes (about 5-fold) (Fig. 55), previous 
studies showed that about 20% of gene-corrected neutrophils (which have commonly 
lower superoxide production levels than wild-type neutrophils ) is the critical threshold 
required to reduce infectious complications of CGD (Bu-Ghanim et al., 1995; Goebel 
and Dinauer, 2002). 
Overall, the data obtained with the EFs.gp91s construct suggest that this construct might 
represent a good candidate for gene therapy of CGD. 
D.3.4  Targeting of SIN gammaretroviral vectors 
D.3.4.1  The SP146 promoter 
Gp91
phox  is  primary  required  in  granulocytes  and  it  is  still  unknown  if  the  ectopic 
expression  of  the  protein  can  cause  side  effects.  Therefore,  the  development  of 
transcriptional targeting vectors was one of the main goals of the present study. In the 
present  study,  three different myeloid-specific promoters were tested in combination 
with the improved SIN vector backbone and the synthetic gp91
phox sequence. 
The SP146 promoter is a synthetic promoter constructed by random ligation of several 
short sequences identified as binding sites for myeloid/macrophage transcription factors, 
such as C/EBPα, AML-1, PU.1A, PU1B, SP1 and AP1 (Fig. 35b and c) (He et al., 
2006).  The  SP146  was  selected  from  a  pool  of  sequences  because  it  showed  clear 
myeloid/macrophage  specificity  in  cell  lines  as  well  as  in  vivo  mouse  studies.  This 
artificial  promoter  also  showed  a  high  efficiency  in  transgene  expression  when 
incorporated upstream of GFP in a lentiviral backbone. 
When  the  SF  promoter  was  replaced  by  the  SP146  in  the  SERS11.SF.gp91s.Wm 
construct, a decrease in retroviral particle production was also observed. In contrast to 
the EFs promoter, this loss in titer was not due to a decrease in the proviral particle 
production, since the Northern blot analysis of transfected cells revealed even higher 
amounts  of  genomic  RNA  than  those  obtained  by  the  SF-containing  construct 
(Fig. 36a and b). In order to assess the presence of proviral integrations in transduced 
cells, Southern Blotting analysis was performed and two fragments corresponding to 
proviral genomes were detected. One of the bands had the expected size corresponding 
to the genomic viral RNA (Fig. 37b). The second band was smaller and it was expected 
to  be  an  integrated  provirus  without  the  ability  to  express  gp91
phox  leading  to  the 
reduction in titer. To investigate this hypothesis a Southern blot analysis of the genomic 
DNA from sorted transduced cells (93% expressing cells) was performed (Fig. 38) and, 
surprisingly,  this  band  still  appeared  indicating  that  it  was  the  genome  form  of  an 
integrative vector, which may also contain and express the gp91
phox gene (Fig. 39c). 
This suggests that a recombination or rearrangement event occurred most likely during D. DISCUSSION  119 
the  viral  particle  production  or  during  reverse  transcription.  Moreover,  since  the 
promoter was based on the ligation of several motifs, a loop may have formed by the 
binding of two identical sequences responsible for the loss of a part of the sequence 
overlooked  by  the  polymerases.  This  event  did  not  affect  the  functionality  of  the 
promoter since gp91
phox expression was detected in transduced cells having also the 
proper transcript size (Fig. 40a). Nevertheless, this event is an uncontrolled process, 
which might cause unpredictable side effects. Although having an efficient transgene 
expression reaching equal or even higher levels than the SF construct, both in RNA and 
protein from cell lines, this promoter cannot be used for gene therapy vectors. 
D.3.4.2  The c-fes promoter 
To achieve transcriptional targeting also the c-fes promoter, which has been described 
above,  was  used.  It  was  cloned  in  the  SERS11.SF.gp91s.Wm  substituting  the  SF 
promoter.  When  tested  this  myeloid-specific  promoter  in  X-CGD  PLB-985  cells  it 
showed encouraging results. It reached the highest titer compared to all the non-viral 
promoters, and it showed one of the highest amounts of genomic transcript as assessed 
by  Northern  blotting  analysis  of  transfected  cells  (Fig.  36a  and  b).  Moreover,  the 
internal transcript was undetectable in transfected cells which might be due to a high 
tissue-specific  transcription  or  a  weak  transcriptional  activity  of  the  c-fes  promoter, 
thereby favoring the transcription from the LTR promoter and thus the generation of 
higher titers. This hypothesis was confirmed by Northern and Western blot analyses of 
sorted transduced cell populations (Fig. 40a and b). These analyses revealed rather low 
amounts of internal transcript and protein, respectively. When comparing differentiated 
sorted populations transduced with the c-fes- and SF-containing constructs 2.1-, 1.4- and 
1.3-fold lower levels of RNA, protein and  MFI were observed, respectively. All these 
data followed the same tendency confirming the low transcriptional activity of the c-fes 
promoter. Nevertheless, cytochrome c assays revealed that the c-fes containing construct 
drove  efficient  transgene  expression  when  transduced  in  X-CGD  PLB-985  cells. 
Superoxide production reached levels that went even beyond those obtained with the SF 
promoter (Fig. 41). In contrast, the superoxide production levels of each individual cell 
as indicated by the  MFI in the DHR assay showed a 1.6- and 1.4-fold decrease when 
compared to the PLB-985 and SF transduced cells, respectively (Fig. 42). The cause for 
the observed differences in superoxide production measured with the two methods have 
been already mentioned (D.3.3 The EFs promoter). 
The c-fes construct reached transduction efficiencies up to 89% when assessed 4 days 
post transduction within the mSca-1
+ subpopulation of Lin
Neg transduced cells and up to 
85% as assayed by NBT test in the CFUs derived from mSca-1
+ transduced cells both 
with a final MOI of 3 (Fig. 50 and Fig. 48). These data correlated with previous studies 
showing abundant expression of the c-fes protein in undifferentiated progenitors (Care 
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When ex vivo myeloid differentiation was induced a 1.3 ± 0.1-fold increase in transgene 
expression was observed whereas in the sorted mSca-1
+ in vivo assays the situation was 
inversed (Fig. 44a and Fig. 49). A slight decrease in gp91
phox expression was found if 
stem  cells  were  differentiated  towards  myeloid  precursor  and  then  to  granulocytes. 
Furthermore, the expression pattern of this construct in Lin
Neg transplanted mice was the 
same as for the EFs.gp91s construct. The levels of transgene expression decreased from 
ex vivo transduced cells to myeloid marrow derivatives and then experienced a huge 
variability  in  peripheral  blood  granulocytes  of  the  individual  mice.  Half  the  mice 
showed an increase in transgene expression and the other half a decrease (Fig. 51). 
A  tissue-specific  expression  of  the  c-fes  promoter  was  assessed  in  the  mSca-1
+ 
transplanted mice, a decrease of gp91
phox positive cells was detected from bone marrow 
Sca-1
+  cells  towards  the  B  lymphoid  precursos  cells  (2.3  ±  0.2-fold)  (Fig.  49a). 
However, this tendency was not followed in the peripheral B lymphocytes. Here 50% of 
the mice experienced an increase and in the other half a decrease was observed after 
differentiation into peripheral blood B lymphocytes (Fig. 49b). Additionally, these data 
were  not  consistent  with  those  of  Lin
Neg  transplanted  mice  where  an  increase  in 
transgene expression towards B lymphocyte differentiation was also observed in seven 
out of eight mice (Fig. 51). These observations did not correlate with previous studies 
showing lower or even absent levels of c-fes expression in B-cell lines from the bone 
marrow (Heydemann et al., 2000). It might be due to the lack of additional genomic 
sequences that may play a role in the control of the c-fes expression, such as the 2495 bp 
of Locus Control Region sequence. 
Interestingly,  the  behavior  of  the  c-fes  promoter  was  extremely  encouraging  when 
functionally  tested  in  mouse  primary  cells  since  it  reached  the  higher  levels  of 
superoxide producing cells than the EFs promoter regardless of the assay. In ex vivo 
functional assays, one fifth of the cells were DHR positive while gp91
phox expressing 
granulocyte-like  cells  ranged  from  20  to  42%  (Fig.  44a  and  b).  Furthermore,  in 
transplanted mSca-1
+ mice up to 70% DHR reactive cells compared to the wild-type 
mice were detected although only 35% gp91
phox positive granulocytes in the peripheral 
blood (Fig. 49b). In mice transplanted with transduced Lin
Neg cells, where the DHR 
assay was combined with the Gr-1
+ & CD11b
+ immunostaining, 6 out 8 eight mice 
reached 40% DHR positive cells although slightly lower ∆MFI values were obtained 
compared to the EFs.gp91s construct (Fig. 54 and Fig. 55). 
All these data indicate that the c-fes-containing construct might be a good choice for the 
development of an X-CGD gene therapy vector. It showed the highest titer production 
between  all  non-viral  tested  promoters,  it  reached  high  enough  levels  of  transgene 
expression and, when compared to the EFs promoter, it performed slightly better in all 
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D.3.4.3  The MRP8 promoter 
A  third  promoter  tested  for  transgene  expression  was  the  MRP8  promoter.  In  this 
construct a sequence of about 1700 bp of the upstream regulatory regions of the MRP8 
gene (Fig. 35a), including the first exon and intron, were cloned (Lagasse and Clerc, 
1988).  This  version  of  the  MRP8  promoter  showed  efficient  and  myeloid-specific 
transgene expression in previous mouse leukemia models as mentioned above (Lagasse 
and Weissman, 1994; Yuan et al., 2001). 
This promoter showed the lowest titer of all tested vectors although one of the highest 
levels  of  genomic  RNA  was  detected  in  the  packaging  cells  (Fig.  36a  and  b).  This 
suggests  that  there  was  no  competition  between  the  internal  and  LTR  promoter  in 
producer cells, but might point out a lack in translation or a packaging problem being 
responsible for the lower titer. Additionally, the transcript detected in the Northern blot 
assay corresponded to the unspliced RNA form. This can be explained by the fact that 
this splicing should be a myeloid-restricted event which cannot occur in the transfected 
293T cells, a human embryonic kidney cell line. The cell-specific splicing is a common 
phenomenon  which  has  shown  to  help  regulating  the  expression  of  cellular  genes 
(Black, 2003). In molecular assays the MRP8 promoter showed to be transcriptionally 
weaker  when  compared  to  the  SF  regulatory  sequence,  since  1.8-fold  less  gp91
phox 
transcript  amounts  were  detected  in  the  differentiated  population  (Fig.  40a).  This 
tendency also corresponded to a 2.4- and 1.6-fold lower level of gp91
phox protein and 
 MFI values, respectively (Fig. 40b and Fig. 38). Since the expression levels of the 
endogenous MRP8 gene have shown to be extremely high in neutrophil and monocyte 
lineages  (representing  up  to  45% of neutrophil cytosolic proteins (Edgeworth et al., 
1991; Hessian et al., 1993)) the results of the present study might indicate that possibly 
still  additional  sequences  are  required  to  achieve  higher  transcriptional  rates. 
Nevertheless,  this  construct  showed  the  highest  levels  of  superoxide  production  in 
sorted cells as assessed by the cytochrome c assay, and slightly lower levels, 1.6-fold 
less,  MFI in the DHR assay compared to the SF promoter (Fig. 41 and Fig. 42). 
The performance of the MRP8 construct was then addressed in murine primary Sca-1
+ 
cells. A markedly low expression of the transgene (17% gp91
phox positive cells per copy 
of integrated provirus (Fig. 47)) was observed one day post transduction. It also showed 
the  lowest  levels  of  transgene  expressing  cells  when  measured  within  the  Sca-1
+ 
subpopulation 4 days post transduction of Lin
Neg cells, although reaching up to 72% of 
positive gp91
phox cells (Fig. 50). The functional reconstitution of the NADPH oxidase 
activity assessed by the NBT assay in CFUs derived from mSca-1
+ transduced cells 
showed  up  to  63%  NBT
+  colonies  representing  a  3.7-fold  increase  (Fig.  48).  These 
higher levels might be explained by the higher specificity of the MRP8 promoter than 
the  previously  tested  promoters.  However,  when  the  gp91
phox  expression  was 
investigated after ex vivo myeloid differentiation an extremely low increase (1.2-fold) D. DISCUSSION  122 
was observed, even lower than the increase obtained by the EFs promoter (Fig. 44a). 
When analyzed in the in vivo context of mSca-1
+ transplanted mice, a slight decrease 
was observed after maturation towards myeloid common precursors, and even lower 
levels of gp91
phox were detected in the granulocytic population of the peripheral blood 
(Fig. 49). This decrease in expression towards maturation to peripheral granulocytes was 
not observed in the Lin
Neg transplanted mice (Fig. 51). Instead of a decrease, an increase 
was detected although the rather low levels of gp91
phox positive cells were maintained. 
These observations were not consistent with the previous published data showing that 
the MRP8 protein reached up to 45% of the cytosolic protein content in neutrophils 
(Edgeworth et al., 1991; Hessian et al., 1993). As expected, in the lymphoid populations 
the  MRP8  promoter  was  turned  off  and  consequently  the  gp91
phox  protein  was 
undetectable in B and T lymphocytes of the peripheral blood both in mSca-1
+ and Lin
Neg 
recipients (Fig. 49 and Fig. 51). 
Ex vivo functional assays revealed similar levels of DHR positive cells for the MRP8 
promoter than compared to the c-fes construct, but showing slightly lower values of 
gp91
phox  expressing  cells  (Fig.  44b).  Moreover,  when  assessed  in  peripheral  blood 
granulocytes of mSca-1
+ transplanted mice, the MRP8 construct showed surprising high 
levels of superoxide generating cells, up to 2-fold of the wild-type mice regardless of the 
lowest percentages of gp91
phox positive granulocytes (Fig. 49b). On the contrary, in the 
Lin
Neg transplanted mice only two mice reached values over 40% of DHR reactive cells 
and the ∆MFI values were highly variable between the mice (from 3- to 6-fold lower 
than those of wild-type granulocytes) (Fig. 54 and Fig. 55). 
With all these results, it can be concluded that despite of the high myeloid specificity of 
the MRP8 promoter, which might represent a great advantaje for a myeloid cell defect, 
this construct was less effective in restoring the NADPH oxidase activity than the EFs 
and c-fes promoters, which is one of the most important aspects for the gene therapy of 
CGD. 
D.4  Conclusions 
The  EFs  and  c-fes  promoters  showed  the  highest  values  of  superoxide  production 
reconstitution,  although  on  the  other  hand  a  constitutive,  non  tissue-specific 
transcriptional activity was observed. The c-fes promoter showed the highest values in 
functional assays but also the expressed in differentiated cell of other lineages than the 
myeloid.  Furthermore,  these  data  were  consistent  with  additional  tests  performed  in 
repopulating human CD34
+ cells transduced with these vectors. In the cytochrome c 
assay the c-fes promoter almost mimicked the activity observed in wild-type cells, the 
EFs  reached  intermediate  values  whereas  the  MRP8  promoter  showed  the  lowest 
superoxide production levels among all (Dr. M. Grez, pers. commun.). D. DISCUSSION  123 
Overall, these data showed that with the novel SIN gammaretroviral vectors constructed 
in the present study fulfill two crucial points in vector development bringing the clinical 
application of such vector closer. The constructs are able to generate high titers and to 
drive efficient transgene expression reaching at least the minimal therapeutic threshold 
levels  of  superoxide  require  to  reduce  or  even  avoid  the  occurrence  of  recurrent 
infections. 
Between all constructs tested, the c-fes containing construct in combination with the 
codon  optimized  gp91
phox  sequence  showed  the  best  performance  within  the  SIN 
gammaretroviral backbone. It generated the highest titers in combination with a better 
NADPH oxidase reconstituting ability. 
One  main  goal  in  the  development  of  SIN  gammaretroviral  vectors  is  reducing  the 
genotoxic  effect  due  to  random  vector  integration.  An  improved  gene  transfer  and 
expression,  and  a  constant  performance  are  also  highly desirable. The present study 
shows that the SERS11.fes.gp91s.W construct may be considered as an effective gene 
therapy strategy for the restoration of the NADPH oxidase activity in CGD. It allows the 
use of a cellular promoter generating adequate physiological levels of the therapeutic 
protein and reduces the number of vector copies required for a therapeutic benefit. 
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Chronic granulomatous disease (CGD) is a rare inherited primary immunodeficiency 
characterized by defective intracellular oxidative killing of ingested invading microbes 
by PMN and monocytes. It is caused by mutations in one of the four genes coding for 
the essential subunits of the NADPH oxidase (gp91
phox, p47
phox, p67
phox and p22
phox). 
Approximately 75% of the CGD cases are due to mutations in the gp91
phox gene.  
If regular care and conventional therapy fail, the recommended therapy is allogeneic 
bone  marrow  transplantation  (BMT),  but  only  if  a  matched  donor  is  available.  A 
therapeutic option for patients lacking suitable donors is the genetic modification of 
autologous hematopoietic stem cells. The gene therapy offers an interesting alternative 
to  BMT  since  it  implies  a  less  invasive  treatment  and  represents  a  possibly  unique 
curative option for patients with no suitable donor. 
Gammaretroviral vectors were already used in some gene therapy trials for CGD and 
other  immunodeficiencies  showing  relevant  clinical  benefit.  However,  these  trials 
uncovered an unexpected mutagenic side effect. If the retrovial integration ocurrs near 
to,  or  into  proto-oncogenes  this  might  lead  to  clonal  dominance  or  even  malignant 
transformation (Hacein-Bey-Abina et al., 2003a; Ott et al., 2006). Therefore, there was a 
need to further improve the safety of these vectors and to this end the self-inactivating 
gammaretroviral vectors were engineered. Non essential sequences for virus infectivity 
and integration, which might influence the surrounding gene expression, were deleted in 
these vectors. 
In the first set of experiments, a series of SIN gamma retroviral vectors was cloned 
driving  the  expression  of  the  wild-type  gp91
phox  cDNA  under  the  control  of  a  viral 
constitutive SFFV promoter. However initial studies with these vectors failed because 
the titers of the virus produced by transient transfection protocols were extremely low 
(<5x10
5 TU/ml). Therefore, a codon optimization of the gp91
phox cDNA was considered 
as an alternative. 
The  codon  optimized  synthetic  gp91
phox  gene  was  used  to  construct  a  SIN 
gammaretroviral vector, again under the control of the SFFV promoter  (Schambach et 
al., 2006c). With this vector an increase in titer was observed compared to the native 
gp91
phox sequence, which was due to the improved transcription in 293T transfected 
cells. The enhancement of the synthetic gp91
phox transcription led to a higher internal 
transcript  production  and  protein  expression.  An  enhanced  superoxide  production  in 
transduced myelomonocytic X-CGD PLB-985 populations was also detected. All these 
data indicate that the synthetic gp91
phox might represent an excellent alternative to those 
former constructs expressing the native gp91
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Since  it  was  postulated  that  the  SFFV  promoter  could  still  cause  transactivation  of 
neighboring genes due to its strength (Modlich et al., 2006), three different non-viral 
promoters were tested, one constitutive (the EFs promoter) and two myeloid-specific 
promoters (the c-fes and MRP8 promoter). 
The three SIN gammaretroviral vectors were able to generate high titers after transient 
transfection of 293T packaging cells, to efficiently transduce the X-CGD PLB-985 cell 
line  and  to  reconstitute  the  NADPH  oxidase  activity  to  a  high  degree.  In  mouse 
transplantation  experiments,  the  EFs  promoter  showed  a  high  variable  transgene 
expression  in  the  different  lineages  analyzed,  and  the c-fes promoter showed also a 
ubiquitinous  expression.  In  contrast,  the  MRP8  promoter  showed  a  high  myeloid 
specificity  since  gp91
phox  expression  in  mSca-1
+  cells  and  lymphoid  B  cells  from 
transplanted mice was extremly low and even absent. However, the lowest levels of 
transgene expression were observed in the myeloid populations both in bone marrow 
and peripheral blood with this vector.  
When the oxidase reconstitution ability of these promoters was tested, the numbers of 
superoxide producing cells obtained were similar than those observed in the clinical 
X-CGD trial conducted by the groups of Dr. M. Grez and Prof. R. A. Seger (over 35% 
in  one  patient  and  ~15%  in  the  second),  which  led  to  the  eradication  of  therapy 
refractory  infections  (Ott  et  al.,  2006).  Between  the  three  constructs,  the  MRP8 
promoter was less effective in restoring the NADPH oxidase activity than the EFs and 
c-fes promoters. The c-fes promoter reached the highest levels of DHR reactive cells in 
the highest number of mice. 
Overall,  these  data  showed  that  between  all  constructs  tested,  the  c-fes  containing 
construct in combination with the codon optimized gp91
phox sequence showed the best 
performance within the SIN gammaretroviral backbone. It generated the highest titers in 
combination with a better NADPH oxidase reconstituting ability. 
One  main  goal  in  the  development  of  SIN  gammaretroviral  vectors  is  reducing  the 
genotoxic  effect  due  to  random  vector  integration.  An  improved  gene  transfer  and 
expression,  and  a  constant  performance  are  also  highly desirable. The present study 
shows  that  the  c-fes  SIN  vector  in  combination  with  the  synthetic  gp91
phox  may  be 
considered  as  an  effective  gene  therapy  strategy  for  the  restoration  of  the  NADPH 
oxidase activity in CGD. It allows the use of a cellular promoter generating adequate 
physiological levels of the therapeutic protein and reduces the number of vector copies 
required for a therapeutic effect. 
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Bei der Septischen Granulomatose (engl.: CGD chronic granulomatous disease) handelt 
es sich um eine seltene, vererbbare primäre Immunschwäche, welche sich durch einen 
Defekt im oxidativen Abtöten intrazellulär aufgenommener Mikroben durch Phagozyten 
auszeichnet.  In  Folge  dessen  erleiden  Patienten  mit  CGD  immer  wieder  schwerste 
Infektionen durch Bakterien und Pilze. 
Ursache  für  die  Septische  Granulomatose  ist  eine  Mutation  in  einem  der  vier  Gene 
(gp91
phox,  p47
phox,  p67
phox  und  p22
phox),  die  für  die  essentiellen  Untereinheiten  der 
NADPH  Oxidase  kodieren.  In  zirka  75%  aller  CGD-Fälle  treten  die  Mutationen  im 
gp91
phox  Gen  auf.  Weil  dieses  Gen  auf  dem  X-Chromosom  liegt  (Xp21.1  Locus), 
handelt es sich somit um eine X-chromosomal gekoppelte Vererbung. In den übrigen 
Fällen  der  CGD  erfolgt  die  Vererbung  autosomal-rezessiv.  Bei  dieser  Form  der 
Krankheit sind Frauen und Männer gleichermaßen betroffen. 
Führen  Standardbehandlungen  und  konventionelle  Therapien  zu  keinem  Erfolg, 
verbleibt als einziger Therapieansatz eine allogene Knochenmarktransplantation. Diese 
kann jedoch nur durchgeführt werden, wenn ein passender Spender vorhanden ist. Die 
begrenzte  Verfügbarkeit  adäquater  Spender,  die  methodisch  bedingte  Toxizität  der 
Transplantationsprozedur  sowie  posttransplantationale  Komplikationen,  wie 
beispielsweise  die  Transplantat-Wirt  Krankheit  (engl.  graft  versus  host  disease), 
erschweren  eine  breite  Anwendung  der  allogenen  Knochenmarktransplantation  zur 
Behandlung von CGD. 
Ein  alternativer  therapeutischer  Ansatz  ist  die  genetische  Modifikation  der  eigenen 
(=autologen)  hämatopoetischen  Stammzellen.  Zwei  der  wichtigsten  Vorteile  einer 
Gentherapie im Vergleich zur allogenen Knochenmarktransplantation sind die geringere 
Belastung  für  die  Patienten  sowie  die  Möglichkeit  der  Therapie  von  Patienten  ohne 
passenden Spender. 
In  einigen  gentherapeutischen  Studien  zur  CGD  und  anderen 
Immundefizienzkrankheiten  konnten  Gammaretrovirale  Vektoren  einen  deutlichen 
klinischen  Nutzen  für  die  Patienten  aufzeigen.  Die  Studien  zeigten  jedoch  teils 
erhebliche Nebenwirkungen, wie die Entwicklung maligner Zellpopulationen oder einen 
selektiven Wachstumsvorteil der genkorrigierten Zellen, der zu einer oligo- oder gar 
monoklonalen Expansion der Zellen führte. Diese Phänomene entstehen in Folge der 
Integration des Vektors in das Wirtsgenom, welche jedoch ein unumgänglicher Schritt 
im Replikationszyklus der Retroviren darstellt. Aus diesem Grund bestand der Bedarf 
die Sicherheit dieser Vektoren weiter zu verbessern, was in der Weiterentwicklung der 
sog.  Selbst-Inaktivierenden  Gammaretroviren  (SIN  Retrovektoren)  resultierte.  Bei 
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wodurch der Einfluss auf die Genexpression in der Nachbarschaft der Integrationsstelle 
minimiert werden soll. Wenngleich diese Vektoren häufig eine geringere Effizienz in 
der  Virusproduktion  zeigen,  stellt  die  Verwendung  eines  internen  Promotors  einen 
entscheidenden  Vorteil  dar.  So  ermöglichen  es  diese  Vektoren  z.  B.  die  Expression 
eines  Transgens  unter  die  Kontrolle  geeigneter,  gewebespezifischer  Promotoren  in 
unterschiedlichen Zellen zu stellen. 
Die vorliegende Studie begann mit der Klonierung SIN Gammaretroviraler Vektoren. 
Die  ersten  getesteten  Vektoren  exprimieren  die  gp91
phox  Wildtyp  cDNA,  wobei  der 
konstitutive SFFV LTR als interner Promotor fungiert. Anfängliche Studien mit diesen 
Vektoren  scheiterten,  da  der  Virustiter  nach  transienter  Transfektion  zu  niedrig  war 
(<5x10
5 TU/ml). Da der Spleißvorgang im Zellkern mit dem Kernexportmechanismus 
der endogenen mRNA gekoppelt ist, wurde vermutet, dass das Einbringen eines Introns 
in das virale Genom eine Steigerung des mRNA Exports zur Folge hätte. Der Einbau 
eines Spleißakzeptors und einer Spleißdonorstelle in die Leader Sequenz des Vektors 
brachte  jedoch  keine  Erhöhung  des  Titers.  Genauso  wenig  zeigte  die  gerichtete 
Mutation  (site-directed  mutagenesis)  eines  kryptischen  Spleißakzeptors  (cSA)  in  der 
gp91
phox Sequenz (gp91m) einen Effekt auf den Virustiter. Als Alternative kam daher 
eine vollständige Codonoptimierung der gp91
phox cDNA in Betracht. Die Strategie der 
Codonoptimierung wird benutzt, um die heterologe Genexpression von Genen, die in 
fremde  Genome  eingeführt  werden,  zu  verbessern.  Alle  Codons  einer 
proteinkodierenden  DNA  werden  dabei  auf  den  bevorzugten  Codongebrauch  im 
Zielorganismus  abgestimmt.  Diese  Methode  wurde  bereits  für  Reporterproteine  wie 
GFP und Luziferase angewandt. In verschiedenen Organismen konnte gezeigt werden, 
dass eine vorher niedrige Genexpression durch diese Methode erhöht werden kann. 
Die Firma GeneArt (Regensburg, Deutschland) analysierte und verbesserte die Sequenz 
der gp91
phox mRNA des Wildtypes. Dabei wurde die Sequenz zunächst so modifiziert, 
dass  wenig  verwendete  Codons  durch  häufiger  benutzte  ersetzt  wurden.  Der  Codon 
Adaption Index (CAI) ist ein relatives Maß dafür wie nahe - verglichen mit einer Reihe 
von  Referenzgenen  -  der  Codongebrauch  eines  Genes  am  Optimum  liegt.  Der  CAI 
konnte beim gp91
phox von 0,77 auf 0,99 optimiert werden. Zusätzlich wurden einige 
Motive  identifiziert,  die  entweder  die  Genexpression  oder  die  Virusproduktion 
beeinträchtigen  könnten.  Aufgrund  dessen  wurden  interne  Polyadenylierungsstellen, 
zusätzliche  kryptische  Spleißstellen  und  RNA  instabilisierende  Motive,  wie  z.  B. 
AU-reiche  Elemente,  gegen  weniger  kritische  Sequenzen  ausgetauscht.  Wichtig  ist 
dabei anzumerken, dass die Aminosäuresequenz des Gp91
phox Proteins bei all diesen 
Modifikationen nicht verändert wurde. 
Die so veränderte synthetische gp91
phox cDNA (gp91s) wurde im Folgenden für den SIN 
Gammaretroviralen  Vektor  SERS11.SF.gp91s.Wm  verwendet.  Dieses  Plasmid 
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im  5´LTR  wie  die  vorherigen  Vektoren.  Zusätzlich  wurde  ein  233bp  langer  SV40 
Enhancer (E) dem RSV Promotor vorgeschaltet. Es ist bekannt, dass der SV40 Enhancer 
die Genexpression in einer Vielzahl von Organismen und Geweben signifikant steigert. 
In  der  Verpackungszelllinie  wird  dadurch  die  Expression  durch  den  im  5´LTR 
befindlichen RSV Promotor zu Gunsten der verpackbaren genomischen Virus mRNA 
gesteigert.  (Schambach  et  al.,  2006c).  Des  Weiteren  wurde  im  WPRE  Element  der 
X-Promotor deletiert und die offenen Leserahmen mutiert (Schambach et al., 2006a). 
Tatsächlich  war  nach  transienter  Transfektion  von  293T-Zellen  mit  dem 
SERS11.SF.gp91s.Wm-Vektor  der  Titer  im  Vergleich  zu  Transfektionen  mit  dem 
SERS11.SF.gp91m.W-Konstrukt 2,7 fach erhört. Mit Hilfe einer Northern Blot-Analyse 
konnte gezeigt werden, dass der erhöhte Titer die Folge einer gesteigerten Transkription 
dieses  Konstrukts  in  den  transfizierten  293T-Zellen  ist.  In  transduzierten 
myelomonozytischen  X-CGD  PLB-985  Zellen  zeigen  Northern-  bzw.  Western 
Blot-Analysen  von  Zellen  mit  gleicher  Anzahl  integrierter  Vektorkopien,  dass  die 
verstärkte  Transkription  des  synthetischen  gp91
phox  zu  erhöhter  Transkriptproduktion 
und zu gesteigerter Proteinexpression führt. In Übereinstimmung mit der beschriebenen 
konstitutiven,  transkriptionellen  Aktivität  des  SFFV-Promotors  wurde  keine 
Veränderung der Expressionsstärke (∆MFI) nach Differenzierung der Zellpopulationen 
in Granulozyten-ähnliche Zellen beobachtet. Die Analyse der Proteinmengen in diesen 
Zellen zeigte eine Korrelation mit den höheren ∆MFI-Werten des synthetischen gp91
phox 
im  Vergleich  zum  gp91m.  Dies  deutet  darauf  hin,  dass  eine  erhöhte  intrazelluläre 
Gp91
phox-Proteinmenge  auch  zu  einer  vermehrten  Bildung  des  Flavocytochrom  b558 
Komplexes  an  der  Membran  der  differenzierten  Zellen  führt.  Zudem  war  die 
Proteinmenge in sortierten transduzierten Zellen deutlich höher als in der parentalen 
PLB-985 Zelllinie. Es wurde eine 2,7 bzw. eine 5,5fache Steigerung mit der gp91m 
Sequenz bzw. der synthetischen Sequenz gp91s erreicht. 
Die Fähigkeit des Vektors die Superoxid-Erzeugung wieder herzustellen wurde durch 
einen Test der Cytochom C-Reduktion bestimmt, welcher eine quantitative Methode zur 
Messung der zellulären Superoxid Anionenproduktion bei einer definierten Anzahl von 
Zellen  darstellt.  Hierzu wurden DMSO differenzierte Populationen mit PMA, einem 
starken  Stimulans  zur  O2¯-Produktion,  inkubiert.  Anschließend  wurde  die 
Superoxidproduktion pro Zelle durch die Reduktion des Cytochrome C in Abhängigkeit 
der  Zeit  gemessen.  Als  Referenz  wurden  differenzierte  Wildtyp  PLB-985-Zellen 
verwendet. Die Messung ergab eine 1,7fach höhere Superoxidproduktion in sortierten 
Zellpopulationen  mit  SERS11.SF.gp91s.Wm  im  Vergleich  zu  sortierten 
Zellpopulationen mit Vektoren zur Expression von gp91m. Der funktionale Unterschied 
zwischen  beiden  transduzierten  Populationen  korreliert  mit  den  Protein-  und  ∆MFI-
Werten, daher ist die vermehrte Superoxid-Produktion auf eine Steigerung des Proteins 
pro  Zelle  zurückzuführen.  Die  Mengen  der  O2
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SERS11.SF.gp91s.Wm  transduzierten  Zellen  waren  sogar  höher  als  in  Wildtyp 
PLB-985-Zellen. 
Vorrausgehende  molekulare  Untersuchungen  sowie  Klinische  Phase  I  Gentherapie 
Studien  zeigen,  dass  die  Menge  der  NADPH-Oxidase  Aktivität  pro  Zelle  ein  ganz 
wichtiger  Faktor  für  die  Wirksamkeit  der  Infektionsabwehr  bestimmter 
Mikroorganismen  ist,  insbesondere  wenn  nur  wenige  der  O2¯  produzierenden 
neutrophilen  Granulozyten  vorhanden  sind.  Die  vorliegende  Arbeit  zeigt,  dass  die 
synthetische gp91
phox cDNA eine ausgezeichnete Alternative zu den bisher verwendeten 
gp91
phox Transgensequenzen darstellt. 
Da  der  SFFV-Promotor  wegen  seiner  Stärke  auch  als  interner  Promotor  die 
Transaktivierung  von  Nachbargenen  verursachen  kann,  wurde  im  zweiten  Teil  der 
vorliegenden  Arbeit  der  SERS11.SF.gp91s.Wm  Vektor  ausgewählt  um  die  Effizienz 
schwächerer, nicht-viraler Promotoren zu untersuchen (Modlich et al., 2006). Es wurden 
drei verschiedene zelluläre Promotoren getestet: ein konstitutiv exprimierender (der EFs 
Promotor)  und  zwei  myeloid-spezifische  Promotoren  (c-fes  bzw.  MRP8),  Letztere 
sollten die spezifische Expression der korrekten gp91
phox cDNA in Phagozyten erlauben, 
deren  defekte  NADPH  Oxidase  die  Hauptursache  der  Symptome  der  Septischen 
Granulomatose ist. 
Der  ubiquitäre  EFs  Promotor  ist  eine  kurze  Intron-deletierte  Version  des  EF-1α 
Promotors,  welcher  eine  effiziente  Expression  des  Transgens  in  myeloiden  oder 
lymphoiden Zellen erlaubt. Dieser EFs Promotor ist schon in Gammaretroviralen- und 
Lentiviralen-  SIN-Vektoren  getestet  worden,  und  zeigte  eine  mittelstarke 
Transkriptionsaktivierung mit moderaten Titern. 
C-fes gehört zu der Familie der sog. Nicht-Rezeptortyrosinkinasen und ist für mehrere 
zelluläre Prozesse, darunter Differenzierung und Proliferation, von großer Bedeutung. 
Während der myeloischen Differenzierung ist der c-fes Promotor konstitutiv aktiv, wird 
jedoch  während  der  Reifung  der  Erythrozyten  inaktiviert.  Zusätzlich  besitzt  dieser 
Promotor  eine eigene Kontrollregion (LCR; engl.: locus control region), welche die 
Expression der Fes-Kinase beeinflusst. Frühere Studien zeigten, dass ein 446 bp langes 
Fragment  des  c-fes  Promotors  ausreicht,  um  eine  gewebespezifische 
Transgenexpression sicherzustellen. 
Der MRP8 Promotor steuert die Expression des Myeloid Restricted Protein 8. Es wurde 
gezeigt,  dass  MRP8  nicht  nur  an  mehreren  zellulären  Prozessen  während  der 
transendothelialen  Migration  von  Phagozyten,  sondern  auch  an  der  myeloischen 
Differenzierung  beteiligt  ist.  Ist  die  MRP8  Protein-Expression  in  myeloischen 
Vorläufern  noch  äußerst  gering,  so  steigt  diese  bis  auf  45%  des  zytosolischen 
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Um die Titer der neuen Vektoren zu ermitteln, wurden X-CGD PLB-985 Zellen mit 
transient  produziertem  Virusüberstand  transduziert  und  analysiert.  Die  Titer  der 
Vektoren mit den zellulären Promotoren lagen in der Größenordnung von 1x10
6 TU/ml. 
Dies  entspricht  einer  drei  fachen  Reduzierung  im  Vergleich  zum  internen  SFFV 
Promotor.  Das  c-fes  Konstrukt  zeigte  mit  bis  zu  1.8x10
6 TU/ml die höchsten Titer, 
während das MRP8-Konstrukt die niedrigsten Titer produzierte. In transduzierten und 
sortierten X-CGD PLB-985 Zellen zeigten alle Promotoren im Cytochrome C Test eine 
sehr  hohe  Produktion  von  Superoxide,  welche  höher  als  die  der  Wildtyp  PLB-985 
Zellen war. Da die beschriebenen drei gammaretroviralen Vektoren ausreichend hohe 
Titer produzierten, in der Lage sind X-CGD PLB-985 Zellen effizient zu transduzieren 
und die NADPH-Oxidase Aktivität in vitro in hohem Maße wiederherstellen, wurde im 
nächsten Schritt die Effizienz dieser Vektoren in primären, murinen Zellen untersucht. 
Hierbei  zeigte  der  EFs-Promotor  in  Transplantationsexperimenten  im  X-CGD 
Mausmodell  eine  recht  hohe  Variabilität  der  Transgenexpression  in  verschiedenen 
Zellreihen, wohingegen der c-fes Promotor eine mehr oder weniger ubiquitäre gp91
phox 
Expression  bewirkte.  Dieses  Ergebnis  korreliert  nicht  mit  den  Daten  aus  früheren 
Studien transgener Mäuse, die außerhalb des myeloischen Zellkompartments bestenfalls 
eine  niedrige  Expression  des  c-fes  Promotors  in  B-Zellen  aus  dem  Knochenmark 
zeigten. Die konstitutive Expression des c-fes Promotors könnte damit erklärt werden, 
dass im verwendeten Vektor einige zusätzliche genomische Sequenzen, wie z.B. die 
LCR, abwesend waren, die gegebenenfalls die Expression des c-fes Promotors weiter 
feinregulieren  können.  Der  MRP8  Promotor  dagegen  zeigt  eine  hohe  myeloische 
Spezifität, da die gp91
phox-Expression in Sca-1
+ Zellen und lymphoiden B-Zellen der 
transplantierten  Mäusen  sehr  niedrig  bzw.  abwesend  war.  Allerdings  besitzt  dieser 
Promotor  im  Vergleich  zu  den  beiden  anderen  die  niedrigste  Expressionsstärke  des 
Transgenes in myeloischen Zellpopulationen des Knochenmarks so wie im peripheren 
Blut der Tiere. 
Die Fähigkeit der verschiedenen Vektoren die Oxidase-Aktivität im peripheren Blut von 
transplantierten Mäusen wiederherzustellen wurde mittels des DHR-Assays verglichen. 
Dabei  ist  die  Anzahl  der  Superoxid-produzierenden  Zellen  vergleichbar  mit  den 
anfänglichen Werten in der klinischen X-CGD Studie, welche in Frankfurt durchgeführt 
wurde  (über  35%  in  Patient  1  und  etwa  15%  in  Patient  2).  Dieser  Prozentsatz  war 
ausreichend um Infektionen in den Patienten zu eliminieren, die vorher nicht mehr auf 
konventionelle  Therapien  ansprachen  (Ott  et  al.,  2006).  Unter  den  drei  Konstrukten 
hatte der MRP8 Promotor im Vergleich zum EFs und c-fes Promotor die niedrigste 
Effizienz, was die Wiederherstellung der NADPH-Oxidase-Aktivität betrifft. Der c-fes 
Promotor dagegen erzielte die höchste Anzahl an DHR-reaktiven Zellen. 
Parallel in der Arbeitsgruppe Grez durchgeführte Experimente mit humanen X-CGD 
CD34
+  Zellen  bestätigen  diese  Daten.  Im  Cytochrom  C  Test,  welcher  nach  ex  vivo G. ZUSAMMENFASSUNG  149 
Differenzierung  in  Granulozyten  durchgeführt wurde, zeigte der c-fes Promotor eine 
ähnlich starke Aktivität wie differenzierte Zellen aus einem Normalspender. Das EFs 
Konstrukt erreichte durchschnittliche Werte. Der MRP8 Promotor hingegen zeigte auch 
hier die niedrigste Superoxid-Produktion (Dr. M. Grez, pers. Mitteilung). 
Insgesamt zeigen diese Daten, dass die in der vorliegenden Arbeit neu konstruierten SIN 
gammaretroviralen Vektoren zwei wichtige Punkte in der Entwicklung von Vektoren 
erfüllen, um eine Weiterführung der klinischen Studie für X-CGD zu ermöglichen: 
•  Zum  einen  erzeugen  die  Vektoren  hohe  Titer  und  zeigen  eine  effiziente 
Transgenexpression. 
•  Darüber  hinaus  wird  die  Produktionsmenge  an  Superoxid  erreicht,  die 
therapeutisch notwendig ist, um eine Infektionen wirksam zu bekämpfen. 
Innerhalb  des  SIN  gammaretroviralen  Hintergrundes  zeigte  von  allen  getesteten 
Konstrukten der c-fes Vektor in Kombination mit der synthetischen gp91
phox Sequenz 
das beste Ergebnis. Dieser erzeugte die höchsten Titer und führte zur Wiederherstellung 
der NADPH-Oxidase Aktivität in einem Ausmaß, das im Bereich der Normalaktivität 
lag. 
Ein Ziel bei der Entwicklung von SIN retroviralen Vektoren ist, die Wahrscheinlichkeit 
der  Entstehung  unerwünschter  Nebenwirkungen  zu  reduzieren,  die  aufgrund  der 
Vektor-Integration  entstehen.  Grundvoraussetzungen  hierfür  bleiben  aber  ein 
verbesserter Gen-Tranfer und eine optimale, stabile Gen-Expression der SIN Vektoren. 
Die vorliegende Arbeit zeigt, dass das SERS11.fes.gp91s.Wm Konstrukt als effizienter 
neuer  Gentherapievektor  zur  Wiederherstellung  der  NADPH-Oxidase-Aktivität  bei 
X-CGD Patienten angesehen werden kann. Dieser Vektor erlaubt die Verwendung eines 
zellulären Promotors, welcher physiologisch angemessene Proteinmengen erzeugt und 
so die für einen therapeutischen Effekt benötige Menge an Vektorkopien reduziert. 
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SERS11.SF.gp91s.W proviral sequence 
 
AATGAAAGACCCCACCGCTAGCGATATCGAATTCACAACCCCTCACTCGGGCGCCAGTCCTC
CGATTGACTGAGTCGCCCGGGTACCCGTATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAA
TCGTGGACTCGCTGATCCTTGGGAGGGTCTCCTCAGATTGATTGACTGCCCACCTCGGGGGT
CTTTCATTTGGAGGTTCCACCGAGATTTGGAGACCCCTGCCCAGGGACCACCGACCCCCCCG
CCGGGAGGTAAGCTGGCCAGCGGTCGTTTCGTGTCTGTCTCTGTCTTTGTGCGTGTTTGTGCC
GGCATCTAGTGTTTGCGCCTGCGTCTGTACTAGTTGGCTAACTAGATCTGTATCTGGCGGTCC
CGCGGAAGAACTGACGAGTTCGTATTCCCGGCCGCAGCCCCTGGGAGACGTCCCAGCGGCCT
CGGGGGCCCGTTTTGTGGCCCATTCTGTATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGC
TCCGCCACTGTCCGAGGGGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGC
CCCCGTCTGAATTTTTGCTTTCGGTTTTACGCCGAAACCGCGCCGCGCGTCTTGTCTGCTGCA
GCATCGTTCTGTGTTGTCTCTGTCTGACGTGGTTCTGTATTGTCTGAAAATAGCGGCCGCAGC
TAGCTGCAGTAACGCCATTTTGCAAGGCATGGAAAAATACCAAACCAAGAATAGAGAAGTTC
AGATCAAGGGCGGGTACATGAAAATAGCTAACGTTGGGCCAAACAGGATATCTGCGGTGAG
CAGTTTCGGCCCCGGCCCGGGGCCAAGAACAGATGGTCACCGCAGTTTCGGCCCCGGCCCGA
GGCCAAGAACAGATGGTCCCCAGATATGGCCCAACCCTCAGCAGTTTCTTAAGACCCATCAG
ATGTTTCCAGGCTCCCCCAAGGACCTGAAATGACCCTGCGCCTTATTTGAATTAACCAATCAG
CCTGCTTCTCGCTTCTGTTCGCGCGCTTCTGCTTCCCGAGCTCTATAAAAGAGCTCACAACCC
CTCACTCGGCGCGCCAGTCCTCCGACAGACTGAGTCGGCCGGTCGAATCAAGCTTATCGATA
CCGTCGACCGATCCTGCCACCATGGGCAACTGGGCCGTGAACGAGGGCCTGAGCATCTTCGT
GATCCTGGTGTGGCTGGGCCTGAACGTGTTCCTGTTCGTGTGGTACTACCGGGTGTACGACA
TCCCCCCCAAGTTCTTCTACACCCGGAAGCTGCTGGGCAGCGCCCTGGCCCTGGCCAGAGCC
CCTGCCGCCTGCCTGAACTTCAACTGCATGCTGATCCTGCTGCCCGTGTGCCGGAACCTGCTG
TCCTTCCTGCGGGGCAGCAGCGCCTGCTGCAGCACCAGAGTGCGGCGGCAGCTGGACCGGAA
CCTGACCTTCCACAAGATGGTGGCCTGGATGATCGCCCTGCACAGCGCCATCCACACCATCG
CCCACCTGTTCAACGTGGAGTGGTGCGTGAACGCCCGGGTGAACAACAGCGACCCCTACAGC
GTGGCCCTGAGCGAGCTGGGCGACCGGCAGAACGAGAGCTACCTGAACTTCGCCCGGAAGC
GGATCAAGAACCCCGAGGGCGGCCTGTACCTGGCCGTGACCCTGCTGGCCGGCATCACCGGC
GTGGTGATCACCCTGTGCCTGATCCTGATCATCACCAGCAGCACCAAGACCATCCGGCGGAG
CTACTTCGAGGTGTTCTGGTACACCCACCACCTGTTCGTGATCTTTTTCATCGGCCTGGCCAT
CCACGGCGCCGAGCGGATCGTGAGGGGCCAGACCGCCGAGAGCCTGGCCGTGCACAACATC
ACCGTGTGCGAGCAGAAAATCAGCGAGTGGGGCAAGATCAAAGAGTGCCCCATCCCCCAGT
TCGCCGGCAACCCCCCCATGACCTGGAAGTGGATCGTGGGCCCCATGTTCCTGTACCTGTGC
GAGCGGCTGGTGCGGTTCTGGCGGAGCCAGCAGAAAGTGGTGATTACCAAGGTGGTGACCC
ACCCCTTCAAGACCATCGAGCTGCAGATGAAGAAAAAGGGCTTCAAGATGGAAGTGGGCCA
GTACATCTTTGTGAAGTGCCCCAAGGTGTCCAAGCTGGAATGGCACCCCTTCACCCTGACCA
GCGCCCCTGAAGAGGACTTCTTCAGCATCCACATCAGAATCGTGGGCGACTGGACCGAGGGC
CTGTTCAATGCCTGCGGCTGCGACAAGCAGGAATTCCAGGACGCCTGGAAGCTGCCCAAGAT
CGCCGTGGACGGCCCCTTTGGCACCGCCAGCGAGGACGTGTTCAGCTACGAGGTGGTGATGC
TGGTCGGAGCCGGCATCGGCGTGACCCCCTTCGCCAGCATCCTGAAGAGCGTGTGGTACAAG
TACTGCAACAACGCCACCAACCTGAAGCTGAAGAAGATCTACTTCTACTGGCTGTGCCGGGA
CACCCACGCCTTCGAGTGGTTCGCCGATCTGCTGCAGCTGCTGGAAAGCCAGATGCAGGAAC
GGAACAACGCCGGCTTCCTGAGCTACAACATCTACCTGACCGGCTGGGACGAGAGCCAGGCC
AACCACTTCGCCGTGCACCACGACGAGGAAAAGGACGTGATCACCGGCCTGAAGCAGAAAA
CCCTGTACGGCAGGCCCAACTGGGACAACGAGTTTAAGACCATCGCCAGCCAGCACCCCAAC
ACCCGGATCGGCGTGTTTCTGTGCGGCCCTGAGGCCCTGGCCGAGACACTGAGCAAGCAGAG
CATCAGCAACAGCGAGAGCGGCCCCAGGGGCGTGCACTTCATCTTCAACAAAGAAAACTTCT
GATGACTCGACGAATTCGAGCATCTTACCGCCATTTATTCCCATATTTGTTCTGTTTTTCTTGASEQUENCES  155 
TTTGGGTATACATTTAAATGTTAATAAAACAAAATGGTGGGGCAATCATTTACATTTTTAGG
GATATGTAATTACTAGTTCAGGTGTATTGCCACAAGACAAACATGTTAAGAAACTTTCCCGTT
ATTTACGCTCTGTTCCTGTTAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGATA
TTCTTAACTATGTTGCTCCTTTTACGCTGTGTGGATATGCTGCTTTATAGCCTCTGTATCTAGC
TATTGCTTCCCGTACGGCTTTCGTTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTTA
GAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCTGTGTTTGCTGACGCAAC
CCCCACTGGCTGGGGCATTGCCACCACCTGTCAACTCCTTTCTGGGACTTTCGCTTTCCCCCT
CCCGATCGCCACGGCAGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTAGGT
TGCTGGGCACTGATAATTCCGTGGTGTTGTCGAATTCGAAGCTTAACACGAGCCATAGATAG
AATAAAAGATTTTATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCACCGCTAGCGAT
ATCGAATTCACAACCCCTCACTCGGGCGCCAGTCCTCCGATTGACTGAGTCGCCCGGGTACC
CGTATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAATCGTGGACTCGCTGATCCTTGGGAG
GGTCTCCTCAGATTGATTGACTGCCCACCTCGGGGGTCTTTCATTTGGAGGTTCCACCGAGAT 
5' delta U3 SFFV region – 1...50 
5' R MESV region – 51...119 
5' U5 MESV region – 120...195 
SFFV promoter – 686...1086 
gp91
phoxs – 1145...2857 
mWPRE – 2872...3454 
3' delta U3 SFFV region – 3522...3571 
3' R MESV region – 3572...3640 
5' U5 MESV region – 3641...3716 
 
 
SERS11.EFs.gp91s.W proviral sequence 
 
AATGAAAGACCCCACCGCTAGCGATATCGAATTCACAACCCCTCACTCGGGCGCCAGTCCTC
CGATTGACTGAGTCGCCCGGGTACCCGTATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAA
TCGTGGACTCGCTGATCCTTGGGAGGGTCTCCTCAGATTGATTGACTGCCCACCTCGGGGGT
CTTTCATTTGGAGGTTCCACCGAGATTTGGAGACCCCTGCCCAGGGACCACCGACCCCCCCG
CCGGGAGGTAAGCTGGCCAGCGGTCGTTTCGTGTCTGTCTCTGTCTTTGTGCGTGTTTGTGCC
GGCATCTAGTGTTTGCGCCTGCGTCTGTACTAGTTGGCTAACTAGATCTGTATCTGGCGGTCC
CGCGGAAGAACTGACGAGTTCGTATTCCCGGCCGCAGCCCCTGGGAGACGTCCCAGCGGCCT
CGGGGGCCCGTTTTGTGGCCCATTCTGTATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGC
TCCGCCACTGTCCGAGGGGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGC
CCCCGTCTGAATTTTTGCTTTCGGTTTTACGCCGAAACCGCGCCGCGCGTCTTGTCTGCTGCA
GCATCGTTCTGTGTTGTCTCTGTCTGACGTGGTTCTGTATTGTCTGAAAATAGCGGCCGCTTC
GTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
GGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAG
TGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAG
TAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGTCGACCGATCCT
GCCACCATGGGCAACTGGGCCGTGAACGAGGGCCTGAGCATCTTCGTGATCCTGGTGTGGCT
GGGCCTGAACGTGTTCCTGTTCGTGTGGTACTACCGGGTGTACGACATCCCCCCCAAGTTCTT
CTACACCCGGAAGCTGCTGGGCAGCGCCCTGGCCCTGGCCAGAGCCCCTGCCGCCTGCCTGA
ACTTCAACTGCATGCTGATCCTGCTGCCCGTGTGCCGGAACCTGCTGTCCTTCCTGCGGGGCA
GCAGCGCCTGCTGCAGCACCAGAGTGCGGCGGCAGCTGGACCGGAACCTGACCTTCCACAAG
ATGGTGGCCTGGATGATCGCCCTGCACAGCGCCATCCACACCATCGCCCACCTGTTCAACGT
GGAGTGGTGCGTGAACGCCCGGGTGAACAACAGCGACCCCTACAGCGTGGCCCTGAGCGAG
CTGGGCGACCGGCAGAACGAGAGCTACCTGAACTTCGCCCGGAAGCGGATCAAGAACCCCGSEQUENCES  156 
AGGGCGGCCTGTACCTGGCCGTGACCCTGCTGGCCGGCATCACCGGCGTGGTGATCACCCTG
TGCCTGATCCTGATCATCACCAGCAGCACCAAGACCATCCGGCGGAGCTACTTCGAGGTGTT
CTGGTACACCCACCACCTGTTCGTGATCTTTTTCATCGGCCTGGCCATCCACGGCGCCGAGCG
GATCGTGAGGGGCCAGACCGCCGAGAGCCTGGCCGTGCACAACATCACCGTGTGCGAGCAG
AAAATCAGCGAGTGGGGCAAGATCAAAGAGTGCCCCATCCCCCAGTTCGCCGGCAACCCCCC
CATGACCTGGAAGTGGATCGTGGGCCCCATGTTCCTGTACCTGTGCGAGCGGCTGGTGCGGT
TCTGGCGGAGCCAGCAGAAAGTGGTGATTACCAAGGTGGTGACCCACCCCTTCAAGACCATC
GAGCTGCAGATGAAGAAAAAGGGCTTCAAGATGGAAGTGGGCCAGTACATCTTTGTGAAGT
GCCCCAAGGTGTCCAAGCTGGAATGGCACCCCTTCACCCTGACCAGCGCCCCTGAAGAGGAC
TTCTTCAGCATCCACATCAGAATCGTGGGCGACTGGACCGAGGGCCTGTTCAATGCCTGCGG
CTGCGACAAGCAGGAATTCCAGGACGCCTGGAAGCTGCCCAAGATCGCCGTGGACGGCCCCT
TTGGCACCGCCAGCGAGGACGTGTTCAGCTACGAGGTGGTGATGCTGGTCGGAGCCGGCATC
GGCGTGACCCCCTTCGCCAGCATCCTGAAGAGCGTGTGGTACAAGTACTGCAACAACGCCAC
CAACCTGAAGCTGAAGAAGATCTACTTCTACTGGCTGTGCCGGGACACCCACGCCTTCGAGT
GGTTCGCCGATCTGCTGCAGCTGCTGGAAAGCCAGATGCAGGAACGGAACAACGCCGGCTTC
CTGAGCTACAACATCTACCTGACCGGCTGGGACGAGAGCCAGGCCAACCACTTCGCCGTGCA
CCACGACGAGGAAAAGGACGTGATCACCGGCCTGAAGCAGAAAACCCTGTACGGCAGGCCC
AACTGGGACAACGAGTTTAAGACCATCGCCAGCCAGCACCCCAACACCCGGATCGGCGTGTT
TCTGTGCGGCCCTGAGGCCCTGGCCGAGACACTGAGCAAGCAGAGCATCAGCAACAGCGAG
AGCGGCCCCAGGGGCGTGCACTTCATCTTCAACAAAGAAAACTTCTGATGACTCGACGAATT
CGAGCATCTTACCGCCATTTATTCCCATATTTGTTCTGTTTTTCTTGATTTGGGTATACATTTA
AATGTTAATAAAACAAAATGGTGGGGCAATCATTTACATTTTTAGGGATATGTAATTACTAG
TTCAGGTGTATTGCCACAAGACAAACATGTTAAGAAACTTTCCCGTTATTTACGCTCTGTTCC
TGTTAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGATATTCTTAACTATGTTGC
TCCTTTTACGCTGTGTGGATATGCTGCTTTATAGCCTCTGTATCTAGCTATTGCTTCCCGTACG
GCTTTCGTTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTTAGAGGAGTTGTGGCCCG
TTGTCCGTCAACGTGGCGTGGTGTGCTCTGTGTTTGCTGACGCAACCCCCACTGGCTGGGGC
ATTGCCACCACCTGTCAACTCCTTTCTGGGACTTTCGCTTTCCCCCTCCCGATCGCCACGGCA
GAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTAGGTTGCTGGGCACTGATAA
TTCCGTGGTGTTGTCGAATTCGAAGCTTAACACGAGCCATAGATAGAATAAAAGATTTTATT
TAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCACCGCTAGCGATATCGAATTCACAACCC
CTCACTCGGGCGCCAGTCCTCCGATTGACTGAGTCGCCCGGGTACCCGTATTCCCAATAAAG
CCTCTTGCTGTTTGCATCCGAATCGTGGACTCGCTGATCCTTGGGAGGGTCTCCTCAGATTGA
TTGACTGCCCACCTCGGGGGTCTTTCATTTGGAGGTTCCACCGAGAT 
5' delta U3 SFFV region – 1...50 
5' R MESV region – 51...119 
5' U5 MESV region – 120...195 
EFs promoter – 680...923 
gp91
phoxs – 942...2654 
mWPRE – 2669...3251 
3' delta U3 SFFV region – 3319...3368 
3' R MESV region – 3369...3437 
5' U5 MESV region – 3438...3513 
 SEQUENCES  157 
SERS11.SP146.gp91s.W proviral sequence 
 
AATGAAAGACCCCACCGCTAGCGATATCGAATTCACAACCCCTCACTCGGGCGCCAGTCCTC
CGATTGACTGAGTCGCCCGGGTACCCGTATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAA
TCGTGGACTCGCTGATCCTTGGGAGGGTCTCCTCAGATTGATTGACTGCCCACCTCGGGGGT
CTTTCATTTGGAGGTTCCACCGAGATTTGGAGACCCCTGCCCAGGGACCACCGACCCCCCCG
CCGGGAGGTAAGCTGGCCAGCGGTCGTTTCGTGTCTGTCTCTGTCTTTGTGCGTGTTTGTGCC
GGCATCTAGTGTTTGCGCCTGCGTCTGTACTAGTTGGCTAACTAGATCTGTATCTGGCGGTCC
CGCGGAAGAACTGACGAGTTCGTATTCCCGGCCGCAGCCCCTGGGAGACGTCCCAGCGGCCT
CGGGGGCCCGTTTTGTGGCCCATTCTGTATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGC
TCCGCCACTGTCCGAGGGGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGC
CCCCGTCTGAATTTTTGCTTTCGGTTTTACGCCGAAACCGCGCCGCGCGTCTTGTCTGCTGCA
GCATCGTTCTGTGTTGTCTCTGTCTGACGTGgTTCTGTATTGTCTGAAAATAGCGGCCGCCGG
TACCGAGCTCTTACGCGTGCTAGCGAGGGCGGACAAGCGACTTCCTCTTTCCAGCAGAAAAG
GAGAAGTAGGAGCCAAGATTTCCAAACTCTGTGGTTGCCTTGAAGCGACTTCCTCTTTCCAG
AAGCGACTTCCTCTTTCCAGCAGAAAAGGAGAAGTAGGAGCTCCTACTTCTCCTTTTCTGCCA
AGATTTCCAAACTCTGTGGTTGCCTTGCTCCTACTTCTCCTTTTCTGCAGAAAAGGAGAAGTA
GGAGCTGGAAAGAGGAAGTCGCTTGAGGGCGGACGCTAGCCCGGGCTCGAGTACCCTCCCT
GCCCCCTGTCCCGACCGCGACAAAAGCGACTTCCTCTTTCCAGTGCATTTAAGGCGCAGCCTG
GAAGTGCCAGGGAGCACTGGAGGCCACCCAGTACCGGTTGTCGACCGATCCTGCCACCATGG
GCAACTGGGCCGTGAACGAGGGCCTGAGCATCTTCGTGATCCTGGTGTGGCTGGGCCTGAAC
GTGTTCCTGTTCGTGTGGTACTACCGGGTGTACGACATCCCCCCCAAGTTCTTCTACACCCGG
AAGCTGCTGGGCAGCGCCCTGGCCCTGGCCAGAGCCCCTGCCGCCTGCCTGAACTTCAACTG
CATGCTGATCCTGCTGCCCGTGTGCCGGAACCTGCTGTCCTTCCTGCGGGGCAGCAGCGCCT
GCTGCAGCACCAGAGTGCGGCGGCAGCTGGACCGGAACCTGACCTTCCACAAGATGGTGGCC
TGGATGATCGCCCTGCACAGCGCCATCCACACCATCGCCCACCTGTTCAACGTGGAGTGGTG
CGTGAACGCCCGGGTGAACAACAGCGACCCCTACAGCGTGGCCCTGAGCGAGCTGGGCGAC
CGGCAGAACGAGAGCTACCTGAACTTCGCCCGGAAGCGGATCAAGAACCCCGAGGGCGGCC
TGTACCTGGCCGTGACCCTGCTGGCCGGCATCACCGGCGTGGTGATCACCCTGTGCCTGATC
CTGATCATCACCAGCAGCACCAAGACCATCCGGCGGAGCTACTTCGAGGTGTTCTGGTACAC
CCACCACCTGTTCGTGATCTTTTTCATCGGCCTGGCCATCCACGGCGCCGAGCGGATCGTGAG
GGGCCAGACCGCCGAGAGCCTGGCCGTGCACAACATCACCGTGTGCGAGCAGAAAATCAGC
GAGTGGGGCAAGATCAAAGAGTGCCCCATCCCCCAGTTCGCCGGCAACCCCCCCATGACCTG
GAAGTGGATCGTGGGCCCCATGTTCCTGTACCTGTGCGAGCGGCTGGTGCGGTTCTGGCGGA
GCCAGCAGAAAGTGGTGATTACCAAGGTGGTGACCCACCCCTTCAAGACCATCGAGCTGCAG
ATGAAGAAAAAGGGCTTCAAGATGGAAGTGGGCCAGTACATCTTTGTGAAGTGCCCCAAGG
TGTCCAAGCTGGAATGGCACCCCTTCACCCTGACCAGCGCCCCTGAAGAGGACTTCTTCAGC
ATCCACATCAGAATCGTGGGCGACTGGACCGAGGGCCTGTTCAATGCCTGCGGCTGCGACAA
GCAGGAATTCCAGGACGCCTGGAAGCTGCCCAAGATCGCCGTGGACGGCCCCTTTGGCACCG
CCAGCGAGGACGTGTTCAGCTACGAGGTGGTGATGCTGGTCGGAGCCGGCATCGGCGTGACC
CCCTTCGCCAGCATCCTGAAGAGCGTGTGGTACAAGTACTGCAACAACGCCACCAACCTGAA
GCTGAAGAAGATCTACTTCTACTGGCTGTGCCGGGACACCCACGCCTTCGAGTGGTTCGCCG
ATCTGCTGCAGCTGCTGGAAAGCCAGATGCAGGAACGGAACAACGCCGGCTTCCTGAGCTAC
AACATCTACCTGACCGGCTGGGACGAGAGCCAGGCCAACCACTTCGCCGTGCACCACGACGA
GGAAAAGGACGTGATCACCGGCCTGAAGCAGAAAACCCTGTACGGCAGGCCCAACTGGGAC
AACGAGTTTAAGACCATCGCCAGCCAGCACCCCAACACCCGGATCGGCGTGTTTCTGTGCGG
CCCTGAGGCCCTGGCCGAGACACTGAGCAAGCAGAGCATCAGCAACAGCGAGAGCGGCCCC
AGGGGCGTGCACTTCATCTTCAACAAAGAAAACTTCTGATGACTCGACGAATTCGAGCATCT
TACCGCCATTTATTCCCATATTTGTTCTGTTTTTCTTGATTTGGGTATACATTTAAATGTTAATSEQUENCES  158 
AAAACAAAATGGTGGGGCAATCATTTACATTTTTAGGGATATGTAATTACTAGTTCAGGTGT
ATTGCCACAAGACAAACATGTTAAGAAACTTTCCCGTTATTTACGCTCTGTTCCTGTTAATCA
ACCTCTGGATTACAAAATTTGTGAAAGATTGACTGATATTCTTAACTATGTTGCTCCTTTTAC
GCTGTGTGGATATGCTGCTTTATAGCCTCTGTATCTAGCTATTGCTTCCCGTACGGCTTTCGT
TTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTTAGAGGAGTTGTGGCCCGTTGTCCGT
CAACGTGGCGTGGTGTGCTCTGTGTTTGCTGACGCAACCCCCACTGGCTGGGGCATTGCCAC
CACCTGTCAACTCCTTTCTGGGACTTTCGCTTTCCCCCTCCCGATCGCCACGGCAGAACTCAT
CGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGG
TGTTGTCGAATTCGAAGCTTAACACGAGCCATAGATAGAATAAAAGATTTTATTTAGTCTCC
AGAAAAAGGGGGGAATGAAAGACCCCACCGCTAGCGATATCGAATTCACAACCCCTCACTCG
GGCGCCAGTCCTCCGATTGACTGAGTCGCCCGGGTACCCGTATTCCCAATAAAGCCTCTTGCT
GTTTGCATCCGAATCGTGGACTCGCTGATCCTTGGGAGGGTCTCCTCAGATTGATTGACTGCC
CACCTCGGGGGTCTTTCATTTGGAGGTTCCACCGAGAT 
5' delta U3 SFFV region – 1...50 
5' R MESV region – 51...119 
5' U5 MESV region – 120...195 
SP146 promoter – 680...1102 
gp91
phoxs – 1121...2833 
mWPRE – 2848...3430 
3' delta U3 SFFV region – 3498...3547 
3' R MESV region – 3548...3616 
5' U5 MESV region – 3617...3692 
 
SERS11.fes.gp91s.W proviral sequence 
 
AATGAAAGACCCCACCGCTAGCGATATCGAATTCACAACCCCTCACTCGGGCGCCAGTCCTC
CGATTGACTGAGTCGCCCGGGTACCCGTATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAA
TCGTGGACTCGCTGATCCTTGGGAGGGTCTCCTCAGATTGATTGACTGCCCACCTCGGGGGT
CTTTCATTTGGAGGTTCCACCGAGATTTGGAGACCCCTGCCCAGGGACCACCGACCCCCCCG
CCGGGAGGTAAGCTGGCCAGCGGTCGTTTCGTGTCTGTCTCTGTCTTTGTGCGTGTTTGTGCC
GGCATCTAGTGTTTGCGCCTGCGTCTGTACTAGTTGGCTAACTAGATCTGTATCTGGCGGTCC
CGCGGAAGAACTGACGAGTTCGTATTCCCGGCCGCAGCCCCTGGGAGACGTCCCAGCGGCCT
CGGGGGCCCGTTTTGTGGCCCATTCTGTATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGC
TCCGCCACTGTCCGAGGGGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGC
CCCCGTCTGAATTTTTGCTTTCGGTTTTACGCCGAAACCGCGCCGCGCGTCTTGTCTGCTGCA
GCATCGTTCTGTGTTGTCTCTGTCTGACGTGGTTCTGTATTGTCTGAAAATAGCGGCCGCCAG
TGTGATGGATATCTGCAGAATTCGCCCTTGAATTCCGTGAGGTGGGGAGGGCTGGGACCAGG
GTTCCCTCTTTCTCTTCTGCGGTGGCCCTGGCCTGGTGCTAGGACTGCGCGCCTCCCCTCAGT
ACCCGCGGACACCCTGGGCTTCCCTGGGCCCAGCATCTGCCTGGGGCCTCGCCCTGGGCTCC
CCCTCCTGACCCCCACCTTGCGCCCCTTCCCGGTGTTCCCGGGGCGCTGCCGGGCCCTGGGGC
CTGCGGGGCGCGGGCGGCTCTTGGCTGGGCCATTCTTTCCCGGCCCCCTCCTCCCTTCCGTTT
CCGTGGCCGTGCGGCCGGCTAGAGGCTGCGGCCCAGCGCGGAGCAGGGGGGCTGGCAGGCG
TCGGGGCGGTCGGGCCGGTCCCGCCCGCCCCTTCCCCTCCACAGGCCCGCCCCGGGGCCTGG
GCCAACTGAAACCGCGGGAGGAGGAAGCGCGGAATCAGGAACTGGCCGGGGTCCGCACCGG
GCCTGAGTCGGTCCGAGGCCGTCCCAGGAGCAGCGCCCGAAGGTCGACCGATCCTGCCACCA
TGGGCAACTGGGCCGTGAACGAGGGCCTGAGCATCTTCGTGATCCTGGTGTGGCTGGGCCTG
AACGTGTTCCTGTTCGTGTGGTACTACCGGGTGTACGACATCCCCCCCAAGTTCTTCTACACC
CGGAAGCTGCTGGGCAGCGCCCTGGCCCTGGCCAGAGCCCCTGCCGCCTGCCTGAACTTCAA
CTGCATGCTGATCCTGCTGCCCGTGTGCCGGAACCTGCTGTCCTTCCTGCGGGGCAGCAGCGSEQUENCES  159 
CCTGCTGCAGCACCAGAGTGCGGCGGCAGCTGGACCGGAACCTGACCTTCCACAAGATGGTG
GCCTGGATGATCGCCCTGCACAGCGCCATCCACACCATCGCCCACCTGTTCAACGTGGAGTG
GTGCGTGAACGCCCGGGTGAACAACAGCGACCCCTACAGCGTGGCCCTGAGCGAGCTGGGC
GACCGGCAGAACGAGAGCTACCTGAACTTCGCCCGGAAGCGGATCAAGAACCCCGAGGGCG
GCCTGTACCTGGCCGTGACCCTGCTGGCCGGCATCACCGGCGTGGTGATCACCCTGTGCCTG
ATCCTGATCATCACCAGCAGCACCAAGACCATCCGGCGGAGCTACTTCGAGGTGTTCTGGTA
CACCCACCACCTGTTCGTGATCTTTTTCATCGGCCTGGCCATCCACGGCGCCGAGCGGATCGT
GAGGGGCCAGACCGCCGAGAGCCTGGCCGTGCACAACATCACCGTGTGCGAGCAGAAAATC
AGCGAGTGGGGCAAGATCAAAGAGTGCCCCATCCCCCAGTTCGCCGGCAACCCCCCCATGAC
CTGGAAGTGGATCGTGGGCCCCATGTTCCTGTACCTGTGCGAGCGGCTGGTGCGGTTCTGGC
GGAGCCAGCAGAAAGTGGTGATTACCAAGGTGGTGACCCACCCCTTCAAGACCATCGAGCTG
CAGATGAAGAAAAAGGGCTTCAAGATGGAAGTGGGCCAGTACATCTTTGTGAAGTGCCCCA
AGGTGTCCAAGCTGGAATGGCACCCCTTCACCCTGACCAGCGCCCCTGAAGAGGACTTCTTC
AGCATCCACATCAGAATCGTGGGCGACTGGACCGAGGGCCTGTTCAATGCCTGCGGCTGCGA
CAAGCAGGAATTCCAGGACGCCTGGAAGCTGCCCAAGATCGCCGTGGACGGCCCCTTTGGCA
CCGCCAGCGAGGACGTGTTCAGCTACGAGGTGGTGATGCTGGTCGGAGCCGGCATCGGCGTG
ACCCCCTTCGCCAGCATCCTGAAGAGCGTGTGGTACAAGTACTGCAACAACGCCACCAACCT
GAAGCTGAAGAAGATCTACTTCTACTGGCTGTGCCGGGACACCCACGCCTTCGAGTGGTTCG
CCGATCTGCTGCAGCTGCTGGAAAGCCAGATGCAGGAACGGAACAACGCCGGCTTCCTGAGC
TACAACATCTACCTGACCGGCTGGGACGAGAGCCAGGCCAACCACTTCGCCGTGCACCACGA
CGAGGAAAAGGACGTGATCACCGGCCTGAAGCAGAAAACCCTGTACGGCAGGCCCAACTGG
GACAACGAGTTTAAGACCATCGCCAGCCAGCACCCCAACACCCGGATCGGCGTGTTTCTGTG
CGGCCCTGAGGCCCTGGCCGAGACACTGAGCAAGCAGAGCATCAGCAACAGCGAGAGCGGC
CCCAGGGGCGTGCACTTCATCTTCAACAAAGAAAACTTCTGATGACTCGACGAATTCGAGCA
TCTTACCGCCATTTATTCCCATATTTGTTCTGTTTTTCTTGATTTGGGTATACATTTAAATGTT
AATAAAACAAAATGGTGGGGCAATCATTTACATTTTTAGGGATATGTAATTACTAGTTCAGG
TGTATTGCCACAAGACAAACATGTTAAGAAACTTTCCCGTTATTTACGCTCTGTTCCTGTTAA
TCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGATATTCTTAACTATGTTGCTCCTTT
TACGCTGTGTGGATATGCTGCTTTATAGCCTCTGTATCTAGCTATTGCTTCCCGTACGGCTTT
CGTTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTTAGAGGAGTTGTGGCCCGTTGTC
CGTCAACGTGGCGTGGTGTGCTCTGTGTTTGCTGACGCAACCCCCACTGGCTGGGGCATTGC
CACCACCTGTCAACTCCTTTCTGGGACTTTCGCTTTCCCCCTCCCGATCGCCACGGCAGAACT
CATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTAGGTTGCTGGGCACTGATAATTCCG
TGGTGTTGTCGAATTCGAAGCTTAACACGAGCCATAGATAGAATAAAAGATTTTATTTAGTC
TCCAGAAAAAGGGGGGAATGAAAGACCCCACCGCTAGCGATATCGAATTCACAACCCCTCAC
TCGGGCGCCAGTCCTCCGATTGACTGAGTCGCCCGGGTACCCGTATTCCCAATAAAGCCTCTT
GCTGTTTGCATCCGAATCGTGGACTCGCTGATCCTTGGGAGGGTCTCCTCAGATTGATTGACT
GCCCACCTCGGGGGTCTTTCATTTGGAGGTTCCACCGAGAT 
5' delta U3 SFFV region – 1...50 
5' R MESV region – 51...119 
5' U5 MESV region – 120...195 
c-fes promoter – 718...1224 
gp91
phoxs – 1247...2959 
mWPRE – 2974...3556 
3' delta U3 SFFV region – 3624...3673 
3' R MESV region – 3674...3742 
5' U5 MESV region – 3743...3818 
 SEQUENCES  160 
SERS11.M8dN.gp91s.W proviral sequence 
 
AATGAAAGACCCCACCGCTAGCGATATCGAATTCACAACCCCTCACTCGGGCGCCAGTCCTC
CGATTGACTGAGTCGCCCGGGTACCCGTATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAA
TCGTGGACTCGCTGATCCTTGGGAGGGTCTCCTCAGATTGATTGACTGCCCACCTCGGGGGT
CTTTCATTTGGAGGTTCCACCGAGATTTGGAGACCCCTGCCCAGGGACCACCGACCCCCCCG
CCGGGAGGTAAGCTGGCCAGCGGTCGTTTCGTGTCTGTCTCTGTCTTTGTGCGTGTTTGTGCC
GGCATCTAGTGTTTGCGCCTGCGTCTGTACTAGTTGGCTAACTAGATCTGTATCTGGCGGTCC
CGCGGAAGAACTGACGAGTTCGTATTCCCGGCCGCAGCCCCTGGGAGACGTCCCAGCGGCCT
CGGGGGCCCGTTTTGTGGCCCATTCTGTATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGC
TCCGCCACTGTCCGAGGGGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGC
CCCCGTCTGAATTTTTGCTTTCGGTTTTACGCCGAAACCGCGCCGCGCGTCTTGTCTGCTGCA
GCATCGTTCTGTGTTGTCTCTGTCTGACGTGGTTCTGTATTGTCTGAAAATAGCGGCCGCCAT
ATGCTTATTGACCATTTGTATATCTTCTTCGGAGAAGTGTCTATTTGAGTCTTTTCCCCAATTT
TTGATTGGTTTGTTTGTTTTTTGTTGTTGAGTTGTAGGGATTCTTTTATATTCTGGATATTAAT
CCCTTATCAGATATTTGTTTTACAAATATTTTCTTTGTAACAACAGAAACACACCACAGTCTT
CAAGGTTGGAAGCCAGTTAATCTGAGTAGCATTTTGTTAGTGGTGGGGAGAGGATTTGTTCC
TCCTGAAATCCTGGGGAATTGGCCACCTCCTCTTCTCCTCTTAGGCATGAAGCGCGTCTGGCT
TCTCCAAAGAACTCTTCCCCTCCACTACCTCAGAGTTAGCTTCCTCTCTTCAGCCAGTGATCC
TGGGGTCCCAGACACAATAATTAACCAAGAGAGGGTGAAAGGCTCCCTGCTGTGTTTATGCA
ATGGCTCAGGCCCTTGTGAAGTGCCGAGGGACCCCAAGCAGCCTCCATCTCCCAGGGCATGG
TCCATCCCCAGCTTCACAGAACAGGAAAGCTGTGGAGGAGTGTGGGCAGCAGGGTAGGAAT
GGATATAGCCCTTGGCAACAACACATTTCCCCACAAAGCACCCACCCAAAAGAACAACAACG
ATAGTTTTAGTTTTTAGTAATGAGAACAATAGTTCTCATGACTAAAAGCCATCAGCCAGGAC
ACGTGTTCTCAACCCTTTTGCGGTCTTTGGACCCTTTGAAACTCTGACAGAAGCCATGGAGGA
ATGTTCTCACTGAGTGCATGCACTCAAAATGATGCATTCAACTTCAATTCAGTTTCAGGGATG
TATGGCCTGACCACCAATGCAGGGGATTAGCAATCGCAATAGTGGAGAGGGCATGGGAGTG
GGAATCTGGCTGGATCAAGCAAGTGGATGCCAGCAGCCCAGAAAAAGAGCCCCCCTACCTGC
TTTTTCCTTCTGGGCACTATTGCCCAGCAAATGCCTTCCTCTTTCCGCTTCTCCTACCTCCCCA
CCCAAAATTTTCATTCTGCACAGTGATTGCCACATTCACCTGGTTGAGAAACCAGAGACTGT
AGCAACTCTGGCAGGGAGAAGCTGTCTCTGATGGCCTGAAGCTGTGGGCAGCTGGCCAAGCC
TAACCGCTATAAAAAGGAGCTGCCTCTCAGCCCTGCATGTCTCTTGTCAGCTGTCTTTCAGAA
GACCTGGTAAGTGGGACTGTCTGGGTTGGCCCCGCACTTTGGGCTTCTCTTGGGGAGGGTCA
GGGAAGTGGAGCAGCCTTCCTGAGAGAGGAGAGAGAAAGCTCAGGGAGGTCTGGAGCAAAG
ATACTCCTGGAGGTGGGGAGTGAGGCAGGGATAAGGAAGGAGAGTATCCTCCAGCACCTTC
CAGTGGGTAAGGGCACATTGTCTCCTAGGCTGGACTTTTCTTGAGCAGAGGGTGGGGTGGTA
AGGAAAGTCTACGGGCCCCGTGTGTGTGCACATGTCTCTGTGTGAATGGACCCTTCCCCTTCC
CACACGTGTATCCCTATCATCCCACCCTTCCCACCAGAGCCATAGCCATCTGCTGGTTTGGTT
ATTTGGAGAGTGCAGGCCAGGACAAGGCCATCGCTTGGGGCATGAATCCTCTGCGTACTGCC
CTGGCCAGATGCAAATTCCCTGCCATGGGATTCCCCAGAAGGTTCTGTTTTTCAGGTGGGGC
AAGTTCCGTGGGATCATAGATCTGTCATGATGATCATTGCAATTGGATCCATATATAGGGCC
CGGGTTATAATTACCTCAGGTCGACCGATCCTGCCACCATGGGCAACTGGGCCGTGAACGAG
GGCCTGAGCATCTTCGTGATCCTGGTGTGGCTGGGCCTGAACGTGTTCCTGTTCGTGTGGTAC
TACCGGGTGTACGACATCCCCCCCAAGTTCTTCTACACCCGGAAGCTGCTGGGCAGCGCCCT
GGCCCTGGCCAGAGCCCCTGCCGCCTGCCTGAACTTCAACTGCATGCTGATCCTGCTGCCCGT
GTGCCGGAACCTGCTGTCCTTCCTGCGGGGCAGCAGCGCCTGCTGCAGCACCAGAGTGCGGC
GGCAGCTGGACCGGAACCTGACCTTCCACAAGATGGTGGCCTGGATGATCGCCCTGCACAGC
GCCATCCACACCATCGCCCACCTGTTCAACGTGGAGTGGTGCGTGAACGCCCGGGTGAACAA
CAGCGACCCCTACAGCGTGGCCCTGAGCGAGCTGGGCGACCGGCAGAACGAGAGCTACCTGSEQUENCES  161 
AACTTCGCCCGGAAGCGGATCAAGAACCCCGAGGGCGGCCTGTACCTGGCCGTGACCCTGCT
GGCCGGCATCACCGGCGTGGTGATCACCCTGTGCCTGATCCTGATCATCACCAGCAGCACCA
AGACCATCCGGCGGAGCTACTTCGAGGTGTTCTGGTACACCCACCACCTGTTCGTGATCTTTT
TCATCGGCCTGGCCATCCACGGCGCCGAGCGGATCGTGAGGGGCCAGACCGCCGAGAGCCTG
GCCGTGCACAACATCACCGTGTGCGAGCAGAAAATCAGCGAGTGGGGCAAGATCAAAGAGT
GCCCCATCCCCCAGTTCGCCGGCAACCCCCCCATGACCTGGAAGTGGATCGTGGGCCCCATG
TTCCTGTACCTGTGCGAGCGGCTGGTGCGGTTCTGGCGGAGCCAGCAGAAAGTGGTGATTAC
CAAGGTGGTGACCCACCCCTTCAAGACCATCGAGCTGCAGATGAAGAAAAAGGGCTTCAAG
ATGGAAGTGGGCCAGTACATCTTTGTGAAGTGCCCCAAGGTGTCCAAGCTGGAATGGCACCC
CTTCACCCTGACCAGCGCCCCTGAAGAGGACTTCTTCAGCATCCACATCAGAATCGTGGGCG
ACTGGACCGAGGGCCTGTTCAATGCCTGCGGCTGCGACAAGCAGGAATTCCAGGACGCCTGG
AAGCTGCCCAAGATCGCCGTGGACGGCCCCTTTGGCACCGCCAGCGAGGACGTGTTCAGCTA
CGAGGTGGTGATGCTGGTCGGAGCCGGCATCGGCGTGACCCCCTTCGCCAGCATCCTGAAGA
GCGTGTGGTACAAGTACTGCAACAACGCCACCAACCTGAAGCTGAAGAAGATCTACTTCTAC
TGGCTGTGCCGGGACACCCACGCCTTCGAGTGGTTCGCCGATCTGCTGCAGCTGCTGGAAAG
CCAGATGCAGGAACGGAACAACGCCGGCTTCCTGAGCTACAACATCTACCTGACCGGCTGGG
ACGAGAGCCAGGCCAACCACTTCGCCGTGCACCACGACGAGGAAAAGGACGTGATCACCGG
CCTGAAGCAGAAAACCCTGTACGGCAGGCCCAACTGGGACAACGAGTTTAAGACCATCGCCA
GCCAGCACCCCAACACCCGGATCGGCGTGTTTCTGTGCGGCCCTGAGGCCCTGGCCGAGACA
CTGAGCAAGCAGAGCATCAGCAACAGCGAGAGCGGCCCCAGGGGCGTGCACTTCATCTTCAA
CAAAGAAAACTTCTGATGACTCGACGAATTCGAGCATCTTACCGCCATTTATTCCCATATTTG
TTCTGTTTTTCTTGATTTGGGTATACATTTAAATGTTAATAAAACAAAATGGTGGGGCAATCA
TTTACATTTTTAGGGATATGTAATTACTAGTTCAGGTGTATTGCCACAAGACAAACATGTTAA
GAAACTTTCCCGTTATTTACGCTCTGTTCCTGTTAATCAACCTCTGGATTACAAAATTTGTGA
AAGATTGACTGATATTCTTAACTATGTTGCTCCTTTTACGCTGTGTGGATATGCTGCTTTATA
GCCTCTGTATCTAGCTATTGCTTCCCGTACGGCTTTCGTTTTCTCCTCCTTGTATAAATCCTGG
TTGCTGTCTCTTTTAGAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCTGTG
TTTGCTGACGCAACCCCCACTGGCTGGGGCATTGCCACCACCTGTCAACTCCTTTCTGGGACT
TTCGCTTTCCCCCTCCCGATCGCCACGGCAGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGG
ACAGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGGTGTTGTCGAATTCGAAGCTTAACAC
GAGCCATAGATAGAATAAAAGATTTTATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACC
CCACCGCTAGCGATATCGAATTCACAACCCCTCACTCGGGCGCCAGTCCTCCGATTGACTGA
GTCGCCCGGGTACCCGTATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAATCGTGGACTCG
CTGATCCTTGGGAGGGTCTCCTCAGATTGATTGACTGCCCACCTCGGGGGTCTTTCATTTGGA
GGTTCCACCGAGAT 
5' delta U3 SFFV region – 1...50 
5' R MESV region – 51...119 
5' U5 MESV region – 120...195 
M8dN promoter – 688...2390 
MRP8 exon 1 – 1850…1882 
MRP8 intron 1 – 1883…2365 
MRP8 exon 2 – 2366…2390 
gp91
phoxs – 2473...4185 
mWPRE – 4200...4782 
3' delta U3 SFFV region – 4850...4899 
3' R MESV region – 4900...4968 
5' U5 MESV region – 4969...5044 